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OSTEOARTHRITIS, AN OVERVIEW 
 
Osteoarthritis (OA) is a degenerative disease of the joints showing increased incidence with 
aging. While the incidence of the disease is steadily increasing due to an increasing population 
of elderly and rising numbers of people suffering from obesity, OA has become part of the top 
5 most common diseases especially in Europe and the United States.[2-4] Of 291 conditions 
included in the Global Burden of Disease 2010 study (GBD 2010) OA ranked 11th highest in 
terms of so-called ‘years of life lived with disability’ (YLDs;[1]) and it is anticipated that OA 
will become a major problem for health systems globally with large socio-economic burden on 
society. Occurrence of OA is rare before the age of 40 years, with prevalence of knee OA 
peaking around 50 years of age while prevalence of hip OA continues to increase with age 
(Figure 1A). Similar to hip OA, prevalence of hand OA increases with age and percentages are 
joint-specific (Figure 1B).[5, 6] 
Since OA is a chronic and painful disability and a major cause of morbidity, development 
of drugs to delay onset and/or progression is essential. This requires however more knowledge 
of the etiology, improved mechanistic insight into the disease, and sensitive biomarkers to 
diagnose OA at an early stage before irreversible damage becomes apparent in X-ray, 
manifested by the presence of osteophytes, joint space narrowing, and subchondral cyst 
formation of the bone. Up until now, treatments that could cure or stop disease progression 
are still poor and osteoarthritis is not diagnosed until late stages when damage is irreversible. 
Therapeutic approaches are aimed at pain relief, controlling symptoms, and minimizing 
disability, until in the end stage total joint arthroplasty is required.[7] Main impediments in OA 
management are the lack of biomarkers that detect OA at an early stage when damage is still 
reversible, or that allow stratification of subsets of OA patients with different disease modes. 
This considerably hampers development of effective therapies and requires better insight into 
the heterogeneous etiology of OA. 
 
 
Figure 1 Prevalence osteoarthritis, stratified by joint-site and sex. A Hip and knee OA (data 
for North American population[1]). B Hand OA stratified for 3 joints (data from an American 
community-based, longitudinal study[5]). Legend: red line: females; blue line: males; diamonds: 
knee OA; filled circles with dashed line: hip OA; asterisks with dashed line: hand OA 2nd DIP; 




ONE NAME, MULTIPLE 
DISEASES 
 
Even though the most common form of 
arthritis has a single name, osteoarthritis, in 
fact it has become manifest that it is a 
heterogenic disease. In general, two 
categories of OA are distinguished (reviewed 
by Johnson and Hunter[8]): primary or 
idiopathic OA which has no clear cause, and 
secondary OA which results from a known 
event (e.g. traumatic events[9]) or diseases 
such as acromegaly[10] or pattelofemoral 
joint osteoarthritis[11]). Although OA is 
most prevalent at the joints of hand, hip, and 
knee, it can occur at any joint.[2]  
For cases of primary OA, depending on 
the occurrence at a specific joint-site or the 
affection of 3 or more joints, respectively 
localized and generalized OA can be 
distinguished. Furthermore, different 
subtypes can be discriminated, for example: 
hypertrophic (when only osteophytosis is 
present), atrophic (only joint space 
narrowing), and classic or normotrophic OA 
(when both, joint space narrowing and 
osteophytosis, are present).[12] 
Diagnosis of OA relies on the 
combination of clinical, radiographical, and 
physical findings. Clinical symptoms of 
osteoarthritis are pain, joint stiffness and 
crepitus, resulting in an increasing loss of 
mobility. Radiographically, OA becomes 
manifest by osteophytes, joint space 
narrowing (JSN), and subchondral cysts of 
the bone. However, the patient’s perception 
of pain is often not proportional to the 
clinical and radiographical stage of the 
disease thereby hampering consistent and 
analogous diagnoses. In addition, substantial 
discordance exists between clinical and 
radiographical OA.[13] 
Osteoarthritis as whole joint disorder. 
Originally, degradation of articular cartilage 
was emphasized most in OA pathology. 
However, based on their studies already 
around 1970 Radin and colleagues proposed 
for the first time that cartilage degeneration 
may in fact result from changes in the 
(subchondral) bone.[14, 15] At present, it is 
generally accepted that OA is a whole joint 
disease involving not only bone and cartilage 
but also ligaments, synovial tissues, and the 
joint musculature,[16, 17] although it is most 
likely that OA originates in bone and/or 
cartilage subsequently affecting the other 
tissues. 
Epidemiological studies have shown that 
the risks for osteoarthritis and osteoporosis 
(OP) are inversely correlated, with higher 
systemic bone mass being a risk factor for 
OA which was recently confirmed in a study 
by Hardcastle and colleagues.[18] 
Unfavorable mechanical forces imposed on 
the cartilage during movement due to 
suboptimal (higher) bone mineral density 
(BMD) could result in the accumulation of 
microtraumas throughout life, eventually 
leading to OA. Despite the fact that bone 
and cartilage seem of solid, impermeable 
composition it has been shown that 
molecules can diffuse into the extracellular 
matrix of both, (calcified) cartilage and 
subchondral bone.[19] Catabolic enzymes or 
other molecules released in the bone 
following subchondral bone remodeling may 
diffuse to the cartilage and activate 
chondrocytes or vice versa. 
 
 
GENETIC EPIDEMIOLOGY OF 
OSTEOARTHRITIS 
 




by the observation that it is transmitted in a 
non-Mendelian manner. Major risk factors 
for development and progression of OA are 
joint injury, aging, poor metabolic health (e.g. 
obesity), and genetic predisposition.[16, 20, 
21] Importantly, genetic factors influencing 
OA can apply via metabolic health[22, 23] as 
well as via skeletal features: bone and 
cartilage structure and composition, and 
aspects of shape[24-26] (Figure 2). The 
heritability of osteoarthritis was already 
hypothesized in the beginning of last century 
and it was firstly confirmed in family-based 
studies showing that 39-60% of OA 
incidences can be attributed to 
heritability.[27, 28] In fact, Dieppe et. al.[29] 
stated that development of OA is the result 
of the dynamics between genetics and 
environment, with a continuous distribution 
between the extremes of predominantly 
genetic and predominantly environmental 
influences.  
Since clear insight into the etiology of 
OA would greatly contribute to early 
 
 





diagnosis as well as to the development of 
disease modifying treatments that are still 
lacking and to the possibility to better predict 
and monitor OA progression, major efforts 
are made to unravel the genetic secrets of 
OA. As a complex disease, the genetic 
component of OA is highly polygenic, with 
multiple risk alleles conferring small effects. 
This adds up to the mentioned clinical and 
radiological heterogeneity among patients. 
Therefore, genetic studies in OA require 
careful consideration of the study design and 
patient selection to increase the chance to 
identify susceptibility genes. Whereas large-
scale cohorts of random samples 
(population-based or case-control studies) are 
more likely to identify common variants with 
small effect sizes, family-based studies of 
more severe OA phenotypes are expected to 
result in the identification of rare variants, 
with larger effects.[30] 
 
Digging into the genetics underlying 
osteoarthritis. Genetic research in OA 
originally included mainly candidate gene 
association studies and genome wide linkage 
analyses. Especially the findings of the 
candidate gene studies appeared difficult to 
confirm in replication studies due to 
problems such as small sample size and the 
small numbers of polymorphic variants 
tested.[27, 31] The HapMap Project has 
shifted genetic epidemiology of complex 
inheritance away from linkage into genome 
wide association mapping of loci affecting 
disease and response to therapy.[32] 
Although the resolution of genome wide 
association studies (GWAS) is limited, the 
use of single nucleotide polymorphisms 
(SNPs) instead of microsatellites which were 
used in linkage studies has substantially 
improved the resolution.[33] Similar to 
genome wide linkage studies, GWA studies 
are hypothesis-free. However, GWAS require 
large sample sizes and are based on high 
throughput genotyping that typically ascertain 
at least 300,000 SNPs per sample nowadays. 
Before going on with the analysis of each of 
these variants for association with the trait of 
interest, genotyping is mostly followed by 
imputation of SNPs from the 1000 Genome 
Project (http://www.1000genomes.org/). 
The imputation methodology increases the 
genetic information per study subjects 
through the prediction of genotypes at 
genomic locations that have not actually been 
measured based on their known linkage 
disequilibrium (LD) with the genotyped 
SNPs. 
A problem that scientists encounter in 
GWA studies is the so-called ‘missing 
heritability’:[34] although heritability 
estimates of OA are relatively high (39-
60%[27, 28]), the common susceptibility loci 
identified thus far only explain a small part of 
the heritability. To some extend this could be 
explained by a possible overestimation of the 
heritability based on twin and family studies. 
On the other hand, it could suggest that 
many loci still remain to be identified. OA 
susceptibility loci identified by GWAS have 
small odds ratios. As explained by Manolio et 
al, this is due to a trade-off between higher 
risk allele frequencies and stronger genetic 
effects,[30] typical for the identification of 
genetic variants predisposing to complex 
diseases. To overcome this problem and to 
increase power, researchers have tried to 
apply GWAS with ever increasing sample 
size: large scale genome wide initiatives were 
established to pile up substantial amounts of 
genome wide association data for meta-
analyses such as the GWAS in 




analyses of GWAS performed within the 
Treat~OA consortium for knee[36] and for 
hip OA.[37] Together, the GWAS approach 
has resulted in the highest number of 
consistent OA susceptibility loci (Table 1A). 
Next generation sequencing (NGS) has 
greatly augmented research possibilities and 
enhanced the pace of discovery of disease-
associated genetic variants. Especially with 
the current increasing speed and decreasing 
costs, most likely NGS will shift its focus from 
sequencing of exomes to sequencing of the 
whole genome. The expectations that this may 
solve ‘the mysterious case of the missing 
heritability’ are high but to identify causal 
variants by NGS, well-selected (severely 
affected) patients and their families are required 
as well as extensive computational tools to 
process the information. Although 
generalizability of results from mutations 
private to a particular family is uncertain, it is 
expected that more common variants in the 
same gene or in the same pathways in which 
the genes function will affect susceptibility in a 
larger population.[38] In OA this paradigm has 
been proven its validity for example for the 
SMAD3,[39, 40] COL11A1,[41-43] and 
ALDH1A2[44] genes. 
 
Established osteoarthritis susceptibility 
loci. At present, based on genome wide 
significance in GWAS (p ≤5x10-8) and/or 
proven functional involvement in OA by 
follow-up studies, 21 independent OA 
susceptibility loci were established from 
candidate gene studies, linkage studies, and 
GWAS (Table 1A and reviewed in references 
31 and/or 45). As a comparison, in the first 
half of 2013 the number of loci known to 
predispose to other complex diseases such as 
type 2 diabetes and coronary heart disease 
were respectively 65[46] and 46.[47] For 
anthropometric traits such as body mass 
index (BMI), waist-hip ratio, and height the 
numbers of associated genetic loci identified 
in May 2013 were 36, 14, and 184, 
respectively.[48] Identified OA susceptibility 
loci resulted in a variety of compelling OA 
candidate genes, however, GWA studies also 
identified loci within gene deserts or within 
regions with multiple genes that have not yet 
been implicated in OA etiology.[35, 49] 
Multiple SNPs in a region can be in strong 
LD with each other (Table 1A), making it 
often challenging to determine the causal 
variant. This illustrates the typical problem in 
mapping complex traits and exposes the 
existing gap between genetic evidence and 
the molecular mechanism underlying the 
disease. In order to defeat these problems 
multiple molecular determinants (genetic, 
transcriptomic, proteomic, and epigenetic) 
will have to be integrated on a more regular 
base.[50, 51] Based on signals found to 
associate with hip OA Evangelou et al 
calculated that, together, the identified OA 
loci contribute only 2-3% to the heritability 
(H2) of hip OA.[37] Using the same formula 
that was used by Evangelou and that was 
described by Park and colleagues,[52] the 
overall heritability is estimated to be around 
13% based on the 17 independent OA 
susceptibility loci identified with GWAS 
(Table 1A below ‘Genome Wide Association 
Study’). This seemingly high percentage as 
compared to the H2 of hip OA alone is 
mainly explained by a few loci with larger 
odds ratios such as rs12907038 annotated to 
the ALDH1A2 gene and associated with 
hand OA, and rs7639618 located within 
DVWA or COL6A4P1 and associated with 
knee OA. However, as compared to the 39-
60% estimated from family-based studies it 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































development of OA remain to be identified. 
Given the fact that 21 established 
susceptibility loci were identified, the number 
of publications reporting on their functional 
follow-up is highly disappointing. In fact, to 
the best of our knowledge as by August 2014 
only 8 of the loci have been characterized in 
more detail following their identification 
(Table 1A). Some of the studies were aimed 
at determining the particular gene affected by 
the genetic variation.[75, 80] Other studies 
have determined the function of the gene 
expected to be targeted by the SNP,[37, 44, 
81] and several studies intended to determine 
the mechanism underlying OA susceptibility 
via the identified locus: either at the 
molecular level or at an organismal level. 
With respect to the latter, in particular 
Growth differentiation factor 5 (GDF5[63-
66]), Frizzled motif associated with bone 
development (FRZB[68-70]), and Deiodenase 
iodothyronine type 2 (DIO2[70, 72, 73]) have 
received full attention. 
Pathway analysis of the genes annotated to 
the OA susceptibility loci with the online 
Database for Annotation, Visualization and 
Integrated Discovery tool (DAVID[82]) 
shows enrichment for genes involved in limb 
development (Table 1B). Since several of the 
identified OA susceptibility genes encode for 
proteins involved in endochondral 
ossification during early development such as 
DIO2, FRZB, and GDF5 (see Figure 3), OA 
has been hypothesized to be an early 
developmental disease with late-life 
onset.[24] The developmental origin of OA is 
twofold: First, genes involved in 
endochondral ossification determine both 
composition of the bone and cartilage and 
the shape of the joint. While a suboptimal 
joint shape will make the tissues more prone 
to damage and thus to development of 
OA,[26] bone and cartilage strength 
determine the capacity to persist mechanical 
stresses. Secondly, the maturational arrested 
phenotype of articular chondrocytes is 
changed during OA and chondrocytes 
retrieve characteristics from hypertrophic 
growth plate chondrocytes.[83] Given this 
hypothesis, and thus the need to investigate 
early as well as late effects of genetic 
variation, the best would be to apply in vivo 
animal models in which developmental 
effects as well as late life effects can be 
studied, and where mechanical stresses can 
be applied in a controlled manner for 
example by using a running model. 
Alternatively, experiments can be performed 
in vitro to study genetic effects on 
chondrogenic potential of mesenchymal stem 
cells and matrix deposition of primary 
chondrocytes. 
 
BIOBANKING IN OA RESEARCH 
 
To achieve the aims of the work presented in 
this thesis and in general for OA research, 
the assembly of a biobank with relevant 
tissues stored tailored to isolate RNA and 
DNA, possibly also to make protein lysates 
 
Figure 3 OA susceptibility genes involved in 




for analysis by Western blotting, and to apply 
immunohistochemistry is required. In 
addition, the collection of relevant cell types 
(mesenchymal stem cells, chondrocytes, 
osteoblasts) would facilitate the setup of 
experimental cell models. Together, this will 
allow analyses at multiple molecular levels.  
Human genome wide gene expression 
datasets are available for OA cartilage from 
non-OA and OA-affected joints[84, 85] as 
well as from unaffected and affected cartilage 
areas of the same joints[86-88]), OA affected 
and unaffected subchondral bone,[89] and 
OA synovial membrane.[90] However, these 
are collected in different studies. Ideally, the 
different datasets should be derived from the 
same study group which could provide 
detailed information on the dynamics of gene 
expression profiles during OA 
pathophysiological processes and also include 
expression profiles of blood which would 
permit detection of biomarkers in the blood 
that reflect ongoing OA. Besides gene 
expression, RNA can also be used to study 
differential allelic expression of genetic 
variants. The isolated DNA can be used for 
genotyping and to perform whole genome or 
exome sequencing and to establish epigenetic 
patterns of the different tissues. 
For the studies performed in this thesis 
we used biomaterials of the ongoing RAAK 
study (Research Arthritis and Articular 
Cartilage), in which joint materials (cartilage 
of healthy and diseased (areas of the) joint, 
bone, and where available ligaments), 
mesenchymal stem cells (hip joints only), and 
primary chondrocytes of controls and 
patients undergoing joint replacement 
surgery in the Leiden University Medical 
Center and collaborating outpatient clinics in 
the Leiden area are collected. In addition to 
the RAAK study, studies were performed in 
the Genetics osteoARthritis and Progression 
(GARP) study. This study consists of sibling 
pairs with symptomatic and radiographic OA 
in at least two joints[91] and is tailored for 
molecular epidemiological research. Of all 
participants a complete collection of 
biomaterials such as DNA, RNA (blood), 
serum, plasma, and urine for biomarker 
detection is available in addition to extended 
clinical (X-rays, MRI) and demographic data 
in a follow-up design at 2 and 5 years. In 
parallel (including follow-up) data on 30 age-
matched controls without OA in the 
indicated joints has been collected, the so-
called NORREF study. 
 
To summarize, genetic studies have identified 
many OA susceptibility loci but most of the 
heritability is still missing. Several issues 
warrant further investigation. In the first 
place, treatment of OA is substantially 
impaired by its late diagnosis, and therapies 
would significantly benefit from the 
availability of biomarkers that can detect the 
disease at an early stage, monitor disease 
progression, and distinguish between 
different OA subtypes. Secondly, further 
insight into genetic factors causal to OA will 
increase insight into the etiology of OA. With 
respect to GWA studies, more severe 
selection of samples to decrease 
heterogeneity is required. Current availability 
of next generation sequencing is likely to 
contribute to the identification of genetic 
variants predisposing to OA. However, this 
will require cutting-edge study design and 
careful selection of samples. Thirdly, 
functional genomic research to generate 
biological understanding of genetic 
susceptibility beyond that of knowing the 
genomic location is lacking way behind the 




RATIONALE AND OUTLINE OF 
THIS THESIS 
 
In this thesis, we set out to characterize in 
detail the ongoing pathophysiological 
processes in arthritic cartilage within the 
RAAK study (chapter 2). Genome wide 
gene expression profiles were generated from 
OA affected and macroscopically intact 
cartilage of the same joint and gene 
enrichment analysis was performed to study 
the major pathways involved. Also genome 
wide expression profiles were determined 
from blood of patients with generalized OA 
from the GARP study and compared to 
those of healthy controls (chapter 3). Results 
were used to identify genes that may serve as 
biomarkers for OA, and overlap between 
both databases (cartilage and blood) was 
investigated in order to learn to what extent 
ongoing OA processes may be reflected in 
the blood. 
Although selection of biomarkers in OA 
is promising, the distinction between 
individual patients and controls is not yet 
possible due to relatively high inter-individual 
variation. Variation in basal levels of 
biomarkers may originate from genetic 
influences, and taking this variation into 
account by stratification for genotype or by 
using other biomarkers for persons with a 
specific genotype could improve the 
informativity of the biomarkers on OA onset 
and progression detection. Therefore, in 
chapter 4 we aimed at the identification of 
genetic loci affecting levels of the promising 
biomarkers serum COMP and urinary CTX-
II. Subsequently, we explored a meta-analysis 
of GWAS to determine whether any of the 
identified loci were associated to OA. 
To identify genetic loci associated with 
OA, 2 different approaches were taken. As 
an alternative to the ever increasing number 
of samples used in GWAS we investigated 
whether selection of OA patients with 
familial and relatively severe phenotype could 
be an alternative (chapter 5). This was done 
by investigating the GARP study, in which 
siblings were selected based on their relatively 
severe generalized OA phenotype. 
Furthermore, exome sequencing was done 
for 2 members of a family characterized by 
early-onset OA (chapter 6). By applying 
exome sequencing we aimed to identify a 
genetic variant with large effect that could 
hint towards general pathways involved in 
OA. Finally, in chapter 7, a 3-dimensional in 
vitro chondrogenesis method was set up that 
can be applied in functional genomic 
research. Here, it was used to functionally 
characterize the effects of variation in thyroid 
signaling during chondrogenesis as a model 
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Objective. Identify gene expression profiles associated with OA processes in articular 
cartilage and determine pathways changing during the disease process. 
Methods. Genome wide gene expression was determined in paired samples of OA 
affected and preserved cartilage of the same joint using microarray analysis for 33 
patients of the RAAK study. Results were replicated in independent samples by RT-
qPCR and immunohistochemistry. Profiles were analyzed with the online analysis 
tools DAVID and STRING to identify enrichment for specific pathways and protein-
protein interactions. 
Results. Among the 1717 genes that were significantly differently expressed between 
OA affected and preserved cartilage we found significant enrichment for genes 
involved in skeletal development (e.g. TNFRSF11B and FRZB). Also several 
inflammatory genes such as CD55, PTGES and TNFAIP6, previously identified in 
within-joint analyses as well as in analyses comparing preserved cartilage from OA 
affected joints versus healthy cartilage were among the top genes. Of note was the high 
up-regulation of NGF in OA cartilage. RT-qPCR confirmed differential expression for 
18 out of 19 genes with expression changes of 2-fold or higher, and 
immunohistochemistry of selected genes showed a concordant change in protein 
expression. Most of these changes associated with OA severity (Mankin score) but 
were independent of joint-site or sex.  
Conclusion. We provide further insights into the ongoing OA pathophysiological 
processes in cartilage, in particular into differences in macroscopically intact cartilage 
compared to OA affected cartilage, which seem relatively consistent and independent 
of sex or joint. We advocate that development of treatment could benefit by focusing 
on these similarities in gene expression changes and/or pathways. 
 
Keywords: osteoarthritis, gene expression profiling, cartilage, skeletal development 
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INTRODUCTION 
 
Osteoarthritis (OA) is a degenerative disease 
of the joints causing pain and disability for an 
increasing proportion of the population 
thereby imposing a large patient and socio-
economic burden [1,2]. Risk factors for OA 
include age, sex, joint injury, obesity, and 
mechanical stresses. In addition, 
predisposition to OA has a considerable 
genetic component and it has been proposed 
that OA can be viewed as a continuum 
resulting from the interaction between 
genetics affecting cartilage extracellular 
matrix composition and joint shape and 
sensitivity to the other factors mentioned 
[3,4]. Major efforts are made to identify loci 
associated with OA susceptibility to elucidate 
underlying mechanisms [5]. Treatment 
options to slow down or reverse the OA 
process are still very limited and at the time 
of diagnosis the damage is already 
irreversible. Together, this emphasizes the 
importance to increase insight into the 
disease process and to identify genes and 
pathways involved in development of OA. A 
way to achieve this is by investigating the 
pathophysiological processes in articular 
cartilage by means of gene expression 
analyses. 
Initially, expression profiles were 
established for cartilage from knee OA joints 
in comparison to healthy joints using only a 
limited number of genes [6]. More recently, 
exploratory genome wide expression 
profiling has been performed for the intact 
cartilage of hip and knee OA joints of 
patients undergoing joint replacement 
surgery compared to non-OA joints either 
derived from autopsies or from neck of 
femur fractures [7,8]. These studies showed 
that many genes involved in extracellular 
matrix (ECM) production as well as genes 
involved in ECM degradation or in 
inflammation were changed. Together, this 
resulted in significant enrichment for genes 
involved in skeletal development and 
response to external stimuli. Although studies 
that compare healthy cartilage with the 
preserved cartilage of joints from OA 
patients are very useful to acquire insight into 
the pathogenetic differences, the findings are 
likely biased by confounding factors such as 
innate differences, age, and stratification by 
joint. Moreover, due to the study design 
distinction between age-related changes and 
early or late changes of OA pathophysiology 
is hampered. 
One of the characteristics of OA is focal 
loss of articular cartilage, resulting in areas of 
degradation as well as areas with a relative 
preservation of cartilage thickness and 
appearance in the joint. Insight into gene 
expression specific for the focal areas of 
cartilage degradation compared to those in 
preserved areas can provide clues towards 
dynamic changes of genes and pathways 
involved in OA pathophysiology 
independent of confounding factors such as 
age. Gene expression profiles of cartilage 
from OA affected and macroscopically 
preserved areas of the same joint have been 
determined before, however, in most of these 
studies limited numbers of donors (4-5 knee 
joints) were included [9-11].  
As part of the ongoing Research Arthritis 
and Articular Cartilage (RAAK) study we set 
out to perform genome wide analysis of 
differential gene expression by comparing 33 
pairs of matched OA affected and preserved 
cartilage samples, originating from the same 
joint of patients that underwent total joint 
replacement of either hip or knee. Results 




disease processes in cartilage, in particular 
into differences in macroscopically intact 
cartilage compared to OA affected cartilage. 
 
 
MATERIALS AND METHODS 
 
Ethics statement. Participants of the 
RAAK study provided written informed 
consent. The ongoing RAAK study and its 
consent procedure is approved by the 
institutional ethics review committee 
(Commissie Medische Ethiek of the Leiden 
University Medical Center; protocol no. 
P08.239). 
 
Discovery cohort. The RAAK study is 
aimed at the biobanking of joint materials as 
well as mesenchymal stem cells and primary 
chondrocytes from patients and controls in 
the Leiden University Medical Center and 
collaborating outpatient clinics in the Leiden 
area. In the current study we used paired 
preserved and OA affected cartilage samples 
for 33 donors undergoing joint replacement 
surgery for primary OA (22 hips, 11 knees). 
Characteristics of the donors are shown in 
Supplementary Table S1. 
At the moment of collection (within 2 
hours following surgery) tissue was washed 
extensively with phosphate buffered saline 
(PBS) to decrease the risk of contamination 
by blood. Cartilage was classified 
macroscopically and collected separately 
from OA affected and preserved regions 
around the weight-bearing area of the joint 
(Supplementary Figure S1). Classification was 
done based on predefined features of OA 
related damage as described previously [9,10]: 
color/whiteness of the cartilage, surface 
integrity as determined by visible 
fibrillation/crack formation, and depth and 
hardness of the cartilage upon sampling with 
a scalpel. Care was taken to avoid 
contamination with bone or synovium. 
Collected cartilage was snap frozen in liquid 
nitrogen and stored at -80°C prior to RNA 
extraction.  
 
Validation and replication cohort. 
Validation was performed by RT-qPCR in 8 
sample pairs of the discovery cohort (3 knee 
and 5 hip) and for replication of the results 
we included 28 additional matched sample 
pairs (20 knee, 8 hip) of similar mean age 
(shown in Supplementary Table S1). 
Sampling procedures were according to the 
discovery cohort. 
 
RNA isolation. Cartilage samples were 
pulverized using a Retsch MM200 under 
cryogenic conditions. On average 150 mg of 
pulverized cartilage was dissolved in 1 ml of 
Trizol reagent, and mixed vigorously. After 
addition of 200 µl of chloroform the sample 
was mixed and centrifuged for 15 minutes 
(16,000 g). The clear aqueous layer was 
transferred to a new vial and 1 volume of 
70% ethanol/DEPC-treated water was added 
to precipitate RNA. RNA was collected using 
Qiagen mini columns according to the 
manufacturers protocol and quality was 
assessed using a Bioanalyzer lab-on-a-chip. 
RNA integrity numbers above 8 were 
considered suitable for microarray analysis. 
 
Microarrays. After in vitro transcription, 
amplification, and labeling with biotin-labeled 
nucleotides (Illumina® TotalPrep™ RNA 
Amplification Kit) Illumina HumanHT-12 v3 
microarrays were hybridized. Sample pairs 
were randomly dispersed over the 
microarrays, however each pair was measured 
on a single chip. Microarrays were read using 
2 
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an Illumina Beadarray 500GX scanner and 
after basic quality checks using Beadstudio 
software data were analyzed in R statistical 
programming language. Intensity values were 
normalized using the “rsn” option in the 
Lumi-package and absence of large scale 
between-chip effects was confirmed using 
the Globaltest-package in which the 
individual chip numbers were tested for 
association to the raw data [12]. After 
removal of probes that were not reliably 
detected (detection p>0.05 in more than 50% 
of the samples) a paired t-test was performed 
for the remaining 13277 probes comprising 
11421 unique genes on all sample pairs while 
adjusting for chip (to adjust for possible 
batch effects) and using multiple testing 
correction as implemented in the “BH” 
(Benjamini and Hochberg) option in the 
Limma-package. Analyses for differential 
expression between OA and healthy and 
between preserved and healthy cartilage was 
performed likewise, adjusting in addition for 
sex and for age. 
 
Quantitative reverse transcription PCR 
(RT-qPCR). 0.5 µg of total RNA was 
processed with the First Strand cDNA 
Synthesis Kit according to the manufacturer’s 
protocol (Roche Applied Science) and RT-
qPCR was performed for the 19 genes 
showing at least 2-fold expression differences 
in the microarray analysis (Taqman gene 
expression assays used are listed in 
Supplementary Table S2) using the 
BiomarkTM 96.96 Dynamic Arrays Fluidigm 
RT-qPCR platform [13]. Relative gene 
expressions were calculated with the 2-∆∆Ct 
method [14], using household gene Beta 
Actin (ACTB) expression as internal 
standard. 
 
Immunohistochemistry and staining 
analysis. For histological examination, joints 
were fixed using a 4% formaldehyde solution. 
Subsequently, samples were decalcified using 
a 10% EDTA solution and embedded in 
paraffin. Sections (5 µm) adjacent to the 
collected area were stained using hematoxilin 
and eosin (H&E) and toluidine blue. 
Immunohistochemistry was performed for 
SERPINE1 (mouse monoclonal antibody 
from American Diagnostica Inc.) without 
antigen retrieval and for CD55 (rabbit 
polyclonal antibody from Santa Cruz 
Biotechnology Inc.) with heat antigen 
retrieval (0,01M Citratebuffer pH=6.0) as 
described previously [15]. 
Quantification of OA related cartilage 
damage was scored by 2 observers (JVMGB 
and YFMR) according to Mankin et al [16]. 
Quantification of SERPINE1 expression was 
performed by scoring staining of 
chondrocytes in the superficial, middle, and 
deep cartilage layer with a score of 0 (no 
staining), 1 (moderate staining), or 2 (strong 
staining). Using Generalized Estimating 
Equations, scores were summed and used as 
a predictor variable with Mankin score as 
outcome whilst correcting for sex and age of 
each donor. 
 
Pathway analysis and protein-protein 
interaction. Gene enrichment among the 
1717 genes showing significant differential 
expression was performed with the Database 
for Annotation, Visualization and Integrated 
Discovery (DAVID) tool [17] selecting for 
biological processes identified in the Gene 
Ontology database (GOTERM_BP_FAT in 
the options menu implemented in DAVID), 
selecting for cell compartment 
(GOTERM_CC_FAT), or selecting for 




and using the microarray background 
(HumanHT-12_V3_0_R2_11283641_A). 
Pathways with p≤0.05 after correction for 
multiple testing according to Bonferroni were 
considered significant (Bonferroni 
corrections were performed by multiplying 
the raw P-values with the number of genes 
included in the analysis). 
Enrichment in protein-protein 
interactions among the significant genes was 
analyzed with the Search Tool for the 
Retrieval of Interacting Genes/Proteins 
(STRING) 9.0 [18] available online. 
 
Literature based candidate genes. Based 
on selected publications of genome wide 
association study meta-analyses [19-28] we 
investigated our expression dataset for 
evidence of differential gene expression of 





Differential expression between 
preserved and OA affected cartilage. To 
identify genes with changed expression in 
response to ongoing OA processes genome 
wide expression profiles were generated for 
preserved and OA affected cartilage of the 
same joint of 33 donors. Characteristics of 
the donors are shown in Supplementary 
Table S1. Males (N=13) and females (N=20) 
included in the study were aged between 54 
 
Table 1 Genes significantly differently expressed in OA affected cartilage. Shown are results of the 
microarray analysis (Discovery) and the replication for genes with at least 2-fold change (Dir: direction of 
effects relative to OA; FC: fold change).  
    DISCOVERY 
 
REPLICATION 
Gene Symbol Function FC Dir p   FC Dir p 
TNFAIP6 cartilage development 2.90 Up 4.40x10-8   4.01 Up 3.61x10-4 
CRLF1 immune response 2.97 Up 4.40x10-8   4.01 Up 8.09x10-6 
LEPREL1 cartilage development 2.37 Up 4.40x10-8   2.88 Up 9.49x10-4 
CD55 complement cascade 2.39 Up 4.40x10-8   3.00 Up 5.18x10-5 
RARRES2 immune response 2.26 Dn 6.06x10-8   3.32 Dn 1.23x10-4 
NGF neurogenesis 2.26 Up 3.36x10-7   4.54 Up 2.50x10-5 
FRZB bone development 2.54 Dn 1.28x10-6   3.04 Dn 4.39x10-4 
SERPINE1 complement cascade 2.40 Up 1.30x10-6   3.13 Up 1.54x10-4 
PTGES immune response 2.34 Up 1.46x10-6   3.29 Up 1.76x10-5 
SPP1 ECM-receptor interaction 2.53 Up 3.40x10-6   2.56 Up 7.05x10-3 
CXCL14 immune response 2.16 Up 3.54x10-6   4.97 Up 1.01x10-4 
TNFRSF11B bone development 2.10 Up 4.23x10-6   2.69 Up 6.58x10-4 
FN1 ECM-receptor interaction 2.31 Up 1.13x10-5   1.52 Up 3.28x10-2 
HBA2 oxygen transport 2.26 Up 2.02x10-5   2.97 Up 6.15x10-3 
HBB oxygen transport 2.00 Up 6.97x10-5   2.50 Up 1.69x10-2 
PAPPA wound healing 2.08 Up 7.69x10-5   2.25 Up 4.05x10-3 
CRISPLD1  -- 2.50 Dn 1.42x10-4   1.05 -- 7.54x10-1 
COL9A1 cartilage development 2.18 Dn 2.67x10-4   3.14 Dn 2.27x10-4 
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and 80 years (mean age: 66.2). In total, 22 
patients received a hip replacement and 11 
patients underwent total knee replacement. 
Among all OA joints included in this study 
(61 in total), 28 pairs were randomly selected 
to assess the Mankin scores of preserved and 
affected areas. Mankin scores were 
significantly higher in the samples 
macroscopically designated as ‘OA affected’ 
as compared to sections distinguished as 
‘preserved’ (mean Mankin score 7.8 vs. 4.7, 
respectively, p=4x10-4, paired t-test) and as a 
result gene expression differences can be 
directly linked to these differences in Mankin 
scores.  
After normalization and correction for 
multiple testing, significant differential 
expression between the OA affected and 
preserved cartilage was identified for 1893 
probes, representing 1717 unique genes 
(Supplementary Table S3A). Among the 1717 
unique genes 19 were differently expressed 
with fold-changes of 2 and higher (Table 1). 
Notably, 14 of these were up-regulated in 
OA as compared to preserved cartilage and 
only 5 were down-regulated. Overall, 748 
(44%) of the differentially expressed genes 
were up-regulated. Larger fold changes were 
observed in expression of genes well known 
for their association with OA cartilage such 
as tumor necrosis factor alpha-induced 
protein 6 (TNFAIP6 also known as TSG-6, 
2.9-fold up in OA cartilage; p=4.4x10-8), 
cytokine receptor-like factor 1 (CRLF1, 3-
fold up in OA cartilage; p=4.4x10-8), and 
Wnt-inhibitor frizzled related protein beta 
(FRZB, 2.5-fold down in OA cartilage; 
p=1.3x10-6). A notable gene highly up-
regulated in OA cartilage was neuronal 
growth factor (NGF, 2.3-fold up; p = 3.4 x 
10-7). 
Validation of the 19 genes with fold- 
changes of 2 or higher in 8 sample pairs used 
in the microarray analyses by means of RT-
qPCR showed similar effect sizes and 
directions as those found in the microarray 
analysis (Supplementary Table S4). 
Replication performed in an additional set of 
28 independent preserved and affected 
cartilage sample pairs also showed 
comparable effect sizes and directions and, 
except for cysteine-rich secretory protein 
LCCL domain-containing 1 precursor 
(CRISPLD1), all genes were significantly 
different expressed (Table 1). Individual 
expression boxplots of the replicated genes 
are shown in Supplementary Figure S2. 
Expression profiles of genes with fold-
changes of 2 and higher were analyzed for 
association with Mankin score as a grade of 
disease severity (Table 2). Almost all genes 
associated with Mankin score, except for 
COL9A1, HBA2 and HBB. To further 
characterize expression of the 19 genes with 
highest fold changes in OA affected cartilage, 
we investigated whether the observed 
changes were either joint or sex specific. As 
shown in Table 2, for most of the genes fold 
changes of the (joint or sex) stratified 
analyses were highly comparable and not 
statistically different from those of the 
discovery analysis. However, increased 
expression of pregnancy-associated plasma 
protein A (PAPPA) was significantly less 
pronounced in knee OA (1.3-fold increase) 
than in hip OA (2.6-fold increase). 
In addition to the gene expression 
profiles of preserved and OA affected 
cartilage, gene expression profiles were also 
generated for 7 healthy cartilage 
(characteristics of the donors are shown in 
Supplementary Table 1C) and explored for 
the 19 genes. For most of these 19 genes we 




healthy and preserved cartilage. However, 
when analyzing the trend of the differences 
between healthy, preserved and OA affected 
cartilage we did find a significant linear effect 
on the expression of most genes. In contrast, 
expression changes of CRISPLD1 and 
COL9A1 in healthy versus preserved 
cartilage were not significant and appeared to 
be increased while the expression in 
preserved versus OA affected cartilage was 
found to be decreased (Supplementary Figure 
S3A). 
 
Functional annotation of genes 
differently expressed in OA affected 
cartilage. To investigate whether the genes 
differently expressed between preserved and 
OA affected cartilage belonged to specific 
pathways, we used the online functional 
annotation tool DAVID. Seven GO-terms 
referring to 6 independent pathways were 
identified (Table 3). The most significant 
GO-term was observed for “skeletal system 
development”. This term captured several of 
the genes with fold-changes of 2 or higher 
(e.g. FRZB and TNFRSF11B). Furthermore, 
of note was the GO-term referring to 
“extracellular matrix organization” including 
decorin (DCN) and several collagens (e.g. 
COL1A2, COL2A1, COL3A1). When 
analyzing for enrichment using the cellular 
compartment option, most significant GO-
term was “extracellular matrix”, and 
analyzing for molecular function showed 
genes involved in “copper ion binding” and 
“glycosaminoglycan binding” to be 
significantly enriched (Table 3B and C).  
Among the 19 genes that were highly 
changed in OA affected cartilage (at least 2-
fold), 3 pathways were significantly enriched 
with lowest P-value for GO-term “response 
to wounding” (Table 3D), which included the 
genes TNFAIP6, SERPINE2, and CD55. 
When analyzing for interaction among 
proteins encoded by these genes using 
STRING, we found significant enrichment 
for protein-protein interactions (p=4.7x10-10) 
in which fibronectin-1 (FN1) seemed to play 
 
 
Figure 1. Protein-protein interaction between the genes with expression changes of at least 
2-fold (Table 1) as determined with STRING. 
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a central role considering that 6 of the 19 
proteins were found to relate to FN1 (Figure 
1). 
 
Immunohistochemical assessment of 
proteins encoded by genes identified in 
the microarray analysis. In addition to 
differential expression of proteins encoded 
by genes found in the microarray analysis, 
immunohistochemical (IHC) staining 
provides insight in expression pattern and 
localization of differentially expressed genes 
in the different cartilage layers. Therefore, as 
a proof of principal, IHC was performed for 
SERPINE1 and CD55. Figure 2 shows 
representative sections for the staining of 
preserved (P) versus OA affected cartilage, 
with Figure 2A and B showing an example of 
the H&E and Toluidine blue staining 
respectively (upper panel: 4x magnification, 
lower panel 20x magnification). 
Immunohistochemistry for SERPINE1 
showed that the protein is expressed in 
chondrocytes and differential expression 
between OA and preserved cartilage at the 
protein level was very pronounced (Figure 
2C). In OA affected cartilage, SERPINE1 
was not only expressed in the superficial 
layer, but also in the middle layer. In the 
most affected parts, we even observed 
SERPINE1 protein expression in 
chondrocytes residing in the deep zone. In 
addition, increasing matrix staining of 
SERPINE1 was observed with increasing 
OA affection state. We performed a 
quantification of the staining as described in 
Materials and Methods, and statistical analysis 
showed a significant difference between 
protein abundance in OA and preserved 
cartilage (p=2.4x10-4). The expression 
difference seemed to correlate mostly with 
toluidine blue staining, and thus with the 
level of proteoglycan constituents of 
chondromucin aggregates in the samples 
(p=2.9x10-9). CD55 protein expression was 
most pronounced in the superficial layer, 
with higher levels in the more OA affected 
zones of the cartilage, while hardly any CD55 
positive cells were detected in the deep layer 
(Figure 2D). The differences, however, were 
more subtle than for SERPINE1 and the 
range in the quantification did not allow for 
statistical analysis.  
 
Prioritization of genes residing in 
compelling genome wide association 
signals. In order to explore whether genes 
identified by genome wide association studies 
are active in cartilage and/or change in 
response to the OA process, we screened for 
differential expression of genes originating 
from recently published large scale meta 
analyses on OA (Table 4). Sixteen of the 29 
genes selected were well detected in the 
microarray (pdetection≤ 0.05) and from these, 8 
were significantly different between OA and 
preserved cartilage. Most genes showed only 
modest expression changes. Of note was 
differential expression of the HMG-box 
transcription factor 1 (HBP1) gene, identified 
in the Rotterdam study [23], which showed 






As part of the RAAK study we compared 
genome wide expression levels between 
preserved and OA affected cartilage of the 
same joint from 33 donors. Such a paired 
study design allows the detection of genes 
specifically involved in the OA 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Representative slides of 
immunohistochemical staining. A) H&E 
staining. B) Toluidine blue staining. C) 
SERPINE1. D) CD55 (magnification 20x; insets 
show larger overview at magnification 4x; white 
scale bars indicate 50 µm and 200 µm, 
respectively). The left panels show preserved 
cartilage area (P) and the right panels show the 
OA affected cartilage area (OA). 
 
inter-individual or age-related confounding 
factors as also reflected by the highly 
comparable differential gene expression 
patterns when stratifying according to joint 
and sex. After correction for multiple testing 
1717 unique genes showed significant 
differential expression, of which 19 genes 
had a fold-change of 2 or higher. In an 
independent paired cartilage sample set, 
differential expression was confirmed for 18 
genes by RT- qPCR. For most of these 
genes, except HBA2, HBB, and COL9A1, 
expression associated with disease severity as 
determined by scoring according to Mankin 
[16], and OA-associated increase in protein 
expression for 2 genes (CD55 and 
SERPINE1) was demonstrated by 
immunohistochemistry. 
We confirmed several genes previously 
identified in within-joint analyses for OA 
affected versus preserved cartilage as well as 
analyses comparing preserved cartilage from 
OA affected joints versus healthy cartilage 
such as the inflammatory genes CD55 [8], 
PTGES and TNFAIP6 [11]. This overlap is 
noteworthy since in our analysis considerably 
more samples were included. A large sample 
size increases power to detect replicable 
findings and allows detection of differences 
that were previously missed or more subtle. 
Our data thus indicate that at least a number 
of genes are consistently involved in the OA 
disease process despite the appreciated 
heterogeneous pathophysiology. Another 
gene present among the top genes and highly 
up-regulated in OA affected cartilage was the 
tumor necrosis factor receptor superfamily 
11b (TNFRSF11B) gene encoding 
osteoprotegerin. Very recently we reported 
for this protein on a gain of function 
mutation likely causal in a family with early 
onset OA with chondrocalcinosis [29]. In this 
respect, the up-regulated expression, could 
contribute to respective mineralization of the 
cartilage and eventually formation of bone, a 
major hallmark of the ongoing osteoarthritis 
disease process.  
Studies comparing intact cartilage with 
OA affected cartilage of the same joint allow 
detection of gene expression changes specific 
to the ongoing OA pathophysiological 
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Table 4 Gene enrichment analysis considering the biological processes option (GOTERM_BP_FAT 
option in DAVID) using the genes with at least 2-fold expression difference between OA affected and 
preserved cartilage. 
Term Count Pct Enr. p padj FDR 
GO:0009611~response to wounding 6 31.58 8.87 2.96E-04 5.63E-03 3.94E-01 
GO:0001501~skeletal system development 5 26.32 12.10 4.95E-04 9.40E-03 6.58E-01 
GO:0006954~inflammatory response 5 26.32 12.06 5.01E-04 9.51E-03 6.65E-01 
 
 
factors such as sex and age and joint as was 
also demonstrated by the highly comparable 
results of our stratified analysis. Identification 
of such genes commonly changing during 
OA independent of joint site or sex could be 
very useful with respect to drug 
development. On the other hand, differences 
identified between the intact cartilage derived 
from patients undergoing joint replacement 
surgery and healthy cartilage of independent 
joints are of a cross-sectional nature and 
provide information on innate differences 
among OA patients as well as genes changing 
during OA. Therefore, genes overlapping 
among the different studies may be of 
interest to better understand dynamic 
changes during onset and ongoing OA. A 
notable example was the expression of the 
COL9A1 gene that was higher in preserved 
as compared to healthy cartilage (3.6-fold), 
but was subsequently decreased in the OA 
affected cartilage (Supplementary Figure 
S3A). Although we acknowledge the fact that 
the included 7 healthy cartilage samples had a 
large age-range, our results are in line with 
the findings of Karlsson et al [8] and Xu et al 
[7] showing increased expression of COL9A1 
in cartilage from patients undergoing joint 
replacement surgery in comparison to healthy 
cartilage. This altered direction of effect in 
ongoing OA may explain the fact that 
COL9A1 was found not to be associated 
with Mankin score and suggests that it is 
mainly involved in the initial response of the 
chondrocyte to cartilage damage. Gene 
enrichment analyses performed with all 
significant genes showed especially that genes 
involved in the skeletal development were 
changed in OA affected as compared to 
preserved cartilage. Notably, this is in 
accordance with observations from Xu et al 
[7] who found enrichment of genes involved 
in skeletal development by comparing healthy 
cartilage versus cartilage of OA affected 
joints, suggesting that this is a pathway 
commonly affected in OA cartilage, both in 
the initiation phases as well as in ongoing 
OA. The fact that genes involved in skeletal 
development (e.g. FRZB and TNFRSF11B, 
but also OSTF1, FGFR3, and IGFBP3; 
Supplementary Table S3A) change during 
ongoing OA processes confirms the 
hypothesis that OA chondrocytes lose their 
maturational arrested phenotype, specific for 
articular cartilage, towards their end-stage 
differentiation, resembling growth plate 
during skeletal development [3].  
As reviewed by Barter and Young [30], 
gene expression differences in OA affected 
tissues may originate from changes in 
epigenetic control mechanisms. More 
recently, a comparison between the 
methylome of hip OA cartilage with cartilage 
of non-OA hips indeed showed more than 
5000 differentially methylated loci whereas 





pathways related to skeletal development [31] 
similar to the current and previous 
transcriptomic analyses [7]. Although direct 
association between such changes in DNA 
methylation and respective gene expression 
remains to be demonstrated, the skeletal 
developmental processes appear to 
consistently mark ongoing OA 
pathophysiology. 
Recently, a GWAS for hand OA 
identified a locus in the aldehyde 
dehydrogenase 1 family, member A2 
(ALDH1A2) gene [32]. Expression of 
ALDH1A2 was shown to be allele 
dependent and with decreased expression in 
OA affected cartilage. Despite this and other 
recent successes of genome wide association 
studies [23,27] a variety of the identified 
signals indicate chromosomal regions without 
obvious OA candidate genes or regions of 
high linkage disequilibrium with many 
relative unknown genes [23,27]. Here, we 
provide a means of exploring the overall 
expression and behavior during disease in 
cartilage. Although OA should be considered 
a ‘whole joint disease’ [2] and expression 
profiles of other OA affected joint tissues 
such as those performed recently in 
subchondral bone [33] are highly valuable, 
expression profiles in OA cartilage could 
serve as one of the selection criteria to 
prioritize genes for functional follow-up 
studies and research directed at 
understanding pathophysiological 
mechanisms of OA and drug design. In our 
cartilage dataset, we found differential 
expression for several of the genes, among 
which PAPPA was most significant 
(p=1.1x10-6), positionally localized in close 
neighborhood of one the arcOGEN genome 
wide hits: rs4836732 within the ASTN2 gene. 
The exact linkage disequilibrium across this 
locus needs to be further explored. We also 
found HBP1, at the chr7q22 locus, to be 
differently expressed, although with small 
effect size in the OA versus preserved 
comparison (1.1-fold higher in OA affected 
cartilage). When comparing diseased cartilage 
(OA affected as well as macroscopically 
intact cartilage) with healthy cartilage we 
observed a much stronger and opposite 
direction of effects: healthy versus OA and 
healthy versus preserved both showed 1.4-
fold lower expression in accordance with a 
previous study by Raine et al. showing 
increased expression of HBP1 in OA affected 
cartilage [34]. Given that HBP1 resides in the 
7q22 gene cluster [23] results mark this gene 
as most likely candidate for further functional 
follow-up investigations. 
Although MCF2L (MCF.2 cell line 
derived transforming sequence-like), a gene 
previously identified in GWA as an OA 
susceptibility gene [21], was not well-detected 
in the microarray analysis, the significant 
increased expression of neuronal growth 
factor (NGF) is worth mentioning in this 
respect. Neurotrophin-3 (NT3), another 
member of the NGF-family of proteins, 
enhances migration of premyelinating 
Schwann cells via Dbs/MCF2L [35], possibly 
implicating nociception in OA. Interestingly, 
antibodies generated against NGF or its 
receptor have been used successfully to treat 
OA patients and effectively reduced their 
pain [36]. The fact that NGF was not 
identified previously by comparing healthy 
with OA affected cartilage [7,8] suggests that 
NGF may be more specific for the “late” OA 
process. Alternatively, selection of druggable 
targets from early-responsive genes that start 
changing before damage is irreversible could 
be more eligible to effectively slow-down or 
stop the OA process. 
2 
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The sample collection is performed by 
well-trained lab personnel, however, we 
cannot exclude the possibility of minor 
contamination with bone tissue. In this 
respect, it is of note that several cartilage-
specific genes (e.g. decorin or DCN, collagen 
type 2 A1 (COL2A1), cartilage intermediate 
layer protein (CILP), and cartilage oligomeric 
matrix protein (COMP) were amongst the 
100 genes with highest levels of expression in 
 
Table 5 Genes identified in robust genome wide approaches with fold-changes and P-values for 
OA versus preserved cartilage (OA vs P). (Ref: reference, where indicated gene was published as OA 
susceptibility gene; FC: fold change; --: not detected on microarray). 
 
   OA vs P 
Gene Symbol Ref Joint published FC p 
ASTN2  [27] Hip&Knee  -- -- 
BCAP29  [23] Knee 1.1 1.7x10-2 
BTNL2  [25] Knee -- -- 
C6ORF130 [26] Hip&Knee 0.88 1.6x10-3 
CDC5L [27] Hip&Knee  -- -- 
CHST11 [27] Hip&Knee  -- -- 
COG5  [23] Knee 0.98 2.1x10-1 
COL11A1  [26] Hip&Knee 0.94 4.5x10-1 
DOT1L  [19] Hip -- -- 
DUS4L  [23] Knee -- -- 
DVWA [24] Knee -- -- 
FILIP1  [27] Hip&Knee  -- -- 
FTO [27] Hip&Knee  1.0 8.5x10-1 
GDF5 [20] Hip&Knee 1.1 4.3x10-2 
GLT8D1 [27] Hip&Knee  1.0 3.0x10-1 
GNL3  [27] Hip&Knee  1.1 4.6x10-2 
GPR22  [23] Knee -- -- 
HBP1  [23] Knee 1.1 2.0x10-3 
HLA-DQB1 [25] Knee -- -- 
KLHDC5  [27] Hip&Knee  1.0 4.8x10-1 
MCF2L  [21] Hip&Knee  -- -- 
MICAL3  [26] Hip&Knee -- -- 
NCOA3 [22] Hip 0.93 7.9x10-3 
PAPPA [27] Hip&Knee  2.1 1.1x10-6 
PRKAR2B  [23] Knee 1.0 9.9x10-1 
PTHLH  [27] Hip&Knee  1.4 1.8x10-3 
SENP6  [27] Hip&Knee  1.1 3.3x10-1 
SUPT3H [27] Hip&Knee  1.0 6.1x10-1 
TP63 [27] Hip&Knee  -- -- 




the dataset while no bone-specific genes (e.g. 
COL1A1, COL1A2, TNFRSF11B, and bone 
sialoprotein II or IBSP) were identified here. 
 
In conclusion, our results add to the insight 
into the ongoing pathological processes in 
OA cartilage by the identification of different 
gene expression patterns depending on OA 
severity as determined by Mankin score. This 
large scale analysis of joint-matched OA 
affected and preserved cartilage seems to hint 
at relatively consistent changes in gene 
expression during OA development. We 
think research and development of OA 
treatment could benefit by focusing on these 
similarities in gene expression changes 
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Supplementary Table S1. A) Characteristics of donors included in the microarray analyses. 
B) Characteristics of donors included in the replication. C) Characteristics of healthy donors 
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Supplementary Material Chapter 2 
Supplementary Table S2. Taqman probes used in the fluidigm RT-qPCR experiment. 
 
























Supplementary Table S3: can be downloaded from 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0103056 
 
A) Genes significantly different expressed between OA and preserved cartilage in microarray 
analysis of 33 paired OA affected and preserved samples (highlighted in yellow the genes that 
are significantly different in the healthy versus preserved cartilage comparison). B) Genes 




Large scale gene expression profiling of OA cartilage 
Supplementary Table S4. Results of the validation of the genes with at least 2-fold significant 
differential expression between OA affected and preserved cartilage in the microarray analyses 
(Dir: direction of effects; FC: fold change). 
 
  DISCOVERY   VALIDATION 
Gene Symbol FC Dir p   FC Dir p 
TNFAIP6 2.90 Up 4.40E-08   3.66 Up 3.00E-03 
CRLF1 2.97 Up 4.40E-08   2.60 Up 3.10E-02 
LEPREL1 2.37 Up 4.40E-08   2.61 Up 2.00E-02 
CD55 2.39 Up 4.40E-08   2.29 Up 1.33E-01 
RARRES2 2.26 Dn 6.06E-08   3.18 Dn 2.00E-02 
NGF 2.26 Up 3.36E-07   3.18 Up 9.20E-02 
FRZB 2.54 Dn 1.28E-06   2.59 Dn 5.60E-02 
SERPINE1 2.40 Up 1.30E-06   2.16 Up 1.70E-02 
PTGES 2.34 Up 1.46E-06   2.50 Up 5.10E-02 
SPP1 2.53 Up 3.40E-06   2.30 Up 6.80E-02 
CXCL14 2.16 Up 3.54E-06   6.52 Up 4.00E-03 
TNFRSF11B 2.10 Up 4.23E-06   1.86 Up 1.25E-01 
FN1 2.31 Up 1.13E-05   1.37 Up 3.36E-01 
HBA2 2.26 Up 2.02E-05   1.51 Up 4.28E-01 
HBB 2.00 Up 6.97E-05   1.69 Up 3.29E-01 
PAPPA 2.08 Up 7.69E-05   3.80 Up 5.60E-02 
CRISPLD1 2.50 Dn 1.42E-04   1.31 Dn 3.62E-01 
COL9A1 2.18 Dn 2.67E-04   2.35 Dn 9.50E-02 






Supplementary Material Chapter 2 
Supplementary Figure S1. Typical example of hip (A) and knee (B) joint with areas of 
macroscopically preserved (arrow head) and OA affected cartilage (arrow; white scale bars 
indicate 500 mm). Insets show detail of preserved (right) and OA affected area (left), in A 







Supplementary Figure S3. Relative changes in gene expression levels in preserved and OA 
affected cartilage relative to healthy cartilage for the 19 genes with at least 2-fold difference in 
the OA versus preserved analysis (note that the line does not imply continues changes given 
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Objective To identify novel gene expression networks in blood of osteoarthritis (OA) 
patients as compared to controls.  
Methods A comprehensive exploration of gene expression in peripheral blood was 
performed by microarray analysis (Illumina HT12_v3_BeadChips) for a subset of OA 
patients from the GARP study in comparison with sex- and age-matched healthy 
controls. To identify pathways, we performed gene enrichment analyses (DAVID and 
STRING). Quantitative PCR analysis in overlapping and in additional OA samples 
was performed for prioritized genes to validate and replicate findings. Classification of 
cases and controls was explored by applying statistical models.  
Results A total of 741 probes representing 694 unique genes were differentially 
expression between cases and controls, including 86 genes expressed with at least 1.5-
fold difference. ATF4, GPR18 and H3F3B were among the top genes identified 
(p<4.5x10-8). We found that in blood of OA patients the apoptosis pathway, including 
the well-known gene CASP3, was significantly enriched among the differentially 
expressed genes. Our findings were validated in independent samples and when using 
a small subset of the validated genes, we could accurately distinguish patients from 
controls (AUC=98%).  
Conclusions In the current study, we have identified specific gene expression 
networks, in the easily accessible tissue blood, that associated consistently to OA 
among GARP study cases. Our data further hint at the relevance of apoptosis as 
etiological factor in OA onset, thereby qualifying expression profiling of blood as 
useful tool to understand underlying molecular mechanisms of OA.  
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INTRODUCTION 
 
Osteoarthritis (OA) is a prevalent, complex, 
disabling disease affecting the articular joints. 
It has a considerable genetic component and 
the architecture is of a polygenic nature.[1] 
Currently, adequate therapies to reverse or 
slow down the disease apart from pain relieve 
are very poor[2] and joint replacement 
surgery at the end stage is commonly applied. 
Diagnosis of OA occurs not before changes 
in the joint tissues are visible on radiographs. 
Such changes, however, reflect irreversible 
damage. Sensitive markers to monitor early 
changes or changes in active disease are not 
yet available and little is known about the 
early molecular processes marking OA onset. 
Such insights however are important to 
prevent irreversible damage and are 
considered crucial for the development of 
effective disease modifying treatments.  
Initial genetic studies have resulted in a 
few consistent OA susceptibility genes, such 
as GDF5[3], FRZB[4], SMAD3[5], and 
DIO2[6]. Together, these genes denominated 
skeletogenesis as a common pathway that 
may be involved in OA susceptibility thereby 
contributing to the hypothesis that OA may 
have an early developmental origin that is 
expressed later in life.[7, 8] More recently, 
large consortia (such as TREAT~OA and 
arcOGEN) started compiling genome wide 
association (GWA) data on OA to perform 
powerful meta-analyses. These efforts have 
contributed to the discovery of a variety of 
genome wide significant signals in OA, some 
of which contained compelling OA candidate 
genes[9, 10] whereas other loci were found in 
gene deserts or in chromosomal regions with 
high linkage disequilibrium containing many 
genes without obvious candidates. These 
results point towards a typical problem in the 
genetic mapping of complex traits and 
expose the gap between genetic evidence and 
the underlying molecular mechanism of the 
disease. In addition, functional effects of 
genetic variation with a vast influence on 
many different biological processes but 
occurring at unknown (trans-acting) 
regulatory elements remain undetected. 
Extensive large scale exploration of gene 
expression networks may be more easily 
established by comparing well selected OA 
cases and controls in a readily accessible 
tissue, such as blood. Moreover, it could be 
advocated that such expression profiles in 
blood reflect genetic background 
predisposing to OA which could be 
undetectable in the affected cartilage tissue 
itself as a result of ongoing disease. 
Expression profiles in blood have 
successfully been used as molecular 
biomarker for classification of disease 
subgroups in other complex diseases.[11, 12] 
We set out to identify gene expression 
networks associated with OA by comparing 
single gene as well as pathway based blood 
expression profiles of 106 patients of the 
Genetics osteoARthritis and Progression 
(GARP) study, consisting of sibling pairs 
with symptomatic and radiographic OA in at 
least two joints, to those of 33 controls. 
Subsequently, we tested whether these 
specific OA signatures in blood reflected 
ongoing disease processes in articular 
cartilage or could discriminate patients from 
controls. Finally, we questioned whether the 
distinctive gene expression signature of blood 
could provide clues in the prioritization of 
OA susceptibility loci detected by large scale 







MATERIALS AND METHODS 
 
Study populations. The GARP study 
consists of 191 sibling pairs (N=382) of 
white, Dutch ancestry. All participants (age-
range: 40-70 years; mean age: 60 years) are 
clinically and radiographically diagnosed with 
primary, symptomatic OA (as defined by the 
American College of Rheumatology, ACR) at 
multiple joint sites in the hand, or in at least 
two joints of the following locations: hand, 
spine (cervical or lumbar), knee, or hip.[13] 
In this study, a subset of 106 (from which 68 
are unrelated individuals) participants of the 
GARP study was selected for gene 
expression analysis (‘Discovery Cohort’). OA 
patients were compared with age- and sex-
matched healthy controls without 
symptomatic and clinical OA according to 
ACR criteria. In addition, similar to 
participants of the GARP study, controls 
were subjected to radiographic examination 
at the indicated joints, and were free of signs 
of OA (KL<1) at the indicated joints except 
for 5 with KL≤2 at a single joint (Table 1). 
Technical validation of the microarray 
analysis was performed in a random selection 
of 28 of the 106 previous GARP participants 
(‘Validation Cohort’) in comparison to 25 of 
the controls, and validated genes were 
replicated in an additional set of 36 unrelated 
individuals of the GARP study (‘Replication 
Cohort’) in comparison to the same 25 
controls supplemented with 5 additional 
controls (characteristics of the study 
participants are shown in Table 1). 
For the comparison of our blood 
expression profiles with gene expression in 
cartilage we used the ongoing Research 
Arthritis and Articular Cartilage (RAAK) 
study, of which gene expression data is 
available for cartilage of 33 donors that 
underwent joint replacement surgery.[14] 
 
RNA isolation. Blood was collected and 
peripheral blood mononuclear cells (PBMCs) 
were separated with Histopaque® gradient. 
Cells were lyzed in 1 ml of TRIzol reagent 
(Life Technologies, Bleiswijk, The 
Netherlands), and stored at -80ºC until 
isolation. After thawing, 200μl of chloroform 
was added before centrifugation (15 min at 
16.000g). The aqueous upper layer was 
separated, 1 v/v 70% ethanol/DEPC-treated 
water was added, and total RNA was isolated 
with the RNeasy mini kit (Qiagen, Venlo, 
The Netherlands) following the 
manufacturer’s recommendations. To assess 
the RNA quality, 36 random samples were 
analyzed on the 2100 Bioanalyzer (Agilent 
Technologies, Amstelveen, The Netherlands) 
which had an RNA integrity number (RIN) 
of at least 8.3 and an average 28S/18S ratio 
of 2.2 (range: 1.8-2.7). The RNA 
concentration was measured using a 
Nanodrop spectrophotometer.  
 
Microarray analysis. For first- and second-
strand reverse transcription 500ng of total 
RNA served as a template. To perform 
cDNA synthesis, amplification, biotin 
labeling, and hybridization onto the 
microarrays the Ambion® TotalPrep™-96 
RNA amplification kit (Life Technologies, 
Bleiswijk, The Netherlands) was used 
according to the manufacturer’s protocol. 
After hybridization on Illumina Human HT-
12_v3_BeadChips (Illumina, Eindhoven, The 
Netherlands) slides were scanned with 
Illumina Beadscanner 500GX. 
Raw data from the beadscanner were 
prepared with GenomeStudio Software 
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(Gene Expression Module v1.0 from 
Illumina), without normalization or 
background substraction and with imputation 
of missing data. Quality control was 
performed in R statistical programming 
language using the lumi-package,[15] and 2 
out of 108 GARP samples analyzed on the 
Illumina BeadChips were excluded from the 
analysis based on their aberrant positions in 
the boxplot, the density plot, and the sample-
relation analysis. Subsequently, high quality 
data of 106 cases and 33 controls were 
prepared for analysis by applying robust 
spline normalization (rsn) and variance-
stabilizing transformation (vst). Differential 
expression between GARP-participants and 
healthy controls was analyzed using the 
limma-package for linear regression 
analysis,[16] correcting for sex, age, body 
mass index (BMI) and chip (to adjust for 
possible batch effects). The “BH” (Benjamini 
and Hochberg) option was used to correct 
for multiple testing. Probes with detection P-
values higher than 0.05 in more than 50% of 
the samples were not included in subsequent 
analysis. 
 
Pathway analysis. Gene enrichment was 
studied using either all significant 
differentially expressed genes (N=694 of 
which 619 were covered by the functional 
annotation algorithms in DAVID) or the 86 
genes (of which 76 were covered) showing an 
expression difference of ≥1.5 fold between 
OA patients and healthy controls. Pathway 
analysis was performed with the Database for 
Annotation, Visualization and Integrated 
Discovery (DAVID) tool,[17, 18] selecting 
for biological processes identified in the 
Gene Ontology database 
(GOTERM_BP_FAT in the options menu 
implemented in DAVID) and for the 
microarray background (HumanHT-
12_V3_0_R2_11283641_A). Genes with p 
≤0.05 after correction for multiple testing 
according to Bonferroni were considered 
significant. 
 
Analysis of protein interaction networks. 
To investigate protein interactions among the 
genes identified in our microarray, we used 
the Search Tool for the Retrieval of 
Interacting Genes/Proteins (STRING) 
9.0[19] available online (data are thus 
analyzed from source ‘previous knowledge’ 
which means it is derived from text-mining 
and therefore not all data are determined 
experimentally). With the option 
‘Enrichment’ we analyzed for enrichment of 
protein-protein interactions, and also ‘GO 
Biological Processes’ were analyzed with 
STRING. 
 
Quantitative RT-PCR analysis. 
Quantitative reverse transcription PCR (RT-
qPCR) was used to validate and replicate the 
results of the microarray analysis. Expression 
levels of 16 genes selected based on P-value 
and fold difference, and 14 genes involved in 
apoptosis, were determined in the ‘Validation 
Cohort’ (NGARP=28) and the ‘Replication 
Cohort’ (NGARP=36) with gene-specific and 
pre-validated Taqman® assays (Life 
Technologies, Bleiswijk, The Netherlands; 
Taqman assays are shown in Supplementary 
Table S1). Synthesis of cDNA using 1µg 
RNA was performed with the First Strand 
cDNA Synthesis Kit (Roche Applied Science, 
Almere, The Netherlands) following the 
manufacturer’s protocol. The cDNA was 
amplified using the DNA Engine Tetrad® 2 
Peltier Thermal Cycler (Bio-Rad, Veenendaal, 
The Netherlands) under standard PCR 




triplicate with the Taqman® method using 
BiomarkTM 96.96 Dynamic Arrays 
(Fluidigm). Relative gene expression was 
calculated using the average of the absolute 
threshold cycle values (Ct values) in the 2-ΔΔCt 
method,[20] and levels were normalized using 
the mean expression of two housekeeping 
genes (YKT6 and ACTB). Commercially 
available human total reference RNA 
(Clontech Laboratories, Mountain View, CA, 
USA) served as reference RNA. 
 
Statistical analysis of RT-qPCR data. 
Gene expression data were analyzed for 
normal distribution and, if necessary, log 
transformed before analysis in R statistical 
programming language using a generalized 
linear mixed model. P-values ≤0.05 were 
considered statistically significant. For 
technical validation, Spearman correlation 
between expression levels of the RT-qPCR 
and expression levels as determined using the 
microarrays were calculated with SPSS. 
 
Classification models. Classification 
models were constructed using multiple, 
penalized logistic regression.[21] Models were 
evaluated by a receiver operating 
characteristic (ROC) analysis using the Z-
scores of the expression for all genes and an 
area under the curve (AUC) criterion. 
Optimism in this procedure was controlled 
by applying leave-one-out cross-validation. 
 
Analysis strategy. Figure 1 shows a 
schematic overview of the study strategy. 
Following microarray analysis, data were 
statistically analyzed. Genes significantly 
different between patients and controls were 
subjected to pathway analysis with the 
DAVID tool. A selection of 30 genes (16 
selected based on P-value and fold difference 
and 14 selected from the apoptosis pathway) 
was used for technical validation of the 
results in the ‘Validation Cohort’, and 27 
genes passing this control were replicated in a 
group of independent participants of the 
Table 1. General information of the participants included in the analysis. A) Characteristics of samples 
included in the microarray analysis (‘Discovery Cohort’). B) Characteristics of samples included in the 
validation with RT-qPCR (‘Replication Cohort’). (Legend: F: females; M:males; ROA: radiographic OA; 
Pain: percentage of cases with pain according to the WOMAC-pain score; Pain>20: WOMAC pain-























ROA Hip (%) 3.0 42.5 
ROA Knee (%) 3.0 61.3 
ROA Hip&Knee (%) 0.0 22.6 
Pain/Pain>20 (%) 0/0 91.5/54.7 























ROA Hip (%) 3.0 27.8 
ROA Knee (%) 0.0 88.9 
ROA Hip&Knee(%) 0.0 25.0 
Pain/Pain>20 (%) 0/0 100/61.1 
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GARP study (the ‘Replication Cohort’). In 
addition, using a classification model 
expression of the 27 genes was used for OA 
prediction in the ‘Replication Cohort’. 
Gene expression data available from the 
microarray analysis were used as a reference, 
to search for OA susceptibility genes known 
from the literature on the one hand, and to 
look up the significant genes in a dataset of 
cartilage expression profiles available in our 





Gene expression profiles of PBMCs, 
accessible at GEO (Gene Expression 
Omnibus) public repository under the 
accession GSE48556, were generated from a 
subset of 106 participants of the GARP study 
(mean age: 61 years and mean BMI: 27 
kg/m2) and 33 sex- and age -matched healthy 
controls (mean age: 58 years and mean BMI: 
24 kg/m2; see Table 1A). For an overview of 
the steps taken in the analysis of the data, see 
Figure 1. 
 
Expression profiles of OA patients. In the 
microarray analysis we identified 741 probes 
comprising 15 non-coding RNA’s and 679 
unique genes (N=694 total) that were 
expressed significantly different between OA 
patients and healthy controls (Supplementary 
Table S2). From these, 89 probes (86 genes) 
differed at least 1.5-fold between patients and 
healthy controls (Table 2; for gene definitions 
see Table 4 or Supplementary Table S2) of 
which 46 were expressed higher in blood of 
 
 




OA patients (52%). The lowest P-value was 
found for ubiquitin conjugating enzyme E2L 
3 (UBE2L3; p=9.26x10-12), followed by 
activating transcription factor 4 (ATF4; 
p=4.14x10-8). Gene expression differences 
range from 2.6-fold higher as detected for G 
protein-coupled receptor 18 (GPR18; 
p=4.31x10-8) to 5.3-fold lower in OA patients 
for early growth response 1 (EGR1; 
p=2.13x10-2). 
 
Expression profiles of apoptosis-related 
genes significantly different in OA 
patients. To gain more insight in the 
pathways most predominantly involved in the 
differential expression, gene enrichment 
analysis was performed for all biological 
processes using DAVID. When analyzing all 
significant genes including those with 
relatively small differences (N=694), we 
identified 8 GO-terms comprising 5 different 
biological process that were significantly 
enriched: protein transport and localization 
(GO:0015031, GO:0045184, GO:0008104, 
GO:0046907), macromolecular complex 
subunit organization (GO:0034621), cell 
cycle (GO:0007049), RNA processing 
(GO:0006396), and apoptosis (GO:0006917; 
Table 3A).  
Gene enrichment analysis for the 86 
genes differing at least 1.5-fold (Table 2), 
showed significant enrichment specifically for 
networks involved in apoptosis (Table 3B). 
The majority of the genes involved in cell 
death (13 out of the 86 genes tested 
according to the DAVID analysis) showed 
higher expression in OA patients. Among 
these genes, we identified increased 
expression (1.6-fold) of the well-known 
apoptosis-inducing gene Caspase 3 (CASP3; 
p=8.94x10-4; Table 2). 
Using STRING, significantly more 
protein-protein interactions were detected 
between the 86 genes than expected based on 
chance (56 interactions total; p=1.05x10-5). 
Also the apoptosis pathway was found in 
STRING (p=5.49x10-2), which was visualized 
by virtue of the multiple interactions between 
proteins involved in this pathway (Figure 2). 
As shown, 6 out of the 13 proteins with 3 or 
more interaction-partners are involved in 
apoptosis. Apparent is also a cluster of 
histone-proteins (HIST1H3H, HIST1H2AC, 
and HIST2H2BE) involved in the above 
mentioned pathway ‘macromolecular 
complex subunit organization’.  
 
Validation and replication. To validate our 
results RT-qPCR was carried out. Genes 
were selected based on P-value and fold 
difference (N=16), or based on a possible 
role in apoptosis (N=14). Technical 
validation was performed in the ‘Validation 
Cohort’ (53 samples previously included in 
the microarray analyses). Here, 27 out of the 
30 genes tested showed similar effect sizes 
and direction as the original data 
(Supplementary Table S3). Next, we tested 
these 27 genes in the ‘Replication Cohort’ (36 
independent individuals of the GARP study 
as compared to 30 controls). In the unrelated 
GARP patients, 22 out of the 27 genes tested 
(82%) were significantly different (Table 4). 
Note that, except for the lunatic fringe gene 
(LFNG, indicated with a red asterisk), the 4 
genes that were not significant in the 
replication (indicated with a black asterisk) 
still had fold differences comparable to those 
as measured in the microarray analysis. 
 
Classification capability of differentially 
expressed genes. Figure 3A shows 
hierarchical clustering based on the 
correlation between the differentially 
3 
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expressed genes across the samples. 
Separation among OA patients and controls 
was quite good (more than 80%), although 
some patients were clustered among the 
healthy controls and vice versa.  
To investigate the possibility to use the 
set of validated genes (depicted in Table 4) 
eventually as a diagnostic tool, a classification 
model was constructed and tested, first in our 
‘Discovery Cohort’, and subsequently in the 
‘Replication Cohort’. As shown in Figure 3B 
and 3C, ROC curves of the baseline model 
containing sex, age, and BMI resulted in a 
fair discriminative capacity with an area 
under the curve (AUC) of 73% and 72%, 
respectively. However, when expression 
levels of the genes were added to the model 
the AUC increased to 95% and 97%, 
respectively, indicating an excellent 
classification of OA patients as compared to 
controls. According to our classification 
model expression of the serine/arginine-rich 
splicing factor 5 (SFRS5) gene contributed 
most in this model (data not shown). The 
possibility was examined to reduce our model 
to a smaller set of genes with which we could 
still obtain good classification between 
patients and controls, and we found a 
combination of 4 genes (SFRS5, together 
with CASP3, cyclin-dependent kinase 
inhibitor 2D (CDKN2D), and RAB GTPase-
binding effector protein 1 (RABEP1) with 
which we obtained ROC curves with 
excellent AUCs as high as 98% in the 
‘Replication Cohort’ (Figure 3C, dashed line). 
 
Dataset searches for genes differentially 
expressed in blood of OA patients. 
Differential gene expression profiles in blood 
of OA patients as compared to controls may 
either reflect different setpoints of innate 
systemic processes taking place in OA 
patients and/or it may indicate that blood 
could reflect pathological processes occuring 
specifically in joint tissues. To look into these 
possibilities we set out to assess the cartilage 
characteristics of the genes we identified as 
being differentially expressed in blood and 
we investigated both the levels of expression 
and their respective differential expression in 
cartilage of another study sample, namely the 
RAAK study. Within the RAAK study, a 
cartilage gene expression dataset is available 
in our laboratory.[14] The median relative 
gene expression level of these cartilage 
samples is 7.1 (range: 6.6-14.9) as measured 
on the microarrays. We found that 24 out of 
the 86 genes expressed with at least 1.5-fold 
difference in blood (depicted in Table 2), also 
showed nominal significant changes when 
comparing cartilage from macroscopically 
unaffected (preserved) with the 
corresponding OA affected sites. The median 
relative expression level of these genes was 
higher than the overall median level (8.6, with 
range: 7.2-11.5; data not shown). Additional 
selection for genes with expression changes 
in the same direction in cartilage and in blood 
resulted in 12 genes with fold changes 
ranging between 1.2 up- and 1.3 down in 
cartilage (Supplementary Table S4). It is of 
note that among these genes we found 
 
 
Table 2 (next page). List of genes significantly different expressed (≥1.5-fold difference). p: P-value 
after Bonferroni correction for multiple testing; Fold Diff: fold difference of individual probes in which 
values below 1 indicate a decreased expression in OA patients compared to healthy controls; 
Fnc.: function of the respective gene; TF= transcription factor, E= enzyme, R= receptor, H= histone 









  Fold 
Diff. 
 
Accession nr p Fnc. 
DECREASED EXPRESSION    
UBE2L3 NM_198157.1 9.26E-12 1.82 E 
ATF4 NM_001675.2 4.14E-08 2.07 TF 
H3F3B NM_005324.3 4.31E-08 2.19 H 
SNORD68 NR_002450.1 1.54E-07 1.76 O 
NFKBIA NM_020529.1 6.02E-06 1.75 TF 
IRF2BP2 NM_182972.2 7.74E-06 1.63 O 
DAB2 NM_001343.1 2.16E-05 1.68 O 
SFRS5 NM_006925.3 2.80E-05 1.87 O 
STK17B NM_004226.2 3.12E-05 1.63 E 
CDKN2D NM_079421.2 4.64E-05 1.62 E 
SFRS17A NM_005088.2 2.29E-04 1.55 O 
SFRS5 NM_006925.3 4.61E-04 1.70 O 
LOC338799 NR_002809.1 5.02E-04 1.70 O 
ABCA7 NM_019112.3 5.14E-04 1.52 O 
MAF NM_005360.3 8.94E-04 1.66 TF 
HS.333764 BG194895 1.18E-03 2.51 O 
FLJ45337 NM_207465.1 1.29E-03 1.76 O 
HS.578214 DA957648 1.45E-03 1.63 O 
HIST2H2BE NM_003528.2 2.38E-03 1.80 H 
MAX NM_145113.1 2.40E-03 1.52 TF 
USP36 NM_025090.2 4.60E-03 1.54 E 
LOC644422 XR_019449.1 4.60E-03 1.67 O 
LEPROT NM_017526.2 4.80E-03 1.59 O 
SNORD13 NR_003041.1 5.09E-03 1.96 O 
PPP1R15A NM_014330.2 5.12E-03 1.65 E 
NBPF10 NM_001039703.1 5.39E-03 1.81 O 
ACTN1 NM_001102.2 5.54E-03 1.55 O 
HS.534061 CR612552 5.54E-03 1.63 O 
NBPF20 NM_001037675.1 5.72E-03 1.93 O 
OSM NM_020530.3 6.78E-03 1.54 O 
HIST1H3H NM_003536.2 7.42E-03 1.96 H 
HIST1H2AC NM_003512.3 8.64E-03 1.78 H 








Accession nr Fnc. 
INCREASED EXPRESSION     
GPR18 NM_001098200.1 4.31E-08 2.62 R 
ZNF564 NM_144976.2 5.22E-08 1.59 TF 
LFNG NM_001040167.1 1.02E-07 1.79 E 
ADRB2 NM_000024.4 4.27E-07 2.23 R 
C16ORF72 NM_014117.2 4.27E-07 1.70 O 
PELO NM_015946.4 1.75E-06 1.65 E 
SIAH1 NM_001006610.1 2.64E-06 1.56 E 
HCP5 NM_006674.2 2.78E-06 1.76 O 
SLA NM_001045557.1 1.90E-05 1.68 O 
LCMT2 NM_014793.3 1.90E-05 1.52 E 
PLAGL2 NM_002657.2 2.18E-05 1.59 TF 
FAM43A NM_153690.4 2.26E-05 1.92 O 
STK39 NM_013233.2 5.81E-05 1.56 E 
USP24 NM_015306.1 1.49E-04 1.67 E 
BCDIN3D NM_181708.1 1.69E-04 1.51 E 
TINF2 NM_012461.1 1.83E-04 1.54 O 
PLEKHF1 NM_024310.4 2.67E-04 1.78 E 
AP3M1 NM_207012.2 2.79E-04 1.53 O 
TM2D3 NM_078474.2 3.11E-04 1.53 O 
CX3CR1 NM_001337.3 4.18E-04 1.71 R 
ZNF217 NM_006526.2 5.83E-04 1.53 TF 
PVRIG NM_024070.3 6.48E-04 1.53 R 
PPM1B NM_177968.2 7.02E-04 1.68 E 
CASP3 NM_032991.2 8.94E-04 1.59 E 
SLA NM_006748.1 1.19E-03 1.65 O 
NFE2L2 NM_006164.2 1.40E-03 1.51 TF 
ID3 NM_002167.2 1.48E-03 2.04 O 
RABEP1 NM_001083585.1 1.93E-03 1.75 E 
KCNJ2 NM_000891.2 2.01E-03 1.56 O 
RSBN1 NM_018364.3 4.98E-03 1.61 O 
CLK1 NM_004071.2 5.34E-03 2.26 E 
RNMT NM_003799.1 5.54E-03 1.59 E 
P2RY13 NM_023914.2 5.54E-03 1.53 R 
EBI2 NM_004951.3 5.72E-03 1.66 R 
BIRC3 NM_001165.3 8.02E-03 2.01 E 
EDG1 NM_001400.3 8.83E-03 1.52 R 
PTPN4 NM_002830.2 1.13E-02 1.60 E 
HSPA1B NM_005346.3 1.34E-02 1.68 O 
RAB22A NM_020673.2 1.43E-02 1.56 E 
ALS2CR13 NM_173511.2 1.61E-02 1.52 O 
PSMC6 NM_002806.2 2.39E-02 1.52 E 
FRYL NM_015030.1 2.53E-02 1.51 O 
CSE1L NM_001316.2 2.68E-02 1.50 R 
IL1B NM_000576.2 2.84E-02 1.76 C 
TGFBR3 NM_003243.2 3.41E-02 1.66 R 
EBI2 NM_004951.3 3.74E-02 1.63 R 
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(continued ‘genes with decreased expression’) 
VCL NM_003373.3 1.39E-02 1.59 O 
EGR1 NM_001964.2 2.13E-02 5.35 TF 
LIMS1 NM_004987.3 2.19E-02 1.77 O 
TNNC2 NM_003279.2 2.60E-02 1.56 O 
IL8 NM_000584.2 2.98E-02 3.07 C 
MGC13057 NM_032321.1 3.84E-02 1.64 O 
ATHL1 NM_025092.3 3.98E-02 1.81 E 
MMD NM_012329.2 4.19E-02 1.55 O 
MPL NM_005373.1 4.19E-02 1.78 R 
C7ORF41 NM_152793.2 4.97E-02 1.68 O 
 
 
SFRS5, the gene that contributed most to 
our prediction model in blood of OA 
patients. SFRS5 is highly expressed in 
cartilage (a relative expression of 11.5 is in 





In the current paper, we have established a 
distinctive gene expression profile of 694 
genes in blood of OA patients of the GARP 
study. Of these, 86 appeared to be expressed 
with at least 1.5-fold difference. The most 
significant gene, which was validated and 
replicated in unrelated samples, was ATF4 
(2-fold lower; p=4.14x10-8). Moreover, of 
note is the H3F3B gene that was significantly 
down-regulated in blood (2.17-fold; 
p=4.31x10-8) and in articular cartilage (1.15-
fold; p=2.05x10-3). Subsequent pathway 
analyses revealed that genes involved in 
apoptosis were significantly enriched in our 
expression profile and included the 
renowned, OA relevant, apoptosis-inducing 
gene CASP3 (p=8.94x10-4). In addition, 
protein-protein interactions appeared to be 
condensed around apoptosis-related genes 
and CASP3 for example was found to 
interact with the protein products of 6 other 
genes identified in the microarray analysis. 
The microarray platform was validated for 27 
out of 30 genes tested, providing high 
confidence in the data. When using these 27 
genes in a classification model a highly 
sensitive distinction between patients and 
healthy controls (AUC=97%) was reached. 
Finally, of the genes identified in our analysis, 
we found that 12 were also differentially 
expressed in cartilage and with the same 
effect directions. Expression of these genes 
in cartilage was higher than average, and 
especially SFRS5, an RNA splice factor 
contributing significantly to our classification 
model, was abundantly expressed in cartilage. 
It may not be surprising that we found 
relatively small overlap in the differentially 
expressed genes between OA cartilage and 
mononuclear blood cells of OA patients 
since gene expression in PBMCs can be the 
result of several processes. As mentioned by 
Attur et al.[22], blood cells passing through 
the different tissues of the joint may be 
activated by the OA process resulting in an 
‘inflammatory profile’, as found by Attur et al. 
in a subset of symptomatic knee OA patients, 
or, as found here, in an ‘apoptotic profile’. In 
most instances changes are subtle and we do 
not expect them to lead to a general pro-
inflammatory state or to direct apoptosis of 
the blood cells of the patients. However, this 
remains to be investigated. Alternatively, 
differential gene expression in PBMCs may 
reflect genetically determined dysregulation 
of processes.  
Our top gene ATF4 encodes a potent 





Indian hedgehog (IHH) expression during 
endochondral ossification.[23] Since we 
could not detect significant differential 
expression of ATF4 in our and other 
published articular cartilage datasets,[24-27] 
the difference in expression of ATF4 in 
blood might be a reflection of distinct innate 
characteristic of OA patients as compared to 
controls. In growth plate cartilage, where 
IHH ensures growth plate chondrocytes to 
proliferate, IHH is considered ‘a master 
regulator in the process of chondrogenesis 
and osteogenesis’.[28] Given the fact that 
ATF4 is significantly lower expressed in 
blood of OA patients, we hypothesize that, 
during endochondral ossification, the IHH 
levels may not optimally be assured resulting 
in suboptimal chondrocyte proliferative 
potential. Furthermore, these results support 
the hypotheses that late-onset OA could have 
a developmental origin.[7] 
By applying pathway analysis (Table 3) 
among the differentially expressed genes in 
blood of OA patients as compared to 
controls we showed enrichment of 
compelling apoptotic genes (e.g. CASP3 and 
FAS-associated death domain (FADD)) but 
also of genes less well-known for their 
involvement in the regulation of apoptosis 
(such as GPR18,[29] and SIAH1[30]). Apart 
from genetic and experimental evidence, the 
incidence of apoptosis/necrosis in OA 
cartilage is also supported by the observation 
of large numbers of empty lacunae and 
hypocellularity.[31-33] However, it remains 
to be established whether chondrocyte death 
is a cause or a consequence of OA.[34] Since 
the apoptotic pathway was not found to be 
significantly enriched in the cartilage specific 
gene expression dataset of the RAAK 
study,[14] we hypothesize that upon the 
occurrence of micro-traumas during life, 
 
Figure 2. Gene networks in STRING. Screenshot of the protein-protein interactions determined 
with STRING for the 89 genes differing at least 1.5-fold between patients and controls (disconnected 
proteins are hided). 
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Table 3. Gene enrichment analysis using DAVID. Biological processes significantly enriched when 
testing all significant genes (A) or 86 genes with an adjusted p ≤0.05 and ≥1.5 fold difference (B) in 
DAVID using gene ontology term GOTERM_BP_FAT (biological processes). Ngenes: number of genes 
in this GO-term; Pct.: percentage of genes from the total number of genes tested; p: P-value for 
enrichment in the indicated pathway; pcorr: P-value corrected for multiple testing; Fold Enr.: fold 
enrichment of the indicated pathway. 
A 
GO-Term Ngenes Pct. p pcorr Fold Enr. 
GO:0015031~protein transport 51 8.24 1.22E-05 8.31E-03 1.91 
GO:0045184~establishment of protein localization 51 8.24 1.61E-05 1.09E-02 1.89 
GO:0034621~cellular macromolecular complex subunit organization 30 4.85 2.36E-05 1.60E-02 2.39 
GO:0008104~protein localization 55 8.89 3.95E-05 2.68E-02 1.78 
GO:0007049~cell cycle 50 8.08 4.60E-05 3.13E-02 1.83 
GO:0006396~RNA processing 39 6.30 4.87E-05 3.31E-02 2.02 
GO:0046907~intracellular transport 44 7.11 6.18E-05 4.19E-02 1.90 
GO:0006917~induction of apoptosis 27 4.36 7.06E-05 4.79E-02 2.38 
 
B 
GO-Term Ngenes Pct p pcorr Fold Enr. 
GO:0008219~cell death 13 17.11 8.52E-05 7.33E-03 3.88 
GO:0012501~programmed cell death 12 15.79 8.92E-05 7.67E-03 4.22 
GO:0016265~death 13 17.11 9.11E-05 7.83E-03 3.85 
GO:0006915~apoptosis 11 14.47 3.69E-04 3.18E-02 3.93 
 
systemic factors present in blood may 
contribute to the onset of apoptosis in the 
joint cells, eventually leading to irreversible 
damage and subsequent onset of OA. 
Among the differentially expressed genes, 
we also found cytokines such as IL1B (up-
regulated) and IL8 (down-regulated) that 
were identified previously in a study with 
peripheral blood cells of knee OA 
patients.[22] Both proteins showed a 
considerable fold change in our analysis (1.8 
and 3, respectively), and had a considerable 
number of interacting partners in the 
network analysis (6 and 7, respectively) 
suggesting that expression changes are likely 
to have a substantial impact on cellular 
processes including apoptosis. Also MAFB 
and EGR1, identified previously as 
biomarkers in blood expression profiles of 
patients with mild knee OA[35] were 
differentially expressed in our dataset. Taken 
together, the overlap between our analysis 
and other studies confirms that OA specific 
gene expression profiles of PBMCs exists. 
Besides the overlap we find differences as 
well most likely due to the fact that patients 
with generalized OA in at least 2 joints were 
included, comprising knee OA, but also OA 
at other joints (hip, hand, and/or spine). In 
addition, it was found previously that 
different subgroups of OA patients exist,[22] 
that differ in their gene expression profiles. 
We showed that 4 of the genes identified 
in our analysis (CASP3, CDKN2D, RABEP1, 
and SFRS5), were sufficient to accurately 




Table 4. Genes replicated by RT-qPCR. Expression of genes was determined by RT-qPCR on the 
fluidigm platform for 36 participants of the GARP study and 30 healthy controls (*: indicates genes that 
were not significantly different in the replication; Fold Diff: fold difference, relative to OA). 
 
    
ARRAY  REPLICATION 
Gene 
SYMBOL Annotated Gene p Fold Diff.  p Fold Diff. 
ATF4 activating transcription factor 4 (tax-responsive enhancer element B67; transcript variant 1) 4.14E-08 0.48  3.59E-04 0.67 
H3F3B * H3 histone, family 3B (H3.3B) 4.31E-08 0.46  2.82E-01 0.95 
GPR18 G protein-coupled receptor 18 (transcript variant 2) 4.31E-08 2.62  1.63E-02 1.39 
ZNF564 zinc finger protein 564 5.22E-08 1.59  1.65E-05 1.91 
ZNF20 zinc finger protein 20 9.14E-08 1.35  4.11E-06 1.96 
LFNG * LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase (transcript variant 1) 1.02E-07 1.79  2.14E-01 0.76 
RIPK1 receptor (TNFRSF)-interacting serine-threonine kinase 1 4.27E-07 1.38  4.08E-03 1.16 
ADRB2 adrenergic, beta-2-, receptor, surface 4.27E-07 2.23  3.40E-02 1.25 
PELO pelota homolog (Drosophila) 1.75E-06 1.65  1.92E-04 1.50 
SIAH1 seven in absentia homolog 1 (Drosophila) (transcript variant 2) 2.64E-06 1.56  4.41E-06 2.60 
NFKBIA * nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 6.02E-06 0.57  3.14E-01 0.70 
SLA Src-like-adaptor (transcript variant 2) 1.90E-05 1.68  4.22E-03 1.19 
SFRS5 splicing factor, arginine/serine-rich 5 (transcript variant 2) 2.80E-05 0.54  9.85E-08 0.56 
CDKN2D cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) (transcript variant 2) 4.64E-05 0.62  5.75E-04 0.65 
PLEKHF1 pleckstrin homology domain containing, family F (with FYVE domain) member 1 2.67E-04 1.78  1.42E-03 1.69 
CASP3 caspase 3, apoptosis-related cysteine peptidase, transcript variant beta 8.94E-04 1.59  2.96E-04 1.59 
ID3 * inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 1.48E-03 2.04  5.06E-01 3.86 
RABEP1 rabaptin, RAB GTPase binding effector protein 1 (transcript variant 2) 1.93E-03 1.75  1.91E-03 1.79 
FADD Fas (TNFRSF6)-associated via death domain 3.20E-03 1.44  1.16E-02 1.33 
PPP1R15A protein phosphatase 1, regulatory (inhibitor) subunit 15A 5.12E-03 0.61  4.51E-05 0.42 
CLK1 CDC-like kinase 1 5.34E-03 2.26  2.65E-02 1.25 
OSM oncostatin M 6.78E-03 0.65  2.06E-03 0.31 
GSTM2 glutathione S-transferase M2 (muscle) 6.97E-03 0.80  5.06E-03 0.57 
EGR1 early growth response 1 2.13E-02 0.19  4.10E-04 0.33 
IL1B * interleukin 1, beta 2.84E-02 1.76  6.40E-02 1.77 
IL8 interleukin 8 2.98E-02 0.33  4.43E-05 0.27 
E2F2 E2F transcription factor 2 3.48E-02 1.44  6.34E-03 1.48 
 
the ‘Discovery Cohort’, but also in the 
‘Replication Cohort’. The classification 
models computed in our analysis combined 
clinical risk factors with expression levels of 
genes. In this way, cross-validated AUCs 
reached values as high as 98%. The AUC has 
the interpretation of a concordance index, 
meaning that the AUC represents the chance 
that for any case-control pair a higher disease 
probability is correctly predicted for the case. 
Therefore, when confirmed in independent 
cases 98% is a clinically relevant value. 
Moreover, expression levels represent risk 
independent of clinical variables (98% vs. 
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72%). It should be noted however that our 
study has a cross sectional design. As a result, 
the ROC curves merely indicate classification 
(diagnosis) but not prediction, and the result 
remains to be tested in independent study 
cohorts. Predictive value needs to be assessed 
and validated in a longitudinal study design. 
In addition, it remains to be investigated 
whether CASP3, CDKN2D, RABEP1, and 
SRFS5 would be useful as early markers, to 
diagnose OA in a population based setting.  
Although the results presented in this 
paper appear very convincing and are in 
agreement with previous studies, it should be 
mentioned that a draw-back of our analyses 
was the fact that the majority of the controls 
(25 of the 33 used) across our validation and 
classification model were overlapping with 
the controls used in our microarray analysis. 
As a result, part of our data could be based 
merely on the severe selection of controls 
(clinically and radiographically confirmed 
healthy joints at age ~60 years) marking 
rather a healthy blood expression profile 
instead of presence of OA. The latter could 
be explored further by replication using 
population based controls. Also, our 
‘Discovery Cohort’ included 38 siblings 
which will have contributed to the robustness 
of the results. However, differential 
expression of 22 out of 27 genes has been 
confirmed by RT-qPCR in the ‘Replication 
Cohort’ consisting in independent cases 
(Table 4), and results of the analysis including 
only the probands of the ‘Discovery Cohort’ 
are generally comparable (data not shown). 
As shown in Table 1, most participants 
suffered from pain due to OA (92%) and 
more than half of our cases were using 
NSAIDs (52%). Adjusting for these 
phenotypes did not significantly affect our 
results (data not shown). It is of note that in 
this study mainly females were included. 
Therefore, although we have adjusted for 
gender we cannot exclude the possibility that 
results are more applicable to females. It 
would be interesting for future research to 
investigate whether sex-differences exist for 
gene expression profiles in PBMCs of OA 
patients. Finally, despite various efforts, we 
were not able to validate by RT-qPCR the 
observed highly significant differential 
expression of UBE2L3 as detected by the 
microarray expression (Table 2).  
 
Taken together, this study in patients with 
generalized OA in a familial background 
provides a valuable tool for a better 
understanding of the pathology of this 
complex disease and for the classification of 
OA. In addition, the gene networks may 
facilitate selection of targets for drug 
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Figure 3. Clustering and classification of the study population. A) Clustering of OA patients of 
the GARP study (N=106; indicated in red in dendrogram) and age-matched healthy controls (N=33; 
indicated in green in dendrogram) based on euclidean distance. Each row represents a probe (N=89), 
and each column represents the expression of the probes for an individual (range from bright red 
[expression in OA higher than control mean] to bright green [expression in OA lower than control 
mean]). B) Receiver operating curve (ROC) for the ‘Discovery Cohort', based on sex, age, and bmi 
alone (dotted line) or with the inclusion of the 27 validated genes (black line) or 4 genes (CASP3, 
SFRS5, RABEP1, and CDKN2D; dashed line) in our classification model. C) ROC as in B, for the 
‘Replication Cohort’ (AUC: area under the curve). 
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Supplementary Table S1. Taqman assays used for RT-qPCR. 
 
Gene Symbol Taqman assay Assay Type 
ACTB Hs99999903_m1 inventoried 
ADRB2 Hs00240532_s1 inventoried 
ATF4 Hs00909569_g1 inventoried 
BIRC3 Hs00154109_m1 inventoried 
CASP3 Hs00234387_m1 inventoried 
CDKN2D Hs00176481_m1 inventoried 
CLK1 Hs00269734_m1 inventoried 
E2F2 Hs00231667_m1 inventoried 
EGR1 Hs00152928_m1 inventoried 
FADD Hs04187499_m1 inventoried 
GPR18 Hs01921463_s1 inventoried 
GSTM2 Hs03044640_gH made to order 
H3F3B Hs00287906_s1 inventoried 
ID3 Hs00171409_m1 inventoried 
IL1B Hs01555410_m1 inventoried 
IL8 Hs00174103_m1 inventoried 
LFNG Hs00385436_g1 inventoried 
NFKBIA Hs00153283_m1 inventoried 
OSM Hs00171165_m1 inventoried 
PELO Hs00560251_g1 inventoried 
PLEKHF1 Hs00759096_s1 inventoried 
PPP1R15A Hs00169585_m1 inventoried 
RABEP1 Hs00388983_m1 inventoried 
RIPK1 Hs00169407_m1 inventoried 
SFRS5 Hs00951031_m1 inventoried 
SIAH1 Hs00361785_m1 inventoried 
SLA Hs00277129_m1 inventoried 
STK17B Hs00892456_m1 inventoried 
UBE2L3 Hs00748530_s1 inventoried 
YKT6 Hs00559914_m1 inventoried 
ZNF20 Hs00397296_m1 inventoried 
ZNF564 Hs00793693_g1 inventoried 
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Supplementary Table S2. List of all significant probes can be downloaded from 
http://ard.bmj.com/content/73/10/1844.full 
 
P-value and fold difference of the 741 significant probes (694 unique genes) that were 






Supplementary Table S4. Genes significantly different expressed between OA and 
preserved cartilage. Depicted are genes significantly different expressed with OA in blood 
(patients versus healthy controls) and in cartilage (OA versus preserved; Fold Diff.=fold 
difference; AveExpr means the average relative gene expression as determined with the 
microarray analysis). 
 




Diff. AveExpr   p 
Fold 
Change AveExpr 
H3F3B 4.31E-08 0.46 9.18   2.05E-03 0.87 9.83 
NFKBIA 6.02E-06 0.57 11.45   6.79E-03 0.91 11.14 
DAB2 2.16E-05 0.59 7.89   4.99E-02 0.90 9.80 
FAM43A 2.26E-05 1.92 8.15   1.13E-02 1.15 8.39 
AP3M1 2.79E-04 1.53 8.85   5.00E-03 1.11 8.60 
SFRS5 4.61E-04 0.59 10.99   3.81E-02 0.93 11.47 
LOC338799 5.02E-04 0.59 7.65   6.14E-04 0.88 7.65 
MAF 8.94E-04 0.60 8.50   2.98E-03 0.83 9.23 
MAX 2.40E-03 0.66 7.99   2.63E-03 0.95 7.23 
ATHL1 3.98E-02 0.55 8.44   2.39E-02 0.91 8.00 
MPL 4.19E-02 0.56 8.17   2.82E-02 0.95 7.22 







Microarray analysis from blood link OA to apoptosis 
Supplementary Table S3. Genes technically validated by RT-qPCR. Expression of genes 
was determined by RT-qPCR on the fluidigm platform for 28 participants of the GARP study 
and 25 healthy controls analyzed in the microarray. Genes that were not significantly different 
in the validation are indicated with an asterisk and these were not included in further analysis. 
Spearman correlation values and P-values are shown (corr.Spear and pSpear respectively), Fold 
Diff.= fold difference, relative to OA. 
 






Diff. corr.Spear. pSpear. 
UBE2L3 * 9.26E-12 0.55  2.42E-01 1.56 -0.36 7.36E-03 
ATF4 4.14E-08 0.48  3.59E-04 0.81 0.48 2.42E-04 
H3F3B 4.31E-08 0.46  2.82E-01 0.57 0.70 5.09E-09 
GPR18 4.31E-08 2.62  1.63E-02 1.36 0.59 3.86E-06 
ZNF564 5.22E-08 1.59  1.65E-05 1.40 0.34 1.20E-02 
ZNF20 9.14E-08 1.35  4.11E-06 1.83 0.69 9.03E-09 
LFNG 1.02E-07 1.79  2.14E-01 1.46 0.68 3.04E-08 
RIPK1 4.27E-07 1.38  5.16E-02 1.24 0.27 4.80E-02 
ADRB2 4.27E-07 2.23  3.40E-02 1.75 0.75 9.82E-11 
PELO 1.75E-06 1.65  1.92E-04 2.00 0.68 1.92E-08 
SIAH1 2.64E-06 1.56  9.02E-08 1.50 0.51 1.10E-04 
NFKB1A 6.02E-06 0.57  9.56E-02 0.64 0.56 1.39E-05 
SLA 1.90E-05 1.68  4.22E-03 1.68 0.59 2.81E-06 
SFRS5 2.80E-05 0.54  9.85E-08 0.30 0.81 1.77E-13 
STK17B * 3.12E-05 0.61  5.33E-01 0.90 0.15 2.72E-01 
CDKN2D 4.64E-05 0.62  4.37E-01 0.91 0.56 1.53E-05 
PLEKHF1 2.67E-04 1.78  7.50E-09 2.46 0.73 4.50E-10 
CASP3 8.94E-04 1.59  2.27E-01 1.23 0.60 2.30E-06 
ID3 1.48E-03 2.04  5.06E-01 3.00 0.88 6.91E-18 
RABEP1 1.93E-03 1.75  3.01E-01 1.37 0.67 3.75E-08 
FADD 3.20E-03 1.44  1.15E-09 2.36 0.62 6.51E-07 
PPP1R15 5.12E-03 0.61  1.15E-03 0.53 0.72 1.04E-09 
CLK1 5.34E-03 2.26  2.65E-02 1.26 0.87 3.75E-17 
OSM 6.78E-03 0.65  1.12E-01 0.40 0.57 9.91E-06 
GSTM2 6.97E-03 0.80  5.06E-03 0.83 0.64 1.99E-07 
BIRC3 * 8.02E-03 2.01  7.78E-01 0.92 0.82 1.08E-13 
EGR1 2.13E-02 0.19  4.10E-04 0.16 0.92 9.07E-19 
IL1B 2.84E-02 1.76  2.63E-01 1.28 0.83 2.88E-14 
IL8 2.98E-02 0.33  4.43E-05 0.04 0.89 2.87E-16 
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Meta-analysis identifies loci affecting levels of the potential OA biomarkers 
sCOMP and uCTX-II with genome wide significance 
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Background Research for the use of biomarkers in osteoarthritis is promising, 
however, adequate discrimination between patients and controls may be hampered due 
to innate differences. We set out to identify loci influencing levels of serum cartilage 
oligomeric protein (sCOMP) and urinary C-telopeptide of type II collagen (uCTX-II). 
Methods Meta-analysis of genome-wide association studies (GWAS) was applied to 
standardized residuals of sCOMP (N=3,316) and uCTX-II (N=4,654) levels available in 
respectively 6 and 7 studies from TreatOA. Effects were estimated using a fixed-effects 
model. Six promising signals were followed-up by de novo genotyping in the CHECK 
study (N=964). Subsequently, their role in OA susceptibility was investigated in large-
scale GWAS meta-analyses for OA. Differential expression of annotated genes was 
assessed in cartilage. 
Results Genome-wide significant association with sCOMP levels was found for a SNP 
within MRC1 (rs691461, p=1.7x10-12) and a SNP within CSMD1 associated with 
variation in uCTX-II levels with borderline genome-wide significance (rs1983474, 
p=8.5x10-8). Indication for association with sCOMP levels was also found for a locus 
close to the COMP gene itself (rs10038, p=7.1x10-6). The latter SNP was subsequently 
found to be associated with hip OA whereas COMP expression appeared responsive to 
the OA pathophysiology in cartilage. 
Conclusions We have identified genetic loci affecting either uCTX-II or sCOMP levels. 
The genome wide significant association of MRC1 with sCOMP levels was found likely 
to act independent of OA-subtypes. Increased sensitivity of biomarkers with OA may 
be accomplished by taking genetic variation into account. 
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INTRODUCTION 
 
Osteoarthritis (OA) is a prevalent, complex, 
disabling disease affecting articular joints. 
Age and unfavorable metabolic states, for 
example high BMI, are strong risk factors of 
OA,[1] however, development of OA is also 
determined by a considerable genetic 
component of a polygenic nature.[2] 
Commonly, OA is diagnosed clinically and 
radiographically at a stage in which joint 
damage is already significant, and non-
surgical therapies to cure or halt progress of 
OA are not yet available. Research directed 
to identify clinical biochemical markers to 
sensitively monitor OA disease activity in an 
individual over time or to assess quantitative 
joint tissue remodeling is currently in 
progress.[3-6] So far, these studies have 
suggested that serum cartilage oligomeric 
protein (sCOMP), and urinary C-telopeptide 
of type II collagen (uCTX-II) are promising 
candidates and they are listed among the 
biomarkers that were recommended to focus 
on in future research efforts.[4]  
Initially, both sCOMP and uCTX-II were 
considered as markers for cartilage 
degradation: sCOMP would be representative 
of cartilage turnover, and uCTX-II is a 
collagen type II cleavage product 
representative of hyaline (articular) cartilage 
degradation. However, some reports indicate 
that uCTX-II may not merely be a cartilage 
specific marker but rather a reflection of joint 
tissue remodeling including calcified cartilage 
and subchondral bone.[7, 8] Moreover, 
Meulenbelt et al[9] showed that in patients 
with generalized OA uCTX-II is a sensitive 
marker of whole body cartilage degeneration 
as reflected by radiographic signs of OA but 
association with a specific joint site could not 
be demonstrated. This was recently 
confirmed in a large-scale meta-analyses 
showing that uCTX-II associated with risk 
for hand, knee, and hip OA.[10] In addition, 
the analyses showed that both, sCOMP as 
well as uCTX-II, can be useful to monitor 
OA disease activity. However, the study also 
highlighted that the use of sCOMP and 
uCTX-II as biomarkers in the clinic still 
remains largely unsatisfactory. 
Importantly, investigations have shown 
that in subjects with familial OA at multiple 
joint sites besides clustering of sCOMP 
together with hand OA and with age, 
sCOMP has a high familial aggregation.[8, 
11] At present, little is known about genetic 
variants affecting basal levels of sCOMP and 
uCTX-II. Identification of genes that 
contribute to these levels may provide 
mechanistic insight into factors that influence 
cartilage tissue turnover, dependent or 
independent of the OA pathophysiology, 
which in the latter case would thus perturb 
the use of these molecules as biochemical 
markers of OA. The objective of the current 
work is, therefore, to identify genetic variants 
involved in the variation in basal levels of 
sCOMP and uCTX-II by means of a large-
scale hypothesis-free meta-analysis of 
genome-wide association studies (GWAS) 
across 3 English and 4 Dutch Caucasian 
studies. Additional replication occurred in the 
Dutch Cohort Hip and Cohort Knee study 
(CHECK) and signals were further tested for 
association with hip and knee OA. Finally, 
given that functional follow-up studies of 
susceptibility loci have demonstrated that 
they frequently result in expression 
differences of positional genes within the 
relevant diseased tissue,[12] we explored the 
behavior of mRNA expression of the 
annotated genes in preserved and 
osteoarthritic articular cartilage. 
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Identification of loci associated with sCOMP and uCTX-II expression 
MATERIALS AND METHODS 
 
Studies. A full detailed description of each 
study cohort is presented in the 
Supplementary Methods section. Baseline 
characteristics and sample sizes are shown in 
Table 1. We included studies from the 
Netherlands: GARP,[13] Leiden Longevity 
(LLS),[14] Rotterdam Study I and II (RS-I 
and RS-II),[15, 16] and the United Kingdom: 
TwinsUK,[17] Chingford,[18] VIDEO.[19] 
All studies were approved by their 
institutional ethics review committees and all 
participants provided written informed 
consent.  
 
Study design. To identify genes associated 
with uCTX-II and sCOMP levels a 2-stage 
design was applied (Figure 1 shows a 
schematic representation of the work-flow). 
In the first (discovery) stage, a meta-analysis 
of GWAS was performed by combining the 
summary statistics of 7 independent studies 
(4 Caucasian studies in the Netherlands and 3 
in United Kingdom) for genome-wide 
association with uCTX-II and sCOMP levels. 
In the second stage, loci (2 for uCTX-II and 
3 for sCOMP) that reached suggestive 
evidence for genome wide association 
(p≤1x10-6) and a locus within the COMP 
gene itself (p=2.3x10-5) were genotyped de 
novo in the CHECK cohort. Subsequently, 
meta-analysis of all results was performed in 
R statistical language similar to the analysis of 
the discovery stage by combining the 
summary statistics of 8 independent studies 
(5 Caucasian studies in the Netherlands and 3 
in United Kingdom) for genome-wide 
association with uCTX-II and sCOMP levels. 
In addition, data for association of the 
variants with hip and knee OA were derived 
from a meta-analysis of GWAS for OA 
associated loci among 6 and 7 studies, 
respectively,[20, 21] and OA-related 
expression changes of annotated genes in 
cartilage were derived from an available 
dataset generated within the ongoing 
Research Arthritis and Articular Cartilage 
study (RAAK study[22]). 
An overview of the populations and 
available measurements is shown in Table 1. 
Detailed description of the populations 
included in this study is provided in 
Supplementary Methods, and Supplementary 
Table S1 shows quality control thresholds 
applied in each study.  
 
Urinary CTX-II and serum COMP 
measurements. All measurements for 
uCTX-II in samples of Chingford, 
Rotterdam (studies I and II), TwinsUK, and 
VIDEO were performed as part of the 
TreatOA consortium with the use of an 
enzyme-linked immunosorbent assay based 
on a monoclonal antibody raised against the 
linear 6-amino acid EKGPDP epitope of the 
CII C-telopeptide (CartiLaps; 
Immunodiagnostic systems, Paris, France). 
Intra- and inter-assay variation was lower 
than 9% and 11%, respectively. Serum 
COMP levels for Chingford, RS-II, Twins-
UK, and VIDEO were measured using a 
two-site immunoassay (COMPTM ELISA kit, 
AnaMar Medical, Lund, Sweden). Both, intra- 
and the inter-assay variation were below 
10%. 
Assessment of uCTX-II and sCOMP 
levels in samples of the GARP study and 
Leiden Longevity study was performed 
previously by Synarc Laboratories Lyon, 
France and has been described in detail 
elsewhere.[8, 9] Measurement of the 
biomarkers in the CHECK cohort was done 




according to the manufacturers protocol as 
described previously.[7]  
 
Genotyping, quality controls and 
imputation. Genotyping of the cohorts was 
done by Illumina Infinium HumanHap550 
Beadchip (RS-I and RS-II), the Illumina 
Infinium HumanHap610 (GARP, LLS and 
TwinsUK), or the Illumina Infinium 
HumanHap300 (VIDEO and 
CHINGFORD). Criteria for quality control 
(QC) are shown in Supplementary Table S2. 
For all studies, normalized intensity data of 
the GWAS were pooled, and genotypes were 
called on the basis of the Illuminus 
algorithm. No calls were assigned if the most 
likely call was less than a posterior probability 
of 0.95. Validation of pooling was done by 
visual inspection of 100 random, shared 
SNPs for overt batch effects (none were 
observed). SNPs that had a low call rate (≤ 
90%), Hardy-Weinberg p-values < 10−6 and 
minor allele frequencies (MAF) < 1% were 
excluded, and samples with call rates < 95% 
were removed.  
Genotype imputations were performed to 
increase the coverage and to evaluate 
association of one and the same SNP across 
samples typed on different genotyping 
platforms. Genotypes were imputed for all 
polymorphic SNPs (MAF > 0.01) using 
either MaCH[23] or IMPUTE[24] software, 
based upon phased autosomal chromosomes 
of the HapMap CEU Phase II panel (release 
22, build 36), orientated on the positive 
strand. Imputation QC metrics from MACH 
and IMPUTE were used to filter out SNPs 
with low-quality data. SNPs that successfully 
passed QC criteria (MaCH r2-hat ≥0.30 or 
IMPUTE proper_info ≥0.40) were 
considered for the analysis. Detailed 
description of QC and imputation 
procedures are provided in Supplementary 
Table S2. 
De novo genotyping of SNPs in 
CHECK[25] was performed by mass 
spectrometry using the homogeneous 
MassARRAY iPlex Gold from Sequenom 
(San Diego, CA) under standard conditions. 
SNP rs691461 was genotyped by means of a 
TaqMan Genotyping Assay (Applied 
Biosystems, Foster City, CA) since this SNP 
did not fit into the iPlex design. 
 
Analysis of GWAS. After selection and QC, 
data of sCOMP and uCTX-II were analyzed 
separately for each study. For both traits log10 
transformations were performed and 
standardized residuals from regression were 
extracted with mean = 0 and standard 
deviation = 1. All studies performed 
regression analysis, adjusting for age, age 
squared, sex and population specific co-
variables such as familial dependencies or 
population stratification. Multiplicative 
(Cochran-Armitage)/additive allele-dose were 
carried out for imputed SNPs where possible 
using a linear regression framework as 
implemented in MACH2DAT,[23] 
QTASSOC (in-house analysis program, 
developed to correct for familial dependence; 
H. W. Uh and Q. Helmer[26, 27]) and 
PLINK[28] (Supplementary Table S3). The 
estimated inflation factors in the sCOMP 
analyses were 1.002, 0.986, 1.033, 1.01, 0.987, 
and 0.977 for Chingford, GARP, LLS, RS-II, 
TwinsUK and VIDEO, respectively. The 
estimated inflation factors in the uCTX-II 
analyses were 1.003, 1.008, 1.026,1.020, 
0.997, 1.008, 1.008 for Chingford, GARP, 
LLS, RS-I, RS-II, TwinsUK and VIDEO, 
respectively (Table 1).  
 
Meta-analyses. Summary statistics of the 
4 
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individual GWAS were combined by means 
of a fixed-effects inverse variance-weighted 
meta-analysis, as implemented in 
METAL[29] across 1,961,964 autosomal 
SNPs. In the meta-analysis the genomic 
control (GC) method[30] was used as 
implemented in METAL which corrects for 
any residual population stratification or 
relatedness that is not accounted for by the 
four most important PCs.[29] The genomic 
control inflation factor of the meta-data was 
than calculated again to assess resulting 
inflation of the test statistics in R statistical 
programming language using the GenABEL-
package.[31] 
P<5x10-8 was considered genome-wide 
significant. Variants with a p≤1x10-6 in the 
meta-analyses were selected for follow-up in 
the replication stage of this study, and for 
these SNPs meta-analyses were performed in 
R (http://www.r-project.org) using the meta 
package. Here, summary regression 
coefficients (effect sizes, betas) were 
estimated using the fixed-effects model of 
DerSimonian and Laird.[32] Heterogeneity 
was quantified using the I2 statistic for 
inconsistency[33] and its statistical 
significance was tested with the χ2 
distributed Cochran Q statistic.[34] I2 
describes the proportion of variation due to 
heterogeneity that is unlikely to be due to 
chance and is considered large for values 
over 50%.[33] Regional association plots of 
the meta-analysis results were obtained with 
LocusZoom.[35] 
 
Exploratory OA phenotype check. To 
explore whether the identified variants in our 
study may share common pathophysiological 
paths and are associated with OA we tested 
for potential associations in previously 
performed meta-analyses of GWAS for hip 
OA (a total of 4,349 cases versus 46,903 
controls, including the following studies: 
arcOGEN stage 1, deCODE, EGCUT, 
GARP, RS-I, RS-II, RS-II, and 
TwinsUK[20]) and knee OA (a total of 5,755 
cases versus 48,578 controls, including the 
same studies as for hip OA and in addition 
the Framingham study[21]). Specifically, 
associations were assessed using a fixed-
effects inverse variance meta-analysis of 
GWAS for the aforementioned phenotypes 
to obtain the summary effect size and the 
magnitude of the association along with the 
direction of the effect. A full detailed 
description of included studies on 
recruitment with radiographic and clinical 
assessment has been published 
previously.[20, 21]  
 
Gene expression analyses. OA-related 
changes in expression levels of positional 
genes were assessed in the RAAK study 
aimed at the biobanking of joint materials 
(cartilage, bone and where available 
ligaments), mesenchymal stem cells, and 
primary chondrocytes of patients and 
controls in the Leiden University Medical 
Center and collaborating outpatient clinics in 
the Leiden area. A gene expression dataset of 
33 paired samples of OA-affected versus 
preserved cartilage of the same joint derived 
from patients that underwent joint 
replacement due to end stage OA was used 
(described previously[20, 22, 36] and 
explained in more detail in Supplementary 
methods). In short, a total of 0.5 µg of RNA 
was used as template. Subsequently, first- and 
second-strand reverse transcription steps and 
labeling with biotin-labeled nucleotides was 
performed using an Ambion RNA 
amplification kit (TotalPrep™ RNA 





(Illumina HT-12 V3) was performed and 
analyzed in R statistical programming 
language using the Limma package to 
compare gene expression in the 33 sample 
pairs with a paired T-Test. Mean expression 
of all genes analyzed was 7.4 (6.6-14.9), 
expressed as the overall relative light intensity 
signals in respectively the preserved and OA 





A meta-analysis of GWAS was performed 
across Caucasian samples to identify loci 
associated with serum levels of COMP 
available in 3,316 subjects across 6 studies 
and of uCTX-II available in 4,654 subjects 
across 7 studies (Figure 1). Of these, two 
studies had only genotyped SNPs (N ~ 
530,000) whereas the other studies used 
additional imputed SNPs (N ~ 2.5 million; 
Table 1 and Supplementary Methods).  
 
GWAS meta-analysis for sCOMP. In the 
sCOMP meta-analysis a total of 1,961,964 
SNPs (directly genotyped or imputed in at 
least 4 studies) were tested for association. 
The overall genomic control lambda (λGC) 
was 1.0131, indicating no significant 
population stratification (Supplementary 
Figure S1). A genome wide significant signal 
was found for SNP rs691461 (p=1.9x10-12), 
located at chromosome 10 (17.9 Mb) within 
intron 7 of the Mannose receptor C type 1 
(MRC1) gene (Figure 2). Two other signals 
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that reached the pre-specified follow-up 
threshold, were rs10429475 with p=7.6x10-8 
and rs17635227 with p=1.4x10-6 located, 
respectively, at chromosome 9 (120.2 Mb) 
between the Deleted in breast cancer 1 
(DBC1) and Toll-like receptor 4 (TLR4) 
genes and at chromosome 14 (83.3 Mb) in a 
gene desert (Supplementary Figure S2 and 
Table S4A). Furthermore, of note was a SNP 
identified within the top 15 of independent 
loci of the meta-analyses, located at 
chromosome 19 (18.8 MB), annotated 1 kb 
downstream of the Cartilage Oligomeric 
Protein (COMP) gene (rs10038; p=2.3x10-5) 
that was as positional candidate included in 
the replication stage of our study. 
Replication of the 4 identified SNPs 
within the Dutch early OA study CHECK 
(N=964) indicated suggestive evidence for 
independent association with sCOMP levels 
only for SNP rs691461 (p=0.066; 
Supplementary Table S4B). When we added 
this result to the meta-analysis the association 
for the G allele (allele frequency: 0.502) of 
rs691461 with lower sCOMP levels became 
stronger (beta: -0.16, p=1.7x10-12) without 
evidence for significant heterogeneity 
(I2=23.8%; p=0.3; Figure 2A). Although the 
independent effect of rs10038, located close 
to the COMP gene, was not significant in the 
CHECK cohort (p=0.106), when we added 
this result to the meta-analysis the 
associationfor the A allele (allele frequency: 
0.334) with increased levels of sCOMP 
became stronger (beta: 0.11; p=7.1x10-6). 
 
GWAS meta-analysis for uCTX-II. In the 
uCTX-II meta-analysis a total of 1,836,485 
SNPs (directly genotyped or imputed in at 
least 4 studies) were tested for association. 
The genomic control inflation factor showed 
no systematic inflation (λGC=1.0132; 
Supplementary Figure S3). Two independent 
variants reached the pre-specified threshold 
for replication, respectively, rs1983474 
(p=1.0x10-6) located at chromosome 8 (4.4 
Mb) within the CUB and sushi domain-
containing protein 1 (CSMD1; Figure 3B) 
 
 
Table 2: Tophits for meta-analyses of GWAS (Legend: CHR: chromosome; POS: chromosomal 
position; EA: Effect Allele; EAF: Effect Allele Frequency; BETA: effect of the indicated Effect Allele; 
SE: Standard Error; Dir.: Direction of the effect for the indicated effect allele in the respective studies 
(Chingford, GARP, LLS, RS-I –only for uCTX-II-, RS-II, TwinsUK, VIDEO, and CHECK). 
*In CHECK rs8104411 was genotyped (pairwise LD (r2) between rs8104411 and rs10038 = 0.9). 
 
SNP CHR POS EA EAF BETA p Dir. Gene 
sCOMP 
        
rs10429475 9 120,165,567 T 0.454 0.11 1.42 x 10-6 +++++++ 
TLR4 
DBC1 
rs691461 10 17,933,215 G 0.502 -0.16 1.66 x 10-12 - - - - - - - MRC1 
rs17635227 14 83,280,425 G 0.262 -0.09 1.49 x 10-4 - - - - - - + 
 
rs10038* 19 18,753,728 A 0.334 0.11 7.11 x 10-6 +++++++ COMP 
uCTX-II 









and rs4518370 (p=1.3x10-6) located at 
chromosome 5 (82.2 Mb) close to 3 different 
genes (Supplementary Figure S4). In 
CHECK we observed significant 
independent association for rs1983474, 
(p=0.032; Supplementary Table S4B). When 
combining discovery and replication results 
of rs1983474, the association with uCTX-II 
became borderline genome-wide significant 
(beta: 0.13; p=8.5x10-8) without evidence for 
heterogeneity (I2=0%; p=0.5; Figure 3A). 
 
Analysis for association with OA 
phenotypes and expression of annotated 
genes in cartilage. We explored whether 
the 6 loci identified in this study by virtue of 
 
Figure 2. Association of sCOMP levels with rs691461 localized within the MRC1 gene. A. 
Forest plot of sCOMP meta-analysis for rs691461 in the MRC1 gene (p=1.7x10-12). EA: Effect 
Allele; Chingford: Chingford 1000 Women Study; GARP: Genetics OsteoArthritis and Progression 
study Leiden; LLS: Leiden Longevity Study; RS-II: Rotterdam study cohort 2; VIDEO: randomized, 
placebo controlled trial of vitamin D replacement study; TwinsUK: the United Kingdom Adult Twin 
Registry; CHECK: Cohort Hip and Cohort Knee. B. LocusZoom plot showing positional genes of 
the sCOMP QTL SNP rs691461. Beta refers to standardized effect. 
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their association with either sCOMP or 
uCTX-II (Table 2) also associated with OA. 
For this, the TreatOA genome wide 
association scan dataset including all 
participants stratified for hip and knee OA 
was examined. As shown in Table 3, evidence 
for nominal significant association (p<0.05) 
was only found for rs10038, within the 
COMP gene, for hip OA (p=8.9x10-3; odds 
ratio (OR): 1.07 per allele, 95% confidence 
interval (CI) 1.02-1.13). Expression of the 
identified annotated genes of Table 2 in 
articular cartilage and their responsiveness to 
OA pathophysiology was examined in a 
 
Figure 3. Suggestive evidence for association of rs1983474 with uCTX-II levels. A. Forest plot 
of uCTX-II meta-analysis for rs1983474 within the CSMD1 gene (p=8.5x10-8). EA: Effect Allele; 
Chingford: Chingford 1000 Women Study; GARP: Genetics OsteoArthritis and Progression study 
Leiden; LLS: Leiden Longevity Study; RS-I: Rotterdam study cohort 1; RS-II: Rotterdam study 
cohort 2; VIDEO: randomized, placebo controlled trial of vitamin D replacement study; TwinsUK: 
the United Kingdom Adult Twin Registry; CHECK: Cohort Hip and Cohort Knee. B LocusZoom 





microarray mRNA expression dataset of 
human matched OA and preserved articular 
cartilage obtained from 33 individuals that 
underwent joint replacement surgery due to 
end stage OA. As expected, very high 
expression of COMP was observed in 
cartilage tissues (relative levels of expression 
are within the highest quartile of the dataset; 
Table 3) reflecting its relative importance 
herein. Furthermore, expression of COMP 
appeared subtle but significantly increased 
(1.1-fold) in cartilage harvested near the OA 
lesion (OA affected cartilage) as compared to 
cartilage distal to the OA lesion (preserved 
cartilage; p=3.6x10-3). In contrast, low overall 
expression in articular cartilage and no 
differential expression between OA affected 
and preserved cartilage was detected for the 





In the current study, we have established 
novel genetic variants influencing levels of 
the well-known OA biochemical markers 
sCOMP and uCTX-II by means of a large-
scale GWAS meta-analysis design. A 
genome-wide significant locus within the 
MRC1 gene (rs691461) was associated with 
variation in the levels of sCOMP (p = 1.7 
x10-12 in the combined analysis of the 
discovery and follow-up stage). The effect 
allele G with a frequency of 0.502 was 
associated with a decrease of sCOMP in a 
fixed-effect model (beta: -0.16). MRC1, 
encoding the Mannose Receptor C type 1, is 
a membrane receptor highly expressed by 
macrophages. It has been shown that MRC1 
mediates specific recognition of sugar 
residues to allow endocytosis of 
glycoproteins.[37] Since carriers of the risk 
allele have decreased levels of sCOMP this 
could reflect enhanced phagocytosis of serum 
glycoproteins such as sCOMP. Such a 
mechanism, likely independent of OA, could 
also explain the fact that MRC1 is only lowly 
expressed in articular cartilage and that the 
MRC1 SNP was not associated to OA 
phenotypes (Table 3). As such, this 
association could negatively affect the 
sensitivity of sCOMP as biomarker of OA in 
a clinical setting. On the other hand, of note 
was the signal detected with rs10038 located 
1 kb downstream of the COMP gene with the 
sCOMP levels (Table 2). In this case, we 
showed that the relative high COMP mRNA 
expression in articular cartilage was 
responsive to the OA process and that the 
SNP rs10038 was associated to hip OA 
(p=8.9x10-3 with OR: 1.07 for the effect allele 
A). Given these data, the sCOMP levels in 
this respect appear to act as an 
endophenotype of OA and, therefore, the 
COMP gene itself may be considered as a 
potential new OA susceptibility gene which 
warrants further investigation. These results 
highlight the virtue and power of our study 
design. 
For uCTX-II levels SNP rs1983474 
located in CSMD1 showed borderline 
genome wide significance in the combined 
analyses of the discovery and replication 
stage (p=8.5x10-8). The C-allele, with a 
frequency of 0.770, was associated with 
increased uCTX-II (beta: 0.13). We did not 
find association between rs1983474 and hip 
or knee OA. A previous study identified 
association between OA and another SNP in 
CSMD1, rs9657371,[38] with negligible 
linkage disequilibrium with rs1983474 
(r2=0.03). However, exploration of the 
TreatOA GWAS dataset for hip and for knee 
OA showed no association for rs9657371 
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(data not shown). The rat homolog of 
CSMD1 was identified in a search for 
proteins of the ‘regulators of complement 
activation’ (RCA) family,[39] and it was 
shown that CSMD1 blocked the classical 
complement pathway activation.[39, 40] It 
may therefore be speculated that innate 
dysregulated expression of CSMD1 results in 
a (slight) activation of the complement 
cascade in articular cartilage independent of 
OA, leading to changes in the release of 
CTX-II. It should be noted, however, that in 
articular cartilage CSMD1 gene expression 
was relatively low (Table 3). Altogether, 
thorough additional investigation is necessary 
to obtain mechanistic insight in this locus 
with respect to uCTX2 levels. 
Our study has some limitation. Despite 
the large number of samples that we have 
assembled, small genetic effects could well 
have been missed in our analyses with the 
biomarker levels or OA phenotypes. Power 
may have eroded due to measurement errors 
in biomarker determinations or due to 
heterogeneity in the marker levels that may 
have been introduced by the OA phenotype 
of some of the subjects in participating 
studies. However, we expect this effect to be 
negligible since the meta-analyses were 
performed using the extracted standardized 
residuals from regression with mean = 0 and 
SD = 1 for all studies included. Alternatively, 
results may have been affected by other 
biological differences such as variation in 
urinary clearance of the biomarkers, body 
mass index, and previous physical exercise. 
Despite applied quality control (e.g. HWE), 
the region surrounding the MRC1 locus 
appears different from the average genomic 
structure which may have affected our 
association (Figure 2B). In the follow-up 
phase, however, de novo genotyping was 
performed on a different genotype platform 
(Taqman assay) and confirmed association 
with borderline significance (p=6.6x10-2) 
making such influences less likely. With 
respect to the gene expression analysis, we 
studied only expression of the genes 
annotated to the identified locus. We, 
therefore, cannot exclude the possibility that 
the identified SNPs affect the expression of 
more distant genes. In addition, the 
expression of COMP was not validated by an 
independent assay such as RT-qPCR. 
 
In conclusion, by applying meta-analysis of 
GWAS we are the first to identify a locus 
within the CSMD1 gene influencing innate 
levels of uCTX-II with borderline genome-
wide significance. Moreover, we identified 2 
loci influencing the sCOMP levels, located 
within respectively the MRC1 and the COMP 
gene. The data and function of MRC1 
indicate that, apart from OA 
pathophysiology, also OA independent 
processes are likely to affect sCOMP levels. 
Taking such effects into account when 
applying sCOMP as OA biomarker increased 
sensitivity of sCOMP may be accomplished. 
In this respect, we advocate that the recently 
published meta-analysis on uCTX-II and 
sCOMP as OA biomarkers[10] should now 
be analyzed by taking into account the 
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Chingford Study:  
This study is a prospective population-based longitudinal cohort, which includes women 
derived from the age/sex register of a large general practice in North London1,2. The study 
design and rationale have been described elsewhere in detail3. The Guy’s St. Thomas’ Trust 
and the Waltham Forest Trust ethics committees approved the study protocol. After study 
procedures were explained to participants, written informed consent was given by each 
participant.   
Genetics OsteoARthritis and Progression (GARP) Study: 
The ongoing GARP study, which consists of Caucasian sib pairs of Dutch ancestry affected 
predominantly with symptomatic OA at multiple sites, is primarily aimed at the identification 
of genetic determinants of OA susceptibility and progression. Details of the ascertainment has 
been described elsewhere.[1] Symptomatic OA of a joint within the study was defined as 
having symptoms of OA in addition to radiographic signs. Informed consent was obtained 
from all patients. The GARP study consists of 382 subjects (312 females and 70 men) which 
meet all inclusion criteria, in this paper we included 10 additional subjects with OA at least at 
one major joint site which had marker levels available.  
Leiden Longevity Study (LLS): 
Between 2002 and 2006, the LLS included 421 Caucasian families were consisting of long-lived 
siblings with their offspring and partners of their offspring. Families were eligible to participate 
in the study when at least two long-lived siblings were alive and over 89 years old for males and 
over 91 years for females, representing less than 0.5% of the Dutch population in 2001. There 
were no selection criteria on health or demographic characteristics. Blood samples were taken 
at baseline, non-fasted between 0930 and 1700h. Urine samples were collected at the time of 
drawing blood and stored at -80°C. In this analysis we included a total of 329 offspring of 
long-lived siblings and 329 of their partners.  
Rotterdam Study I and II (RS-I and RS-II):  
The Rotterdam Study is a population-based prospective cohort study ongoing since 1990 to 
study determinants of chronic disabling disease 24. Two subpopulations of the Rotterdam 
Study were used in the current manuscript, RS-I and RS-II. The Rotterdam Study I (RSI) is the 
first cohort of 7,983 persons living in the Ommoord district of Rotterdam in the Netherlands. 
All subjects were aged 55 years and older and recruitment started in 1990. The Rotterdam 
Study II (RSII) started in 1999 when 3,011 participants moved into the study since they 
became 55 years of age or moved into the study district. The medical ethics committee of 
Erasmus University Medical School approved the study and written informed consent was 
obtained from each participant.   
TwinsUK: 
The study participants were white monozygotic and dizygotic twin pairs from the TwinsUK 
adult twin registry, a group used to study the heritability and genetics of age-related diseases. 
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These unselected twins were recruited from the general population through national media 
campaigns in the United Kingdom. Ethics approval was obtained from the Guy’s and St. 
Thomas’ Hospital Ethics Committee. Written informed consent was obtained from every 
participant  
VIDEO:  
This study is a placebo-controlled randomized controlled trial of 800 unit’s cholecalciferol in 
men and women with knee OA. In total, 477 cases are included in this trial which are classified 
as knee OA patients according to the Kellgren and Lawrence grading system13 (OA defined as 
one definite osteophyte) and patients had to suffer from knee pain and have a medial joint 
space width > 1mm. The study was approved by the local research ethics committee, and all 
subjects provided written, informed consent prior to participation.   
CHECK: 
Cohort Hip and Cohort Knee (CHECK) is a long-term follow-up study (10 years) of early OA 
subjects with pain and/or stiffness of one and/or both knee(s) and/or hip(s), that had never or 
not longer than 6 months ago visited a general practitioner for these complaints for the first 
time. At baseline, CHECK subjects (79% female) were aged 56±5 years (mean ±SD) and had a 
median body mass index (BMI) of 25.5 kg/m2.[2]   
RAAK study: 
The Research Arthritis and Articular Cartilage (RAAK) study is an ongoing study in which 
joint materials are collected (cartilage, bone and where available ligaments) and mesenchymal 
stem cells (hip joints only) of patients and controls in the Leiden University Medical Center 
and collaborating outpatient clinics in the Leiden area. In the current study we used sample 
pairs for 33 donors undergoing joint replacement surgery for primary OA, 22 hips and 11 
knees were included in the study. At the moment of collection (within 2 hours following 
surgery) tissue was washed extensively with phosphate buffered saline (PBS) to decrease the 
risk of contamination by blood. Joints were assessed macroscopically for OA related damage 
such as the loss (depth and hardness) of articular cartilage, surface integrity as determined by 
visible fibrillation or crack formation and color/whiteness of the cartilage,[3, 4] and collected 
separately from OA affected and preserved regions around the weight-bearing area of the joint. 
Care was taken to avoid contamination with bone or synovium. Collected cartilage was snap 




1  Riyazi N, Meulenbelt I, Kroon HM, Ronday KH, Hellio le Graverand MP, Rosendaal FR, et al. 
Evidence for familial aggregation of hand, hip, and spine but not knee osteoarthritis in siblings with 
multiple joint involvement: the GARP study. Ann Rheum Dis 2005;64:438-43. 
2  Wesseling J, Dekker J, van den Berg WB, Bierma-Zeinstra SM, Boers M, Cats HA, et al. CHECK 
(Cohort Hip and Cohort Knee): similarities and differences with the Osteoarthritis Initiative. Ann 
Rheum Dis 2009;68:1413-9. 
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Supplementary Material Chapter 4 
Supplementary Figure S1. A. Manhattan plot showing the significance of association for 
1.9 million SNPs in the meta-analysis with sCOMP. SNPs are plotted on the x-axis according 
to their position on each chromosome. On the y-axis, the association p-values with sCOMP 
are shown (as –log 10 p-values). The blue solid horizontal line represents the preset p-Value 
threshold of 1 x 10-6. The red horizontal line represents the p-Value threshold of 1 x 10-8 (the 
level for genome wide evidence of association). B. Overall Quantile-Quantile (QQ) plot of 
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Supplementary Figure S2. LocusZoom plots showing positional genes of the sCOMP QTL 
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Supplementary Figure S3. A. Manhattan plot showing the significance of association for 
1.8 million SNPs in the meta-analysis with uCTX2. SNPs are plotted on the x-axis according to 
their position on each chromosome. On the y-axis, the association p-values with uCTX2 are 
shown as –log 10 p-Value. The blue solid horizontal line represents the preset p-Value 
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Supplementary Figure S4. LocusZoom plots showing positional genes of the uCTX-II 
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Genome-wide association study: identifying new genes and pathways 
conferring risk to susceptibility of osteoarthritis at multiple joint locations as 
defined in the GARP study 
 
YFM Ramos1*, SD Bos1,2, U Styrkarsdottir3, K Panoutsopoulou4, N Lakenberg1, RGHH Nelissen5, G 
Kloppenburg6, H Kroon7, HJM Kerkhof8,2, AG Uitterlinden8,2, J Loughlin4,9, A Gonzalez10, E Zeggini4, I 
Jonsdottir3, JB van Meurs8,2, PE Slagboom1,2 and I Meulenbelt1,2 
1Dept of Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands; 2The 
Netherlands Genomics Initiative, sponsored by the NCHA, Leiden-Rotterdam, The Netherlands; 
3deCODE Genetics, Reykjavik, Iceland; 4arcOGEN Consortium, Cambridge, UK; 5Dept of 
Orthopaedics, 6Dept of Rheumatology, and 7Dept. of Radiology, Leiden University Medical Center, 
Leiden, The Netherlands; 8Dept. of Internal Medicine, Erasmus Medical Center, Rotterdam, The 
Netherlands; 9Newcastle University, Musculoskeletal Research Group, Institute of Cellular Medicine, 




Objective Several compelling loci associated to osteoarthritis (OA) have been identified 
by genome wide association studies (GWAS), however, with small effects. Here, GWAS 
was conducted in the GARP study characterized by cases with familial, symptomatic 
generalized OA thereby aiming to discover susceptibility loci with larger effects. 
Methods Following discovery GWAS, replication was performed in a 2-phase approach: 
loci with pre-defined threshold (p=1x10-5; N=18) were analyzed in comparable cases 
with OA at ≥3 joints, followed by confirmation of 9 replicating SNPs in 4 additional 
studies with (mainly) single-site OA. Gene expression of annotated genes was explored 
in blood and OA affected and unaffected cartilage. Pathway analysis was performed for 
annotated genes of the discovery GWAS. 
Results The strongest statistical evidence for association was found for rs347842 
located within SLC12A6, a gene related to peripheral neuropathies (odds ratio OR=1.13 
with 95% confidence interval CI95=1.06–1.20 p=2.56x10-4). Of note was a variant within 
CDKAL1 showing small but consistent direction of effects in all studies (OR=1.12 with 
CI95=1.03-1.21 p=4.8x10-3). CDKAL1 was found to be significantly differently expressed 
in blood of OA patients. Pathway analysis in the discovery stage showed significant 
enrichment of genes involved in neurogenesis (p=6.84x10-7). 
Conclusions Compelling loci with suggestive evidence for association were identified, 
and results warrant further investigation for a role of neurogenesis in OA etiology. 
However, replication was complicated due to the specific phenotype of the discovery 
cohort; it remains to be established whether trade-off between more specific 
phenotypes and increasing sample-numbers may result in new consistent susceptibility 
loci. 
 
Keywords: GWAS, meta-analysis, GARP study, osteoarthritis, heterogeneity 
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INTRODUCTION 
 
Osteoarthritis (OA) is a degenerative disease 
of the joint characterized by wear and tear of 
cartilage, subchondral bone remodeling, and 
inflammation of synovial tissues. OA is most 
common in knee, hip, and/or hand joints, 
and prevalence increases with age.[1] Care is 
concentrated on controlling symptoms, 
minimizing disability, and slowing down 
progression until joint replacement is 
indispensable given that no treatment is 
available to cure OA (reviewed in [2]). More 
insight into OA pathophysiological processes 
and the etiology will greatly enhance 
possibilities for therapy and prospects for 
patients. 
A variety of factors such as genetics, 
hormones, metabolism, and environment 
contribute to development of OA.[3] 
Heritability of OA differs per joint site and 
based on twin and sibling studies it has been 
estimated between 40 and 60% depending on 
the site affected.[4, 5] By compiling large 
numbers of cases and controls, consortia 
have recently succeeded to identify robust 
OA susceptibility loci with genome wide 
significance.[6-8] Typically, these loci exert 
small effects[9] partly since the OA 
phenotype is highly heterogeneous thereby 
accounting only for a small part of the OA 
heritability. 
To discover OA genes with larger effect 
sizes we collected sibling pairs, affected by 
symptomatic OA at 2 or more joint locations 
with KL≥2, the GARP study.[10] By 
applying a genome wide linkage to GARP 
sibling pairs and subsequent replication in 
population based cases we previously 
identified the OA susceptibility gene DIO2. 
Here, we initiated a genome wide association 
scan in the GARP study to identify additional 
OA susceptibility genes. For this, we applied 
a 2-stage follow-up design: replication in 
similar severely affected OA patients, 
followed by large scale confirmation to 
population based cases by meta-analysis.  
 
 
MATERIALS AND METHODS 
 
Study populations. In the work presented, 
the Genetics osteoARthritis and Progression 
(GARP) study consisting in sibling pairs with 
symptomatic OA at 2 or more joint locations 
at relative young age (40-70 yr)[10] was used 
as discovery population in a genome wide 
association scan (N=378). For replication of 
our results, we included cases affected in 3 or 
more joints of the deCODE study 
(N=310).[11, 12] From the arcOGEN 
consortium,[13] no information about hand 
OA was available, but all cases with bilateral 
total joint replacement (TJR) due to OA at 
hip or knee were included (N=380). The 
Rotterdam study has been described 
previously,[14] and cases with radiographic 
hip or knee OA were included in the analysis 
(N=1,095). For de novo genotyping, cases with 
TJR for hip or knee OA from a Spanish 
study[15] (N=359) and a Dutch study (the 
Paprika study, N=1,016; a long-term follow-
up study of patients that have undergone TJR 
at hip or knee[16]) were used. Table 1 shows 
characteristics of the different studies, all 
with subjects from Western European 
descent. More details on the studies can be 
found in the corresponding references. All 
studies were approved by their respective 
institutional review boards and informed 
consent was obtained from all participants 
involved. 
 




genotyped using Illumina Infinium HD 
Human660W-Quad BeadChips (Illumina, 
San Diego, CA, USA). Two subjects were 
removed based on low-quality genotyping 
resulting in a total of 378 cases for the 
analysis. A random sample of 1670 
inhabitants of Rotterdam[14] was used as 
population control. Genotyping of these 
controls using Illumina Infinium II 
HumanHap 550K Beadchips and Illumina 
Infinium II HumanHap550-Duo BeadChips 
(Illumina) for the RS-I and the RS-II cohorts, 
respectively, has been described 
previously.[17] A total of 516,834 SNPs, 
genotyped for both GARP and controls, was 
used for the GWAS and analyzed with 
cc_assoc (in-house analysis program, 
developed to correct for familial dependence; 
H. W. Uh and Q. Helmer). Quality control 
was performed selecting for SNPs with call 
rate ≥0.99, pHWE>10-4, and MAF≥0.05, and 
Illumina clusterplots were visually inspected 
to confirm quality of the genotyping. 
Subsequently, imputation for all polymorphic 
SNPs (MAF >0.01) was performed with 
HapMap2 using IMPUTE,[18] and data were 
subjected to a second round of quality 
control as described before, resulting in 
analysis of 1,902,224 SNPs total. There was 
no overlap between the samples used in this 
analysis and controls used for the replication 
in Rotterdam. 
Genotyping of the Paprika study and of 
the Spain cohort was performed using the 
Sequenom MassARRAY iPLEX Gold or 
TaqMan SNP Genotyping assays following 
the manufacturer’s instructions. Controls for 
the Spain cohort were determined like-wise, 
and as a control for the Paprika study we 
used existing GWAS data in the Leiden Lang 
Leven Study after quality control screening 
described by Deelen et al.[19] 
Study design and meta-analysis. 
Discovery GWAS was performed using the 
GARP study. Estimations for this analysis 
using Quanto software (http://biostats.usc. 
edu/software) suggested that for this study 
we would be able to identify loci with 80% 
power for odds ratios (OR) as high as 1.5 and 
allele frequencies of at least 10% with 
genome wide significance (Supplementary 
Table 1; note that results shown are most 
likely overestimated given the fact that the 
data are not corrected for sibling ship). 
To replicate results from the discovery 
GWAS a 2-step approach was taken. First, 
since from all populations available a 
selection of the deCODE study was relatively 
similar to our study, 18 unique loci with a 
preset threshold of p≤1x10-5 were replicated 
in this study. Subsequently, SNPs with 
significant association after correction for 
multiple testing p≤2.8x10-3 in the meta-
analysis GARP-deCODE (8 SNPs) were 
selected for replication in available additional 
studies. Meta-analyses were performed in R 
using the meta package to obtain p-value, 
95% confidence interval (CI95), odds ratio 
(OR), and forrest plots. Figure 1 shows the 
flow chart of the study design. 
 
Exploration of gene expression. OA-
related changes in expression levels of 
positional genes were explored as described 
previously in in-house available gene 
expression datasets of cartilage (the RAAK 
study[20, 21]) and blood (the GARP 
study[22]). Mean expression of all genes was 
7.4 (range: 6.6-14.9), expressed as the overall 
relative light intensity signals in respectively 
the preserved and OA affected cartilage as 
provided by Illumina.  
 
Pathway analysis. Gene enrichment analysis 
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Table 1. Description of the studies included in the genome wide association meta-analysis. 
(GOA: generalized OA; TJR: total joint replacement; F: females) 
 
STUDY N Phenotype Design Mean Age pct F Platform 
GARP 378 familial GOA (KL>2) case-control 60 82% Illumina Human660W 
deCODE 310 GOA (≥ 3 joints) case-control 69 58% Infinium Human300 
arcOGEN 380 TJR both sides case-control NA 60% Illumina Human610 
Rotterdam 1,095 OA population-based 67 57% Illumina Human550v3 
Paprika 1,016 TJR case-control 62 65% Sequenome 
Spain 359 TJR case-control 66 77% Sequenome 
 
was performed with the online available 
Database for Annotation, Visualization and 
Integrated Discovery (DAVID; [23, 24]) 
selecting for all biological processes in the 
gene ontology database 
(GOTERM_BP_FAT). For the analysis, 
genes within 10 kb up- or downstream of the 
SNPs identified in the discovery GWAS with 




Discovery genome wide association. 
Baseline characteristics of the GARP and 
follow-up studies are shown in Table 1. After 
imputation and quality controls data were 
analyzed for 378 cases versus 1670 controls. 
Supplementary Figure 1 provides the 
Manhattan and QQ-plots with an overall 
genomic control lambda (λGC) of 1.0525, 
indicating no significant population 
stratification. Table 2 provides all unique 
locithat reached the pre-specified threshold 
of p≤1x10-5 for replication (N=18). The 
strongest statistical evidence for association 
with symptomatic OA at multiple joint sites 
was obtained for rs10488327 located at 
chromosome 7p12 with odds ratio OR=2.39 
  





(95% confidence interval CI95=1.73-3.30 and 
p=1.23x10-7). Closest gene, located 500 kb 
upstream, is the POM121 Membrane 
Glycoprotein-Like 12 (POM121L12) gene. 
 
Pathway analysis. In order to investigate 
whether the results of our GWAS could link 
OA to a specific biological pathway, gene 
enrichment analysis for biological pathways 
was performed including genes within 10 kb 
up- or downstream of all SNPs with p≤1x10-3 
as identified in the discovery GWAS. 
Remarkably, many of the significant GO-
terms appeared to be related to neuron 
differentiation and strongest statistical 
evidence was for GO:0007399 (nervous 
system development; p=6.84x10-7; see Table 
3). 
 
Replication and confirmation. Following 
 
Figure 2. Forrest plot (A) and LocusZoom plot (B) for rs347842. (legend: OR: odds ratio; 95%-
CI: 95% confidence interval; W: contribution to the meta-anlaysis) 
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the discovery stage, a total of 18 loci were 
tested in silico in independent cases with OA 
in 3 or more joints of the deCODE study. Of 
these, 9 were found to be significant after 
correction for multiple testing in the 
combined analysis of GARP and deCODE 
(N=688; Table 2A). Subsequently, these were 
tested for association with OA by comparing 
a total of 3,538 cases with 49,713 controls in 
a meta-analysis of 6 studies including GARP. 
Although none of the loci were genome wide 
significant, the strongest statistical evidence 
in the meta-analysis was found for rs347842 
on chromosome 15q14 (p=3.3x10-4, with 
OR=1.13 and CI95=1.06-1.20; see Table 2A 
and Figure 2A). As shown in the LocusZoom 
plot (Figure 2B), rs347842 is located within 
the solute carrier family 12 
potassium/chloride transporter member 6 
gene (SLC12A6). Sensitivity analyses by 
excluding the GARP discovery cohort 
indicated an OR=1.09 with CI95=1.01-1.16 
(p=1.9x10-2). Furthermore, of note was the 
association with SNP rs201328 on 
chromosome 6p22 (confirmation: p=4.8x10-3, 
with OR=1.12 and CI95=1.03-1.21) located 
within the CDKAL1 gene (CDK5 regulatory 
subunit associated protein 1-like 1), showing 
consistent effects for all studies included in 
the meta-analysis. However, results of the 
sensitivity analyses were not significant.  
 
Exploring gene expression of annotated 
genes. Next, we explored a dataset of gene 
expression profiles of blood and cartilage 
(unaffected and OA affected cartilage of the 
same joint) for OA-related changes of the 
nearest gene for each SNP. As shown in 
Table 2C, only CDKAL1 was found to be 
expressed at moderate levels in cartilage, 
however, without response to OA 
pathophysiology (Table 2B). In contrast, gene 
expression profiles showed that in blood of 
OA patients expression of CDKAL1 is 
decreased with nominal significance (1.1-





To identify genes and pathways associated to 
relatively severe OA, a genome wide 
association study was performed within the 
GARP study consisting of sibling pairs with 
familial, relatively severe symptomatic OA. 
The strongest statistical evidence in the 
confirmation meta-analysis was found for the 
A allele of rs347842 within the SLC12A6 
gene which mediates electroneutral 
potassium-chloride cotransport (p=3.3x10-4; 
OR=1.13 with CI95=1.06-1.20 in the meta-
analysis). Given that rs347842 is located 
within a linkage disequilibrium (LD) block 
with multiple signals and comprising several 
genes that were well detected in our cartilage 
and blood datasets such as the 
transmembrane domain protein 85 gene 
(TMEM85) or the gene encoding NOP10 
ribonucleoprotein (Figure 2B), OA 
susceptibility could also be caused by 
rs347842 via other genes located in this 
region (Supplementary Table 2). Analysis of 
annotated genes from loci of the discovery 
phase however indicated highly significant 
enrichment of genes involved in 
neurogenesis (p=6.8x10-7), which may 
confirm a role for neuronal genes in OA.[20, 
25] This could either unexpected link 
nociception and OA[26] or aberrant nervous 
system development and OA due to failures 
in the locomotor system resulting in an 
accumulation of joint damage and concurrent 
disposition to incidence of OA during aging. 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































gene in mice leads to a locomotor and a 
sensorimotor gating deficit, suggesting a 
critical role for SLC12A6 in development of 
the nervous system.[27, 28] In addition, a 17-
base deletion within exon 4 of the SLC12A6 
gene was identified by Jiao et al[29] to be the 
cause of giant axonopathy, a neuromuscular 
disease in gaxp mice. Genetic variation at 
rs347842 might therefore dispose to OA via 
aberrations in the neuro-muscular system 
rather than by affecting structure or 
composition of cartilage and/or bone 
directly. The identified association of 
rs347842 with OA remains to be established 
since the signal was not genome wide 
significant and direction of effects in the 
replication were not unequivocal. The fact 
that results were replicated relatively well in 
the deCODE selection suggests that the use 
of more comparable cases in the meta-
analysis could have increased the power to 
detect association with genome wide 
significance. 
Although with small effects, most 
consistent directions of effects for all studies 
included in the meta-analysis were found for 
rs201328 located within the CDKAL1 gene 
(p=4.8x10-3; OR=1.12 with CI95=1.03-1.21 in 
the confirmation meta-analysis). CDKAL1 is 
expressed well in cartilage but its expression 
is not responsive to OA pathophysiology 
(Table 2C). In blood of OA patients 
however, CDKAL1 expression was found to 
be significantly decreased. Genome-wide 
association studies have linked SNPs in 
CDKAL1 with type 2 diabetes,[30] with body 
mass index (BMI) in east Asians,[31] and 
with intrauterine growth, adult height, and 
metabolism.[32] Metabolism and obesity are 
established risk factors for OA[3] and 
another locus associated with BMI was also 
found to establish risk to OA.[33, 34] 
Despite the negligible linkage 
disequilibrium between the previously 
identified loci in CDKAL1 and the here 
identified locus (LD <0.1), we cannot 
exclude the possibility that the association 
found in our analysis is due to association 
with either BMI or height which is in 
consonance with expression differences of 
CDKAL1 in blood of OA patients pointing 
towards a more systemic effect. Since  
 
Table 3. Pathway-analysis with DAVID. The grey shading indicates significant GO-term (Legend: N: 
number of genes in this GO-term; Pct: percentage of genes from the total number of genes tested; Fold 
Enr: fold enrichment of the indicated pathway; padj: P-value adjusted for multiple testing. 
 
GO-Term N Pct p padj. 
Fold 
Enr 
GO:0007399~nervous system development 66 12.07 1.25E-09 6.84E-07 2.22 
GO:0007275~multicellular organismal development 128 23.40 2.25E-09 1.23E-06 1.63 
GO:0048731~system development 107 19.56 2.33E-08 1.27E-05 1.68 
GO:0048856~anatomical structure development 113 20.66 3.33E-08 1.82E-05 1.64 
GO:0032502~developmental process 132 24.13 6.23E-08 3.41E-05 1.53 
GO:0032501~multicellular organismal process 155 28.34 2.66E-05 1.46E-02 1.32 
GO:0048699~generation of neurons 33 6.03 6.29E-05 3.44E-02 2.16 
GO:0030182~neuron differentiation 28 5.12 6.99E-05 3.82E-02 2.34 





direction of effects for this locus were 
consistent but small, increased power and 
concurrent lower p-values could possibly be 
accomplished by increasing the number of 
samples. 
The current study has some limitations 
that should be taken into account. Despite 
the severe selection of familial cases to find 
loci with larger effect sizes, the identified loci 
were not genome wide significant. Most likely 
our discovery analysis lacked power due to 
inclusion of siblings and the relatively small 
number of cases, thereby highlighting the 
difficult trade-off between the specific 
phenotype facilitating detection of SNPs 
potentially with larger effect sizes and large 
sample numbers to allow significant p-values. 
Another drawback of our study design was 
the lack of comparable cohorts to replicate 
results of the discovery GWAS, which is also 
demonstrated by the significant heterogeneity 
in the meta-analysis (p=1x10-4). This 
heterogeneity may have corroded power to 
detect strong associations with OA. In fact, 
when taking this heterogeneity into account 
for rs347842 by applying a random effects 
model instead of the fixed effect model used 
here, result of the meta-analysis is not 
statistically significant. However, results for 
rs201328 and rs12148483 remained 
significant even when random effects models 
are used (Supplementary Figures 2A and C).  
 
Taken together, in this study using a small 
OA cohort with familial, relatively severe 
phenotype we identified compelling 
susceptibility loci albeit without genome wide 
significance. Many of the identified loci are 
localized close to genes involved in 
neurogenesis, however, due to the lack of 
studies with comparable phenotype our 
findings warrant further investigation by 
replication in additional severe familial cases 
before additional conclusions can be drawn. 
Again, this stresses the importance to 
improve homogeneity in selection procedures 




This study was supported by a grant from the 
National Institute for Healthy Ageing (Grant 
05060810) in the framework of the 
Netherlands Genomics Initiative/ 
Netherlands Organization for Scientific 
Research and of the Centre for Medical 
Systems Biology (CMSB). We thank R. van 
der Breggen, E. Suchiman, and D. Kremer 






1  Johnson VL, Hunter DJ. The epidemiology of 
osteoarthritis. Best Pract Res Clin Rheumatol 
2014;28:5-15. 
2  Seed SM, Dunican KC, Lynch AM. Treatment 
options for osteoarthritis: considerations for 
older adults. Hosp Pract (Minneap ) 2011;39:62-
73. 
3  Bay-Jensen AC, Slagboom E, Chen-An P, 
 
 
Alexandersen P, Qvist P, Christiansen C, et al. 
Role of hormones in cartilage and joint 
metabolism: understanding an unhealthy 
metabolic phenotype in osteoarthritis. 
Menopause 2013;20:578-86. 
4  Valdes AM, Spector TD. Genetic 
epidemiology of hip and knee osteoarthritis. 




5  Ikegawa S. The genetics of common 
degenerative skeletal disorders: osteoarthritis 
and degenerative disc disease. Annu Rev 
Genomics Hum Genet 2013;14:245-56. 
6  Evangelou E, Valdes AM, Kerkhof HJ, 
Styrkarsdottir U, Zhu Y, Meulenbelt I, et al. 
Meta-analysis of genome-wide association 
studies confirms a susceptibility locus for knee 
osteoarthritis on chromosome 7q22. Ann 
Rheum Dis 2011;70:349-55. 
7  Evangelou E, Valdes AM, Castano-Betancourt 
MC, Doherty M, Doherty S, Esko T, et al. The 
DOT1L rs12982744 polymorphism is 
associated with osteoarthritis of the hip with 
genome-wide statistical significance in males. 
Ann Rheum Dis 2013;72:1264-5. 
8  Evangelou E, Kerkhof HJ, Styrkarsdottir U, 
Ntzani EE, Bos SD, Esko T, et al. A meta-
analysis of genome-wide association studies 
identifies novel variants associated with 
osteoarthritis of the hip. Ann Rheum Dis 2013. 
9  Panoutsopoulou K, Zeggini E. Advances in 
osteoarthritis genetics. J Med Genet 
2013;50:715-24. 
10  Riyazi N, Meulenbelt I, Kroon HM, Ronday 
KH, Hellio le Graverand MP, Rosendaal FR, 
et al. Evidence for familial aggregation of 
hand, hip, and spine but not knee 
osteoarthritis in siblings with multiple joint 
involvement: the GARP study. Ann Rheum Dis 
2005;64:438-43. 
11  Ingvarsson T, Hagglund G, Lohmander LS. 
Prevalence of hip osteoarthritis in Iceland. 
Ann Rheum Dis 1999;58:201-7. 
12  Stefansson SE, Jonsson H, Ingvarsson T, 
Manolescu I, Jonsson HH, Olafsdottir G, et al. 
Genomewide scan for hand osteoarthritis: a 
novel mutation in matrilin-3. Am J Hum Genet 
2003;72:1448-59. 
13  Panoutsopoulou K, Southam L, Elliott KS, 
Wrayner N, Zhai G, Beazley C, et al. Insights 
into the genetic architecture of osteoarthritis 
from stage 1 of the arcOGEN study. Ann 
Rheum Dis 2011;70:864-7. 
14  Hofman A, Breteler MM, van Duijn CM, 
Krestin GP, Pols HA, Stricker BH, et al. The 
Rotterdam Study: objectives and design 
update. Eur J Epidemiol 2007;22:819-29. 
15  Rodriguez-Lopez J, Pombo-Suarez M, Liz M, 
Gomez-Reino JJ, Gonzalez A. Lack of 
association of a variable number of aspartic 
acid residues in the asporin gene with 
osteoarthritis susceptibility: case-control 
studies in Spanish Caucasians. Arthritis Res 
Ther 2006;8:R55. 
16  Keurentjes JC, Fiocco M, So-Osman C, 
Onstenk R, Koopman-Van Gemert AW, Poll 
RG, et al. Patients with severe radiographic 
osteoarthritis have a better prognosis in 
physical functioning after hip and knee 
replacement: a cohort-study. PLoS One 
2013;8:e59500. 
17  Teichert M, Eijgelsheim M, Rivadeneira F, 
Uitterlinden AG, van Schaik RH, Hofman A, 
et al. A genome-wide association study of 
acenocoumarol maintenance dosage. Hum Mol 
Genet 2009;18:3758-68. 
18  Marchini J, Howie B, Myers S, McVean G, 
Donnelly P. A new multipoint method for 
genome-wide association studies by 
imputation of genotypes. Nat Genet 
2007;39:906-13. 
19  Deelen J, Beekman M, Uh HW, Helmer Q, 
Kuningas M, Christiansen L, et al. Genome-
wide association study identifies a single major 
locus contributing to survival into old age; the 
APOE locus revisited. Aging Cell 2011;10:686-
98. 
20  Ramos YF, den HW, Bovee JV, Bomer N, van 
der Breggen R, Lakenberg N, et al. Genes 
Involved in the Osteoarthritis Process 
Identified through Genome Wide Expression 
Analysis in Articular Cartilage; the RAAK 
Study. PLoS One 2014;9:e103056. 
5 
114 
GWAS in GARP 
21  Ramos YF, Metrustry S, Arden N, Bay-Jensen 
AC, Beekman M, de Craen AJ, et al. Meta-
analysis identifies loci affecting levels of the 
potential osteoarthritis biomarkers sCOMP 
and uCTX-II with genome wide significance. J 
Med Genet 2014;51:596-604. 
22  Ramos YF, Bos SD, Lakenberg N, Bohringer 
S, den Hollander WJ, Kloppenburg M, et al. 
Genes expressed in blood link osteoarthritis 
with apoptotic pathways. Ann Rheum Dis 2013. 
23  Huang dW, Sherman BT, Lempicki RA. 
Bioinformatics enrichment tools: paths toward 
the comprehensive functional analysis of large 
gene lists. Nucleic Acids Res 2009;37:1-13. 
24  Huang dW, Sherman BT, Lempicki RA. 
Systematic and integrative analysis of large 
gene lists using DAVID bioinformatics 
resources. Nat Protoc 2009;4:44-57. 
25  Day-Williams AG, Southam L, 
Panoutsopoulou K, Rayner NW, Esko T, 
Estrada K, et al. A Variant in MCF2L Is 
Associated with Osteoarthritis. Am J Hum 
Genet 2011;89:446-50. 
26  Seidel MF, Wise BL, Lane NE. Nerve growth 
factor: an update on the science and therapy. 
Osteoarthritis Cartilage 2013;21:1223-8. 
27  Howard HC, Mount DB, Rochefort D, Byun 
N, Dupre N, Lu J, et al. The K-Cl 
cotransporter KCC3 is mutant in a severe 
peripheral neuropathy associated with agenesis 
of the corpus callosum. Nat Genet 
2002;32:384-92. 
28  Sun YT, Lin TS, Tzeng SF, Delpire E, Shen 
MR. Deficiency of electroneutral K+-Cl- 
cotransporter 3 causes a disruption in impulse 
propagation along peripheral nerves. Glia 
2010;58:1544-52. 
29  Jiao Y, Jin X, Yan J, Zhang C, Jiao F, Li X, et 
al. A deletion mutation in Slc12a6 is associated 
with neuromuscular disease in gaxp mice. 
Genomics 2008;91:407-14. 
30  Steinthorsdottir V, Thorleifsson G, 
Reynisdottir I, Benediktsson R, Jonsdottir T, 
Walters GB, et al. A variant in CDKAL1 
influences insulin response and risk of type 2 
diabetes. Nat Genet 2007;39:770-5. 
31  Wen W, Cho YS, Zheng W, Dorajoo R, Kato 
N, Qi L, et al. Meta-analysis identifies 
common variants associated with body mass 
index in east Asians. Nat Genet 2012;44:307-
11. 
32  Horikoshi M, Yaghootkar H, Mook-Kanamori 
DO, Sovio U, Taal HR, Hennig BJ, et al. New 
loci associated with birth weight identify 
genetic links between intrauterine growth and 
adult height and metabolism. Nat Genet 
2013;45:76-82. 
33  Zeggini E, Panoutsopoulou K, Southam L, 
Rayner NW, Day-Williams AG, Lopes MC, et 
al. Identification of new susceptibility loci for 
osteoarthritis (arcOGEN): a genome-wide 
association study. Lancet 2012;380:815-23. 
34  Elliott KS, Chapman K, Day-Williams A, 
Panoutsopoulou K, Southam L, Lindgren CM, 
et al. Evaluation of the genetic overlap 
between osteoarthritis with body mass index 
and height using genome-wide association 





Supplementary Material Chapter 5 




MAF OR Power (%) 







 2.0 98.8 







 2.0 100.0 







  2.0 100.0 







 2.0 100.0 







  2.0 100.0 
   







  2.0 100.0 







 2.0 100.0 







  2.0 100.0 





















GWAS in GARP 
Supplementary Table 2. Expression of genes localized in chromosomal region around 
rs347842 in cartilage and in blood (legends: pexpr: p-value for comparison of gene expression in 
OA-affected and unaffected cartilage or in blood of OA patients and healthy controls; 
AveExpr: relative gene expression; FC: fold change, with negative values indicating decreased 
expression; NA: not significantly detected). 
 
  CARTILAGE  BLOOD 
GeneID AveExpr pexpr FC  AveExpr pexpr FC 
C15ORF24 11.1 1.14E-02 1.09 
 
10.2 6.75E-01 1.02 
PGBD4 NA 
   
6.6 1.24E-01 1.03 
C15ORF29 NA 
   
6.5 1.36E-01 -1.02 
TMEM85 10.6 3.56E-01 1.03 
 
10.0 7.49E-01 1.01 
SCLC12A6 NA 
   
6.4 1.98E-01 -1.03 
NOP10 11.0 3.89E-01 1.04 
 
11.4 5.90E-01 1.04 
C15ORF55 NA 
   
6.5 8.31E-01 1.00 
LPCAT4 NA 
   
6.9 6.12E-02 -1.08 






Supplementary Material Chapter 5 
Supplementary Figure 1. Visualization of discovery GWAS results. Manhattan plot (A) 







GWAS in GARP 
Supplementary Figure 2. Forrest plot and LocusZoom plot. For rs201328 (A and B, 
respectively) and for rs12148483 (C and D, respectively; legend: OR: odds ratio; 95%-CI: 95% 
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Objective To identify pathogenic mutations that reveal underlying biological 
mechanisms driving OA.  
Methods Exome sequencing was applied to two distant family members with 
dominantly inherited early onset primary osteoarthritis at multiple joint sites with 
chondrocalcinosis (FOA). Confirmation of mutations occurred by genotyping, and 
linkage analyses across the extended family. The functional effect of the mutation was 
investigated by means of a cell-based assay. To explore generalizability, mRNA 
expression analysis of the relevant genes in the discovered pathway was explored in 
preserved and osteoarthritic articular cartilage of independent patients undergoing 
joint replacement surgery. 
Results We identified a heterozygous, probably damaging, read-through mutation 
(c.1205A=>T; p.Stop402Leu) in TNFRSF11B encoding osteoprotegerin that is likely 
causal to the osteoarthritis phenotype in the extended family. In a bone resorption 
assay, the mutant form of osteoprotegerin showed enhanced capacity to inhibit 
osteoclastogenesis and bone resorption. Expression analyses in preserved and affected 
articular cartilage of independent osteoarthritis patients showed that up-regulation of 
TNFRSF11B is a general phenomenon in the pathophysiological process. 
Conclusions Albeit that the role of the molecular pathway of osteoprotegerin has been 
studied in osteoarthritis, we are the first to demonstrate that enhanced osteoprotegerin 
function could be a directly underlying cause. We advocate that agents counteracting 
the function of osteoprotegerin could comply with new therapeutic interventions of 
osteoarthritis. 
 




OPG mutation directly causal to osteoarthritis 
INTRODUCTION 
 
Osteoarthritis (OA) is a prevalent, complex, 
disabling disease of the articular joints, 
characterized by degradation of the hyaline 
articular cartilage and remodeling of the 
subchondral bone with sclerosis. As the 
population ages and obesity rates rise, OA is 
becoming more prevalent and current 
estimates of men and women aged over 60 
years having symptomatic OA are 9.6% and 
18.0%, respectively.[1] Yet, there is no 
effective therapy to reverse or slow down the 
disease, analgesia, physiotherapy and, at end 
stage, joint replacement surgery are the main 
treatment options. As a result, osteoarthritis has 
a large detrimental impact on the quality of life 
of the elderly and causes a major burden on 
health, and social care systems, with indirect 
costs being predominant.[1, 2] To allow the 
development of new therapies, there is an 
ongoing need for insight into the underlying 
biological mechanisms driving OA. Despite 
the detection of compelling OA susceptibility 
loci[3, 4], such insights, until now, remain 
limited. To detect rare mutations with large to 
moderate effect sizes, recently focus has been to 
apply next generation sequencing of exomes of 
severely affected family-based patients. The 
value of identified rare variants lies in the 
characterization of causal gene functions and 
underlying novel pathways in complex disease 
processes.[5, 6] Notably in this respect; among 
the identified genes with mutations causing 
early-onset families with OA associated 
syndromic skeletal phenotypes such as collagen 
type II (COL2A1),[7] the growth differentiating 
factor 5 (GDF5),[8] collagen type 11-alpha-1 
(COL11A1),[9, 10] cartilage oligomeric protein 
(COMP)[11] and extracellular signaling molecule 
and member of the TGF-β superfamily 
(SMAD3)[12, 13] were three genes that 
appeared to additionally confer risk to common 
OA phenotypes, namely SMAD3,[15] 
COL11A1,[16, 17] and the GDF5 gene which 
reached genome wide significance.[8, 14] 
Previously, we reported on a single early 
onset family with familial generalized 
osteoarthritis (FOA) without any dysplasia, 
with radiographic chondrocalcinosis as 
reflected by calcifications within the joint- 
and fibro-cartilage.[18] Candidate gene 
screening, showed that none of the genes 
encoding the extracellular matrix structural 
proteins were involved in the pathogenesis of 
this osteoarthritic phenotype.[18] 
Furthermore, a genetic linkage search in this 
and 6 other FOA families revealed significant 
linkage on chromosome 2q32 albeit that the 
attribution of this particular family to the 
linkage was moderate and Sanger sequencing 
of positional exons failed to definitively 
indicate the causal mutation.[19] Recently, a 
relevant extension was established in the 
ascertainment of the family under study; 
additionally affected distant family members 
with the phenotype were detected whereas 
third generation family members definitively 
developed the FOA phenotype. Such 
extensions increases the power of successful 
identification of genes considerably. To 
identify pathogenic osteoarthritis mutations, 




MATERIALS AND METHODS 
 
Study design. To identify pathogenic 
mutations underlying development of OA 
exome sequencing was performed for 2 
distantly related FOA family members. After 
applying an eligible prioritization scheme five 




genotyping across the extended family 
(N=16). Linkage analysis was performed for 
the mutation that was shared among all 
affected members and the mutation was 
validated by de novo genotyping of 
independent OA cases (N=1,467) and 
healthy controls (N=744). Functionality of 
the mutation was investigated in an in vitro 
cell-based model, and generalizability was 
investigated by comparing gene expression in 
OA affected cartilage with preserved cartilage 
(N=33). 
An overview of the workflow for the 
analyses, identification of the causal mutant, 
and follow-up on the mutation is provided in 




FOA family members. Previously, we 
reported on an early onset family with 
familial generalized osteoarthritis (FOA MIM 
165720·1) without any dysplasia, and with 
radiographic chondrocalcinosis as reflected 
by calcifications within the joint- and fibro-
cartilage (Figure 1A and Supplementary 
Table 1).[18] Family members were collected 
through Rheumatology clinics from different 
parts of the Netherlands and France. The age 
of onset of osteoarthritis in the family varies 
between 30 and 50 years and osteoarthritis 
arises in the absence of mild or severe 
chondrodysplasia. The phenotype within 
these families is characterized by distinct 
progressive osteoarthritis with symptoms and 
radiographic characteristics of osteoarthritis 
at multiple joint sites simultaneously, 
including involvement of the hands with 
noduli, knees, hips, and spine. More recently, 
relevant additional family members were 
ascertained (Figure 1B, subject 4, 5, and 16) 
with the unique FOA phenotype of this 
family. The study was approved by the 
medical ethic committee and written 




Occurrence of the OPG read-through 
mutation in the population was tested by de 
novo genotyping in healthy subjects and OA 
cases. Middle-aged partners (N=744) of the 
offspring of nonagenarian siblings from the 
Leiden Longevity study (LLS)[20] were 
considered as controls for OA cases and are 
further named ‘random controls’. OA cases 
included were selected from the Genetics 
osteoarthritis and Progression (GARP) study 
(N=177),[21] the Patients Prospectively 
Recruited in Knee and hip Arthroplasty 
(PAPRIKA) study performed at the Leiden 
University Medical Center (Dept. 
Orthopedics; N=1,137),[22] and the ongoing 
Research Arthritis and Articular Cartilage 
(RAAK) study (N=153) aimed at the 
biobanking of joint materials (cartilage, bone 
and where available ligaments) and bone 
marrow derived mesenchymal stem cells (hip 
joints only) of OA patients and controls in 
the Leiden University Medical Center and 
collaborating outpatient clinics in the Leiden 
area. More detailed description of the studies 
included can be found in the Supplementary 
methods. 
 
Ethical permission for all studies described 
was obtained from the appropriate medical 
ethical committee. Written informed consent 
was obtained from all participants following 
detailed explanation of the study.  
 
Exome sequencing. Exome sequencing of 
the FOA family members was performed by 
Illumina HiSeq2000 technology (Beijing 
6 
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Genome Institute). The sequences of each 
individual were generated as 100 bp paired-
end reads, after enrichment of 44 MB exonic 
sequences by NimbleGen EZ (Roche 
NimbleGen, Madison, WI). Raw image files 
were processed by Illumina base calling 
SoftwareV1.7 with default parameters. 
SOAPaligner/SOAP2.21 was used to map 
reads onto the hg19 reference genome 
(GRCh37) at UCSC. Approximately, 71% of 
bases originated from the targeted exome, 
resulting in a mean coverage of 55.93 and 
55.81-fold for subjects one and four, 
respectively. More than 83% of the targeted 
exons were covered more than ten times. 
Single-nucleotide variants were subsequently 
called by the SOAPsnps. The final variant-
filtering scheme, which focused on sharing of 
novel[23] pathogenic mutations between the 
distant related family members, is detailed in 
Supplementary Table 2. 
 
Genotyping. Heterozygous deleterious gene 
variants shared among the two family 
members were chosen to fit efficiently in a 
Sequenom multiplex assay designed by the 
Assay Designer software version 3.1 
(Sequenom, San Diego, CA). Single 
nucleotide polymorphisms (SNPs) were 
genotyped by mass spectrometry (the 
homogeneous MassARRAY system; 
Sequenom, San Diego, CA) using standard 
conditions and as described elsewhere.[24] In 
short, PCR reactions were carried out in a 
final volume of 5 µl and contained 2.5 ng of 
genomic DNA. Genotypes were assigned by 
using Genotyper version 3.0 software 
(Sequenom, San Diego, CA). Variants were 
genotyped across available FOA members 
(Supplementary Table 1 and Supplementary 
Table 3), osteoarthritis case studies (GARP, 
PAPRIKA study and RAAK), and random 
controls (LLS). 
 
Linkage analysis. To assess the logarithm 
of the odds (LOD) score of the mutation in 
TNFRSF11B within the extended family, two 
point model-based linkage analysis was 
performed using the FASTLINK 2.2 version 
of the linkage program MLINK.[25] The 
disease locus was modeled as an autosomal-
dominant trait with a disease frequency of 
0.001, as symptomatic and radiographic 
osteoarthritis at multiple joint sites before the 
age of 50 years is rare. The TNFRSF11B 
allele frequency was set at 0.01. To perform a 
conservative analysis penetrance were 
assumed to be 100% among definitively 
phenotyped individuals (Patient 1, 2, 3, 4, 5, 
6, 7, 8, 12, 14, and 16, Figure 1, and 
Supplementary Table 1). Family members 
with uncertain phenotype were considered 
unknown (Patient 9, 10, 13, and 15, in Figure 
1 and Supplementary Table 1). 
 
In vitro mutagenesis. A mammalian 
expression vector (pORF9) containing the 
human TNFRSF11B open reading frame was 
obtained from InvivoGen. The point 
mutation causing read-through was 
introduced using the QuickChange Site-
Directed Mutagenesis kit (Agilent 
Technologies Inc.) according to the 
manufacturer’s protocol with the following 
primers: Forward 5’-TAAGCTGCTTATCA 
CTGGAAATGGCCATTGAGC-3’; 
Reverse 5’-GCTCAATGGCCATTTCCAGT 
GATAAGCAGCTTA-3’. Introduction of 
the aimed mutation and exclusion of 
additional mutations by PCR artifacts was 





Production of recombinant 
osteoprotegerin and Western blot 
analysis. For the production of recombinant 
osteoprotegerin (OPG), HEK293T cells were 
cultured in OPTI-MEM I-Reduced Serum 
Medium (Invitrogen). Cells were transfected 
either with empty vector or vector with wild-
type or mutant TNFRSF11B using FuGENE 
6 reagent (Roche). Tissue culture 
supernatants were collected after three days, 
cleared of debris by centrifugation, and 
stored frozen. To confirm expression and 
quality of the recombinant proteins in the 
conditioned media, Western blotting was 
performed on 45 µl tissue culture 
supernatant as described previously[26] using 
the rabbit monoclonal antibody EPR3592 
(Epitomics; 1:5000 diluted) to detect OPG. 
Subsequently, concentration of OPG in the 
tissue culture supernatant was determined by 
ELISA (R&D Systems) following the 
manufacturer’s instructions. 
 
In vitro osteoclastogenesis. Putative 
difference in the activity of wild-type and 
mutant OPG was investigated by applying an 
in vitro model of osteoclastogenesis on 96-
wells plates with pieces of human bone. 
PoieticsTM human osteoclast precursors 
(Lonza) were seeded onto the OsteoAssay 
Human Bone Plate (Lonza; 104 cells per well) 
in the absence (negative control) or in the 
presence (positive control) of RANKL. 
Either nothing, or equal volumes of tissue 
culture supernatant from the HEK293T cells 
was added to osteoclast growth and 
differentiation medium (Lonza) to a final 
concentration of 100ng/ml OPG. Osteoclast 
precursors were cultured for 6 days before 
adding fresh osteoclast growth and 
differentiation medium. Subsequently, cells 
were grown for 16-18 hours and media were 
harvested for analysis. 
To analyze osteoclastogenesis, tartrate-
resistant acid phosphatase staining (TRAP; 
Takara Bio Inc.) at day 7 of poietics human 
pre-osteoclast cultures was carried out 
following the manufacturer’s protocol. 
Concentration of CTX-I in the media was 
determined by applying CTX-I CrossLaps® 
enzyme-linked immunosorbent assays 
(ELISAs; IDS Ltd.) according to the 
manufacturer’s protocol. The amount of 
CTX-I released in the tissue culture 
supernatant reflects the amount of bone 
resorption by mature osteoclasts. The in vitro 
osteoclastogenesis assays were carried out 2 
times in triplicate. 
 
Gene expression analysis. To explore the 
generalizability of the discovered pathway 
towards common forms of osteoarthritis, 
mRNA expression was analyzed in an 
available dataset (Illumina HT-12 v3 
microarray) of 33 paired preserved and 
osteoarthritic cartilage samples of the RAAK 
study. Following RNA isolation of the 
collected cartilage, samples were prepared for 
gene expression by microarray analysis as 
described in detail in the Supplementary 
methods. Subsequently, data were exported 
for analyses using Limma.[27] As 
implemented in Limma, a paired t-test was 
applied to all sample pairs. Overall mean 
normalized probe expression levels of the 
measured genes in cartilage ranged from 6.58 
to 14.91 with a mean of 7.4 and a median of 
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RESULTS 
 
Identification of read-through mutation 
in TNFRSF11B. Whole exome sequencing 
was applied to two distant FOA family 
members (Figure 1B; subject 1 and 4) and 
identified 57,018 and 60,652 variants, 
respectively, which fulfilled the quality criteria 
in each patient. To identify pathogenic 
mutations a prioritization scheme was applied 
in which we excluded variants present in 
dbSNPv132 (including 1000 Genomes Pilot 
project data), synonymous variants, tolerated 
missense variants as determined by SIFT 
(http://sift.jcvi.org/), intergenic variants and 
intron variants. In addition, we excluded 
variants detected in in-house analyzed human 
genomes (N=221), in-house analyzed human 
exomes (N=43), and analyzed independent 
human genomes by the Genome of the 
Netherlands project (GoNL N=473; 
www.nlgenome.nl).[28] This reduced the 
number of variants to, respectively, 102 and 
105 variants per subject that were predicted 
to affect gene function (see Supplementary 
Table 2). Given that these two FOA patients 
were distantly related (Figure 1B subject 1 
and 4; six meioses apart) they are expected to 
share the causal variant. We found in total 
five heterozygous deleterious gene variants 
that were shared among the two patients: 3 
novel missense damaging, 1 splice site 
mutation, and 1 read-through mutation 
located in, respectively, the preferentially 
expressed antigen in melanoma family 
member 22 (PRAMEF22), dynein axonemal 
heavy chain 10 (DNAH10), tetraspanin 8 
(TSPAN8), mitotic control homolog gene 
(DIS3), and the tumor necrosis factor 
receptor superfamily member 11b 
(TNFRSF11B; Table 1). 
Genotyping of these variants in all 
 
 
Figure 1. Early onset family with familial generalized osteoarthritis (FOA) without any 
dysplasia. A. Pedigree of the family with primary osteoarthritis at multiple joint locations without 
dysplasia with radiographic chondrocalcinosis. The hatched symbols represents diagnostic 
uncertainty, the filled symbols represent affected subjects. Indicated are phenotypic relevant family 
members. DNA of distant relatives one and four were subjected to exome sequencing. B. Radiograph 
of individual two at age 65 years showing hand joints with marked osteoarthritis at DIP, PIP, CMC1, 


































































































































































































































































































































































































































































































































































































































































































members of the extended FOA family (N=16, 
Figure 1) showed complete co-segregation 
with the phenotype across three generations 
only for the read-through mutation within the 
TNFRSF11B gene, resulting in a genome wide 
significant linkage analysis at this locus (LOD-
score of 3.48; Supplementary Table 4). 
Furthermore, the variant did not occur in 1467 
other osteoarthritis affected subjects (the 
GARP, RAAK, and PAPRIKA study) nor in 
744 random controls (Leiden Longevity study) 
indicating that the mutation may be private for 
this family. These data indicate that the A to T 
nucleotide change (A1205T) at the STOP 
codon of the TNFRSF11B gene encoding 
osteoprotegerin is likely causal to the FOA 
phenotype in this family. The read-through 
mutation results in the generation of a Leucine 
amino acid (X402L) and subsequent 19 
additional amino acids at the C-terminus of 
OPG (c.1205A=>T; p.Stop402Leu; 
Supplementary Figure 3). 
 
Effect of read-through mutation on OPG 
protein function. OPG is a soluble decoy 
receptor which inhibits osteoclastogenesis by 
competing with the receptor activator of the 
nuclear factor-ΚB (RANK), expressed on the 
membrane of pre-osteoclasts, for the binding 
of the nuclear factor-ΚB ligand (RANKL; 
Supplementary Figure 4). To investigate the 
putative effect of the (X402L) read-through 
mutation on OPG protein function, its activity 
was investigated in an in vitro 
osteoclastogenesis assay. Mutant OPG gene 
was generated by site directed mutagenesis and 
recombinant wild-type and mutant OPG 
proteins were produced in transfected 
HEK293T cells. Protein integrity was 
confirmed by Western blotting 
(Supplementary Figure 5). Subsequently, 
recombinant proteins were added to  
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differentiating poietics human pre-osteoclasts 
seeded onto OsteoAssayTM Human Bone 
Plates. After 1 week, efficiency of bone 
resorption upon osteoclastogenesis of the 
osteoclast precursors was quantified by 
determining the amount of CTX-I released in 
the medium of the differentiating osteoclasts 
(Figure 2A). A clear difference could be 
observed between cells cultured in the 
presence or in the absence of OPG. Figure 2 
shows that the addition of RANKL to pre-
osteoclasts greatly enhanced 
osteoclastogenesis as can be concluded from 
the higher concentrations of CTX-I (Figure 
2A, +). Adding medium from HEK293T 
cells transfected with empty vector did not 
have an effect (Figure 2A, ‘+ sup’). However, 
addition of recombinant wild-type OPG 
(Figure 2A, ‘+ wt OPG’) or mutant OPG 
(Figure 2A, ‘+ mt OPG’) significantly 
reduced bone resorption, respectively, 1.2-
fold (p=0.049) and 1.6-fold (p=8.4x10-5) 
reflecting a statistical significant increased 
capacity of the mutant-OPG to inhibit 
osteoclastogenesis as compared to the wild 
type (p=4.7x10-3). To visually inspect the 
osteoclastogenesis in this experiment  
 
Generalizability of the OPG/RANK/ 
RANKL pathway in osteoarthritis. To 
investigate the a tartrate-resistant acid 
phosphatase (TRAP) staining was performed 
for the different conditions. Mature 
osteoclasts are distinguished as large 
multinucleated TRAP positive cells (Figure 
2B, indicated with an arrow). Together, these 
data demonstrate that the identified read-
through mutation in TNFRSF11B, causing 
the FOA phenotype, enhances OPG protein 
function.response of TNFRSF11B and the 
tumor necrosis factor superfamily member 
11 (TNFSF11) gene, encoding RANKL, to 
the general osteoarthritis pathophysiological 
process in articular cartilage, we explored a 
microarray expression dataset of 
osteoarthritis affected and preserved 
cartilage, taken from the same joints, of 33 
independent osteoarthritis patients that 
underwent joint replacement due to end stage 
osteoarthritis disease (RAAK study). 
TNFRSF11A encoding RANK appeared to 
be expressed at a very low level (in the lowest 
quartile of expression) and was therefore not 
detected well. In contrast, the expression 
levels of TNFRSF11B in osteoarthritic and 
preserved cartilage samples appeared in the 
highest expression quartile with little inter-
individual variation. A highly significant up-
regulation of both TNFRSF11B (2.1-fold 
change, p=1.9x10-8) and TNFSF11 (1.2-fold 
change, p=3.1x10-6) was observed in 
osteoarthritic cartilage as compared to 
preserved cartilage of the same joint, 
indicating that these genes are responsive to 
the OA process in articular cartilage 
(Supplementary Table 5). 
It has been shown that bone homeostasis 
merely depends on the ratio between 
TNFRSF11B and TNFSF11.[29] Therefore, 
we compared this ratio in both, osteoarthritic 
and preserved cartilage. As shown in Figure 
3, we found a significant increase of the 
TNFRSF11B/TNFSF11 ratio (p=2.0x10-4) in 
osteoarthritic articular cartilage which may 
contribute to respective mineralization of the 
cartilage and eventually formation of bone, a 






We have identified a heterozygous read-




Leu) in TNFRSF11B that is likely causal to 
the severe osteoarthritis phenotype in the 
here studied extended FOA family. 
Functional analyses showed that this 
mutation establishes a gain of function of the 
encoding protein OPG. Given that the 
mutant OPG decoy receptor more efficiently 
antagonizes osteoclastogenesis and the FOA 
phenotype is characterized by calcifications 
within the joint- and fibro-cartilage, we 
hypothesize that the detected mutation acts 
via an unfavorable interplay between 
(subchondral) bone and cartilage towards 
enhanced matrix mineralization. Gene 
expression analyses of preserved and 
osteoarthritic articular cartilage of 
independent OA patients showed that 
enhanced OPG-mediated antagonism is a 
general phenomenon of the 
pathophysiological process within 
osteoarthritic articular cartilage. This is in line 
with other reports showing increased 
expression of OPG in arthritic cartilage 
compared to healthy cartilage.[31, 32] Also 
during intervertebral disc degeneration, a 
process highly comparable to the 
pathological processes occurring in articular 
cartilage during OA, OPG appeared to be 
increased in correlation with degeneration 
grade and coinciding with the presence of 
microscopic calcifications.[33] Albeit that the 
role of the molecular pathway of OPG has 
 
 
Figure 2. Read-through mutation in the TNFRSF11B gene results in gain of OPG function. 
A. Levels of CTX-I were measured in the medium of the assay. Results shown are the average of two 
independent assays performed in triplicate (*p <0.05 **p <0.005 ***p <0.0001 ANOVA) . Legend: ‘-
-‘: nothing added; ‘+’: RANKL added, ‘+ sup’: RANKL and medium from HEK293T cells 
transfected with empty vector added; ‘+ wt OPG’: RANKL and recombinant wild-type OPG added; 
‘+ mt OPG’: RANKL and recombinant mutant OPG added. Added OPG was present in the tissue 
culture supernatant at a concentration of 100 ng/ml. B. Representative example of histochemical 
staining for Tartrate-resistant acid phosphatase (TRAP) at day 7 of poietics human pre-osteoclast 
cultures on the OsteoAssayTM Human Bone Plate. Active and fully differentiated osteoclasts are 
detected as large multinucleate cells (generally accepted standard for mature osteoclasts is presence 
of 3 or more nuclei per cell) which are characterized by high TRAP expression (visualized as light 
purple; white arrows indicate some of the osteoclasts shown in the pictures and black arrowhead 
points at an example of a bone slices). 
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been studied in osteoarthritis, a direct causal 
role towards matrix mineralization has not 
been reported up until now and it may 
provide new clues to the development of 
anti-osteoarthritic drugs. 
Retrospectively, we observed in our 
family a positional linkage signal at the 
position of the TNFRSF11B gene 
(Supplementary Table 3).[19, 34] 
Additionally, of note is a report of Baldwin et 
al. that indicated linkage to chromosome 8q 
in a family with early onset osteoarthritis and 
chondrocalcinosis at a locus encompassing 
the TNFRSF11B gene.[35] Given the results, 
it would be interesting to further investigate 
the status of the TNFRSF11B gene of the 
reported family by next generation 
sequencing. Although TNFRSF11B was not 
previously detected as OA susceptibility gene 
by virtue of genome wide association studies, 
consistent genetic associations of 
TNFRSF11B with knee OA were found in 
the general population,[32, 36] in particular in 
association with OA progression as measured 
by changes in osteophyte grade. More 
investigations are necessary to explore 
whether genetic variations in genes of the 
OPG pathway confer risk to common OA. 
Transgenic mice that overexpress 
TNFRSF11B had increased skeletal 
radiodensity, osteopetrosis, and increased 
bone density due to decreased numbers of 
mature osteoclasts,[37] however, no 
reference or investigation has been made to 
osteoarthritis as being part of the phenotypes 
of these mice or, for that matter, 
radiographic chondrocalcinosis. Since long, 
epidemiological studies have shown that high 
bone mineral density is associated with 
development of OA[38, 39] and may also 
affect OA progression.[40] Therefore, 
alternatively to the mentioned enhanced 
matrix mineralization of the cartilage, 
expression of mutant OPG could result in 
systemic higher bone mass thereby 
predisposing to OA due to a suboptimal 
cartilage-bone interplay. Since we have no 
bone density measurements available of our 
FOA family members, the role of systemic 
high bone density in the osteoarthritis onset 
requires further investigation. In contrast, 
loss of function mutations in the 
TNFRSF11B gene, that abolish the inhibitory 
action on osteoclastogenesis, have been 
found to cause Juvenile Pagets disease 
characterized by accelerated bone turnover, 
fractures of the long bone and 
hyperphosphatasia.[41] Furthermore, SNPs 
within the TNFRSF11B gene have been 
found to be associated in genome wide 
association studies to common osteoporosis 
or low bone mineral density.[42]  
 
Figure 3. Increased TNFRSF11B gene 
expression in osteoarthritic as compared to 
preserved cartilage. Boxplots showing the 
ratio in expression of TNFRSF11B and 
TNFSF11 in preserved (P) and osteoarthritic 
(OA) cartilage (ratio of the individual samples is 
shown as gray dots). Data is from micro-array 
expression of N=33 patients that underwent 
joint replacement due to end stage OA. Ratios 
are determined using the overall relative light 
intensity signals for both genes as provided by 
IlluminaTM in respectively the preserved and 




Despite the fact that it has been 
convincingly demonstrated that a strong 
interaction between subchondral bone and 
the articular cartilage exists and that changes 
in mineralization of both bone and cartilage 
reflect pathophysiology of osteoarthritis 
several seemingly contradictory observations 
have been made and the direction of the 
changes of the subchondral bone density and 
mineralization in osteoarthritis patients 
appeared unclear and possibly dependable on 
the disease status.[43, 44] More recently, 
osteoarthritis patients were shown to benefit 
from treatment with strontium ranelate, 
which is a drug licensed for osteoporosis and 
acts by increasing bone formation while 
decreasing bone resorption.[45] These 
studies, however, have been subject of 
debate[46, 47] and seem in contrast with our 
current findings and with the extensive 
literature indicating that individuals with high 
systemic bone mass are at increased risk for 
the incidence of osteoarthritis.[48] It could be 
speculated that, initially, strontium ranelate 
enhances stabilization of the dynamically 
changing OPG/RANKL ratios as it was 
observed across different grades of OA,[49] 
resulting in OPG and RANKL levels in the 
joint balancing towards a net ratio of bone 
formation. This may temporarily 
strengthening the joint and decelerate OA 
progression. Although therapeutic treatment 
of rats with another bone-forming agent, 
OPG-Fc, did not directly improve the OA 
phenotype, it did decrease pain in particular 
when starting the treatment at early 
stages.[50] Increased bone thickness as a 
result of the treatment may prevent 
enervation of the joint leading to a 
‘desensitization’. Careful investigation of the 
long term effects of these bone forming 
therapies in osteoarthritis is, definitely, 
necessary[30] thereby taking the existence of 
different (sub)types of OA characterized by 
differences in bone mineral density[51] into 
account.  
The molecular pathway of the 
OPG/RANKL in terms of its manipulation 
for therapeutic benefit has been studied 
extensively, especially to enhance the OPG-
mediated RANK antagonism in osteoporosis, 
or, in the case of cancer, growth of bone 
metastasis.[52] These studies showed that all 
of the C-terminal domains of OPG are 
necessary for high affinity association with 
RANKL.[53] As a result, the design of short 
recombinant, monomeric OPG molecules 
that mimic both the receptor binding and 
dimerization functions of the multi-domain, 
100-kDa homodimeric OPG polypeptide has 
been indicated as challenging.[52] Given that 
the here detected read-through mutation 
results in the addition of 19 amino acids at 
the C-terminus of the OPG protein, we 
hypothesize that the gain of function may be 
established through an enhanced stability of 
OPG dimers thereby increasing the efficiency 
of RANKL binding. The use of the here 
identified X402L mutant OPG protein could 
provide a putative new starting point to 
further establish such a stable molecule. 
 
In summary, we have identified a read-
through, gain of function mutation within the 
TNFRSF11B gene that is likely causal to the 
FOA phenotype in the here studied family. 
With this result, we are the first to 
demonstrate that enhanced OPG mediated 
RANK antagonism could be directly 
underlying the onset of osteoarthritis. The 
exact mechanism on how this is brought 
about remains to be established. Given that 
enhanced OPG-mediated antagonism 
appears to be a more general phenomenon in 
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the pathophysiological process of 
osteoarthritic cartilage, we advocate that, in 
contrast to the use of bone-forming 
therapies, agents counteracting OPG 
function could comply with the development 
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Leiden Longevity Study (LLS). In the current study, the OPG read-through mutation has 
been tested for presence among the partners (N=744) of the offspring LLS referred to as 
random controls. Families were eligible to participate in the LLS study when at least two long-
lived siblings were alive and over 89 years old for males and over 91 years for females, 
representing less than 0.5% of the Dutch population in 2001 (so-called ‘nonagenarians’).[3]  
 
Cases 
Genetics osteoarthritis and Progression (GARP). The GARP study consists of 192 sibling 
pairs concordant for clinical and radiographically (K/L score) confirmed osteoarthritis at two 
or more joint sites among hand, spine (cervical or lumbar), knee or hip. Conventional 
radiographs of the hands (dorso-volar), knees (posterior-anterior (PA) in weight bearing 
semiflexed and lateral), hips (PA), lumbar (PA and lateral), and cervical spine (anterior-
posterior, lateral, and transbuccal) were obtained from all participants. Detailed description of 
the GARP study has been published previously.[4] Occurrence of the OPG read-through 
mutation among OA cases was tested by de novo genotyping of 177 cases from the GARP 
study.  
Patients Prospectively Recruited in Knee and hip Arthroplasty (PAPRIKA). The Paprika 
study is performed at the Leiden University Medical Center (Dept. Orthopedics) and consists 
in a long-term follow-up study of patients that have undergone total joint replacement (TJR) at 
hip or knee.[5] Patients of Caucasian descent were included when they were diagnosed with 
primary osteoarthritis based on radiographs and the ACR rheumatology classification criteria. 
Patients with secondary osteoarthritis or patients requiring a revision were excluded from the 
PAPRIKA study. For the study described here we genotyped the detected mutations in 1137 
patients of the PAPRIKA study.  
Research Arthritis and Articular Cartilage (RAAK). The RAAK study is aimed at the 
biobanking of joint materials (cartilage, bone and where available ligaments) and bone marrow 
derived mesenchymal stem cells (hip joints only) of OA patients and controls in the Leiden 
University Medical Center and collaborating outpatient clinics in the Leiden area. In the 
current study we genotyped the detected mutations in 153 RAAK patients, and determined 
gene expression in 61 paired samples of osteoarthritic and macroscopically unaffected cartilage. 
 
Gene expression analysis 
To explore the generalizability of the discovered pathway towards common forms of 
osteoarthritis, mRNA expression was analyzed in an available dataset (Illumina HT-12 v3 
microarray) of 33 paired preserved and osteoarthritic cartilage samples of the RAAK study.  
Cartilage collection. Within the RAAK study we collected paired preserved and OA affected 
cartilage samples from Caucasian end stage OA patients undergoing joint replacement surgery 
for primary OA in the Leiden University Medical Centre. At the moment of collection (within 
6 
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2 hours following surgery) tissue was washed extensively with phosphate buffered saline (PBS) 
to decrease the risk of contamination by blood, and cartilage was collected of the weight-baring 
area of the joint. Cartilage was classified macroscopically and collected separately for OA 
affected and preserved regions (classification was done according to predefined features for 
OA-related damage based on color/whiteness of the cartilage, based on surface integrity as 
determined by visible fibrillation/crack formation, and based on depth and hardness of the 
cartilage upon sampling with a scalpel). During collection with a scalpel, care was taken to 
avoid contamination with bone or synovium. Collected cartilage was snap frozen in liquid 
nitrogen and stored at -80°C prior to RNA extraction. 
 
RNA isolation. Cartilage samples were pulverized using a Retsch MM200 under cryogenic 
conditions. On average 150 mg of pulverized cartilage was dissolved in 1 ml of Trizol reagent, 
and mixed vigorously. After addition of 200μl of chloroform the sample was mixed and 
centrifuged for 15 minutes at 16,000g. The clear aqueous layer was transferred to a new vial 
and 1 volume of 70% ethanol/DEPC-treated water was added to precipitate RNA. The RNA 
was collected using Qiagen mini columns according to the manufacturers protocol. The RNA 
quality was assessed using a Bioanalyzer lab-on-a-chip and quantity was assessed using a 
nanodrop spectrophotometer. RIN values above eight were considered suitable for gene 
expression analysis. 
 
Microarray expression. 0.5 µg of total RNA was used as template for first- and second-
strand reverse transcription steps using an Ambion (Life Technologies Europe BV, Rijswijk, 
The Netherlands) RNA amplification kit. After in vitro transcription, amplification, and 
labeling with biotin-labeled nucleotides Illumina HT-12 v3 microarrays were hybridized 
(Illumina, San Diego). Sample pairs were randomly dispersed over the microarrays, however 
each pair was measured on a single chip of in total eight chips. The microarrays were read 
using an Illumina Beadarray 500GX and after basic quality checks using Beadstudio the 
intensity values were normalized using the “rsn” option in the Lumi R-package. The 
corresponding signals increase exponentially with relative expression probe-levels. Indicated 
units are light intensity as provided by Illumina. The subsequently obtained raw probe-level 
data were exported for analyses using Limma.[6] As implemented in Limma, a paired t-test was 
applied to all sample pairs. Overall mean normalized probe expression levels of the measured 
genes in cartilage ranged from 6.58 to 14.91 with a mean of 7.4 and a median of 7.1 with a 
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OPG mutation directly causal to osteoarthritis 
Supplementary Table 2. Variant prioritization scheme after exome sequencing. 
 
 
Subject 1 Subject 4 
Total number of variants identified 57018 60562 
exonic (including 5'-utr and 3'-utr) and canonical splice sites 15130 15183 
missense, nonsense, readthrough, frame error, splice site 7735 7699 
novel 618 636 
missense damaging, nonsense, readthrough, frame error, splice site 168 176 
not present in in-house whole genome sequencing data (N=694) 110 115 
not present in in-house exome sequencing data (N=43) 102 105 






Supplementary Table 3. Genotyping of the detected variants in FOA family members. 
*variant was not detected by genotyping. ǂDNA not available. †Total number of individuals 
showing linkage between phenotype and genotype (subjects with diagnostic uncertainty are not 
taken into account). SS = splice site. 
 
  
PRAMEF22 DNAH10 TSPAN8 DIS3 TNFRSF11B 
FamID Status I223T S577Y* V209F SS *=>L 
1 Affected T C C C C A T C T A 
2 Affected T T - C C T C T A 
3 Unaffectedǂ - - - - - 
4 Affected T C C C C A T C T A 
5 Affected T C C C C A T T T A 
6 Affected T C C C C C T C T A 
7 Affected T T C C C A T C T A 
8 Unaffected T C C C C A T C T T 
9 Diagnostic uncertain T T C C C C T C T A 
10 Unaffected T C C C C A T T T T 
11 Unaffected T T C C C C T T T T 
12 Affected T T C C C C T T T A 
13 Diagnostic uncertain T T C C C C T C T A 
14 Affected T T C C C C T T T A 
15 Diagnostic uncertain T T C C C C T T T A 
16 Affected T T C C C C T T T C 
 
Total linked† 5/12 0/12 5/12 7/12 12/12 
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Supplementary Table 4. Two point LOD scores FOA family a. *LOD scores calculated 
with the original family structure and inheritance pattern[2] 
†LOD scores calculated with c.1205A=>T using the updated family structure. 
 
Marker CHR POS (start – stop) LODscore 
   
0 0.05 0.1 
D8S1132* 8 107328821 - 107329072 1.07 0.96 0.83 
TNFRSF11B† 8 119938733 - 119964383 3.48 3.16 3 














Supplementary Table 5: Expression analyses of TNFRSF11B and TNFSF11 in articular 
cartilage. Legend: Expr: relative gene expression, assessed by exploring a microarray mRNA 
expression dataset generated on Illumina HT-12 v3 chips in matched osteoarthritic and 
preserved cartilage samples of 33 patients that underwent joint replacement due to end stage 
osteoarthritis (expression levels are expressed as the light intensity values as provided by 
IlluminaTM. The average level of expression for all probes ranged from 6.58-14.91 with mean 
7.4 and median 7.1 with a strong right tailing); Expr QT: Quartile of the expression level where 
1 = lowest level of expression and 4 = highest level of expression; FC: fold change between 
osteoarthritic and preserved cartilage samples (FC > 1 indicated higher expression in 
osteoarthritic as compared to preserved cartilage).  
TNFRSF11B: tumor necrosis factor receptor superfamily member 11b encoding 
osteoprotegerin (OPG); TNFSF11: tumor necrosis factor (ligand) superfamily, member 11 
encoding the nuclear factor-ΚB ligand (RANKL). 
 
Gene Expr Expr QT FC p 
TNFRSF11B 10.3 4 2.1 1.9 x 10-8 
TNFSF11 7.1 3 1.2 3.1 x 10-6 
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142 
OPG mutation directly causal to osteoarthritis 








Supplementary Figure 2. Knee radiographs. A Right knee joint of FOA family member 
one at age 53 years with diagnosed chondrocalcinosis (not clearly visible on this photo) and 
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Supplementary Figure 3. Amino acid sequence of wild-type and mutant (X402L) 
TNFRSF11B or osteoprotegerin. An T>A base pair change at the stop codon in exon 5 
(A1205T) results in a STOP to Leucine amino acid change (X402L) in the TNFRSF11B gene. 


















Supplementary Figure 4. Bone homeostasis depends on the local OPG/RANK ratio. 
The RANK ligand (RANKL) competitively binds to the OPG decoy and RANK receptor. 
Binding of RANKL to the RANK receptor at the osteoclast precursor cell acts as an osteoclast 





OPG mutation directly causal to osteoarthritis 
Supplementary Figure 5. Recombinant human osteoprotegerin (OPG). To confirm 
integrity of the recombinant proteins, Western blotting was performed using 10 μl of the 
concentrated tissue culture supernatant of HEK293T cells 3 days after transfection with either 
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ABSTRACT 
Objectives To investigate how the genetic susceptibility gene DIO2 confers risk to OA 
onset in humans and to explore whether counteracting the deleterious effect could 
contribute to novel therapeutic approaches.  
Methods Epigenetically regulated expression of DIO2 was explored by assessing 
methylation of positional CpG-dinucleotides and the respective DIO2 expression in 
OA affected and macroscopically preserved articular cartilage from end stage OA 
patients. In a human in vitro chondrogenesis model, we measured the effects when 
thyroid signaling during culturing was either enhanced (excess T3 or lentiviral induced 
DIO2 over-expression) or decreased (Iopanoic Acid). 
Results OA-related changes in methylation at a specific CpG dinucleotide upstream of 
DIO2 caused significant upregulation of its expression (Beta=4.96; p=0.0016). This 
effect was enhanced and appeared driven specifically by DIO2 rs225014 risk-allele 
carriers (Beta=5.58, p=0.0006). During in vitro chondrogenesis DIO2 overexpression 
resulted in a significant reduced capacity of chondrocytes to deposit extra cellular 
matrix (ECM) components, concurrent with significant induction of ECM degrading 
enzymes (ADAMTS5, MMP13) and markers of mineralization (ALPL, COL1A1). Given 
their concurrent and significant upregulation of expression, this process is likely 
mediated via HIF-2α/RUNX2 signalling. In contrast, we showed that inhibiting 
deiodinases during in vitro chondrogenesis contributed to prolonged cartilage 
homeostasis as reflected by significant increased deposition of ECM components and 
attenuated upregulation of matrix degrading enzymes. 
Conclusions Our findings show how genetic variation at DIO2 could confer risk to OA 
and raised the possibility that counteracting thyroid signaling may be a novel 
therapeutic approach. 
 
Keywords: DIO2; thyroid pathway; chondrogenesis; epigenetics; endochondral ossification 
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INTRODUCTION 
 
Osteoarthritis (OA) is a prevalent, complex, 
disabling disease of articular joints, 
characterized by degradation of articular 
cartilage and remodeling of the subchondral 
bone. There is no effective therapy to reverse 
or slow down the disease except for joint 
replacement surgery at the end stage. As a 
result, OA has a large detrimental impact on 
the quality of life of the elderly and causes a 
major burden on health and social care.[1] To 
allow development of new therapies, there is 
an on-going need for insight into the 
underlying mechanisms driving OA. Genetic 
studies provided evidence that genes 
orchestrating growth plate endochondral 
ossification play a underlying role in common 
OA susceptibility,[2] hence functional follow 
up approaches require focus on both the early 
developmental and late acting effects of these 
OA genes. A notable example is the 
deiodinase iodothyronine type 2 (D2) gene 
(DIO2) with the C-allele of the single 
nucleotide polymorphism (SNP) rs225014 
(frequency ~0.35) located in the coding 
region that conferred consistent risk to 
OA.[3, 4] The gene product of DIO2 is 
responsible for catalyzing the conversion of 
intracellular inactive thyroid hormone (T4) to 
active thyroid hormone (T3). T3 
subsequently signals terminal maturation of 
growth plate chondrocytes leading to cell 
hypertrophy, cartilage matrix destruction 
mediated via upregulation of hypoxia 
inducible factor-2α (HIF-2α) and runt-related 
transcription factor-2 (RUNX2),[5, 6] 
mineralization of the cartilage and eventually 
formation of bone.[7] There are striking 
parallels between the chondrocyte signalling 
events that take place in the growth plate and 
those of hypertrophic chondrocytes in OA 
affected articular cartilage.[5] This has led to 
the hypothesis that with age and 
environmental stresses the propensity of the 
highly specialized, maturational arrested 
articular chondrocytes is affected by loss of 
epigenic control. Progression of age and 
disease could result in reactivation of genes 
involved in endochondral ossification, 
leading to loss and mineralization of articular 
cartilage, a process known to contribute to 
OA.[3, 8-10] Functional genomic studies 
showed high expression of DIO2 mRNA and 
D2 protein levels in osteoarthritic as 
compared to healthy cartilage.[5, 11, 12] 
Furthermore, DIO2 allelic imbalance was 
assessed and showed that the OA risk allele 
‘C’ was more abundantly present in articular 
joint tissues than the wild-type allele ‘T’.[11] 
In transgenic rats DIO2 overexpression 
conferred risk to articular cartilage 
destruction.[13] The underlying mechanism 
how the DIO2 SNP confers susceptibility to 
OA in humans remains, however, to be 
determined[14] but most likely acts via 
aberrent up-regulation of its expression. The 
DIO2 locus in humans contains several 
putative CCCTC-binding factor (CTCF) 
binding sites, including one that is 
overlapping with the rs225014 location.[15] 
CTCF is considered to facilitate long-range 
chromatin interactions in order to insulate 
gene expression and distal transcriptional 
elements on the genome are brought in close 
proximity to transcriptional start sites (TSSs) 
of genes to inhibit expression.[16] 
 
In the current study, we focus on regulatory 
mechanisms of DIO2 expression in preserved 
and osteoarthritic human articular cartilage, 
thereby taking into account the DIO2 risk 
allele. The direct effect of changes in DIO2 




human cartilage extracellular matrix (ECM) 
homeostasis, is subsequently studied in 
human in vitro chondrogenesis models which 
should be considered a well defined system 
for studying changes in the ECM when 
chondrocytes differentiate, become 
hypertrophic and start to exhibit cartilage 
debilitating expression paterns. 
 
 
MATERIALS AND METHODS 
 
The ongoing RAAK study is aimed at the 
biobanking of joint materials (cartilage, bone 
and where available ligaments) and 
mesenchymal stem cells and primary 
chondrocytes of patients in the Leiden 
University Medical Center. In the current 
study we used paired preserved and OA 
affected cartilage samples from 52 Caucasian 
end stage OA patients undergoing joint 
replacement surgery for primary OA (23 
hips, 29 knees). For additional details on the 
RAAK study, cell cultures, RNA and DNA 
extraction, quantitative RT-PCR, ChIP and 
the data analysis, see the Supplemental 
Methods. 
 
Electrophoretic Mobility Shift Assay. For 
Electrophoretic mobility shift assays 
(EMSAs) synthetic oligonucleotides 
containing the putative CTCF binding site 
were 5’-end labeled by γ-32P-ATP and 
subsequently purified by gel filtration on 
Sephadex G-25 Medium columns. For 
additional details, see the Supplemental 
Methods. 
 
Quantification of methylation. The 
methylated fraction of CpG dinucleotides 
was assessed with MALDI-TOF mass 
spectrometry (Epityper, Sequenom), a 
commonly applied method to quantify CpG 
methylation.[17-19] For additional details, see 
the Supplemental Methods. 
 
Lentiviral constructs and transduction. C-
terminal FLAG-tagged cys-D2 (kindly 
provided by Prof. Dr. Bianco [20]) was 
digested with EcoR1 followed by Klenow-
treatment and digestion with Xba1. Inserts 
were inserted into the EcoRV-XbaI sites of 
the pLV-CMV-IRES-eGFP Lentiviral 
backbone. For additional details, see the 
Supplemental Methods. 
 
In vitro chondrogenesis. 3D pellets were 
formed using 2.5 x 105 hBMSCs. 
Chondrogenesis was initiated in serum-free 
chondrogenic differentiation medium. From 
day 14 onwards cell pellets were maintained 
either in the standard chondrogenic 
differentiation medium or in the presence of 
T3 (10 nM) or IOP (10 μM). For additional 
details, see the Supplemental Methods. 
 
Relative pixel intensity. The relative pixel. 
intensity was computed by loading the 
 
 Figure 1. (next page). A functional CpG dinucleotide (CpG -2031) significantly modulates 
DIO2 expression. A) Schematic overview of the quantified CpG dinucleotides in pooled preserved 
and paired OA affected samples across the DIO2 locus. B) Methylation between preserved and OA 
affected samples for CpG dinucleotide located 2031 base pairs upstream (CpG -2031) of the DIO2 
TSS (GLMM, N=103, Beta: 0.028, p=0.001, Bonferroni adjusted; see also Table S2). C) Real-time RT-
qPCR data of DIO2 expression between preserved and OA affected cartilage (GLMM, N=87, Beta: 
0.22, p=0.063). D) Association between methylation at CpG -2031 and DIO2 expression (GLMM, 
N=87, Beta: 4.959, p=0.002 Bonferroni adjusted for 23 CpG sites tested). E) Methylation between 
preserved and OA affected cartilage for CpG -2031 among homozygous rs225014 wildtype allele 
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carriers (GLMM, N=44, Beta: 0.018, p=0.112). F) Real-time RT-qPCR data of DIO2 expression 
between preserved and OA affected cartilage among homozygous rs225014 wildtype allele carriers 
(GLMM, N=36, Beta: -0.017, p=0.929). G) Association between methylation at CpG-2031 and DIO2 
expression among homozygous rs225014 wildtype allele carriers (GLMM, N=36, Beta: 3.863, 
p=0.050). H) Methylation between preserved and OA affected cartilage for CpG -2031 among the 
hetero- and homozygous carriers of the rs225014 risk allele (GLMM, N=59, Beta: 0.034, p=2x10-5). I) 
Real-time RT-qPCR data of DIO2 expression between preserved and OA affected cartilage among 
rs225014 risk allele carriers (GLMM, N=51, Beta: 0.35, p=0.012). J) Association between methylation 
at CpG -2031 and DIO2 expression among rs225014 risk allele carriers (GLMM, N=51, Beta: 5.58, 






photos into ImageJ (v.1.47).[21-23] For 





Epigenetic regulation of DIO2 
expression by CpG methylation in 
articular cartilage. Online available ChIP-
seq data revealed multiple transcription 
factors to bind the rs225014 locus of which 
CTCF was predicted to bind with the highest 
certainty (Fig. S1). To assess the regulatory 
properties of the CTCF binding site 
overlapping rs225014 and to test whether the 
rs225014 alleles directly affect the binding, 
we performed an electrophoretic mobility 
shift assay (EMSA). The putative CTCF 
sequence overlapping rs225014 (DIO2-
CTCF1) was found not functional nor, for 
that matter, dependent of the rs225014 alleles 
(Fig. S2, lane 1-6).  
As no further TFs were confidently 
predicted to bind the rs225014 locus, we set 
out to elucidate putative regulatory 
mechanisms of DIO2, independent of the 
rs225014 base change. We, therefore, 
quantified expression of DIO2 and 
methylation of 23 CpG dinucleotides across 
the DIO2 locus in macroscopically preserved 
and OA affected cartilage from joints of 
patients undergoing total arthroplasty of the 
knee (N=29) or hip (N=23) (RAAK study; 
Table S1). We found borderline significant 
upregulation of DIO2 expression (Beta: 0.22, 
p=0.063, Fig. 1C) in OA as compared to 
preserved cartilage. Furthermore, we 
observed several CpG dinucleotides to be 
differentially methylated between preserved 
and OA affected cartilage (Tabe S2). 
However, only for the CpG site 2031 base 
pairs upstream of the DIO2 transcription 
start site (CpG -2031, Fig. 1A), we observed 
significant differential methylation between 
OA and preserved cartilage (Beta: 0.028, 
p=0.0007, Fig. 1B) and a significant positive 
association between methylation and DIO2 
expression in all samples (Beta: 4.959; 
p=0.0016, Fig. 1D; Table S2). To confirm the 
regulatory properties of CpG -2031 on DIO2 
expression, we applied 5-aza-2'-deoxycytidine 
(AZA), a demethylating agent, to the culture 
 
Figure 2. Methylation regulates DIO2 expression in articular cartilage. Each pair of bars 
reflects a unique donor cell culture, deriven from total hip replacement patients. A) Methylation at 
dinucleotide CpG -2031 with no treatment and after treatment with 1.5 µM of the demethylating 
agent 5-aza-2–deoxycytidine (AZA). B) Real-time RT-qPCR data of DIO2 expression with no 
treatment and after AZA treatment. 
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medium in 8 primary chondrocyte cultures 
derived from preserved cartilage of total hip 
replacement patients. Addition resulted in a 
decrease in methylation at CpG -2031 
(p=0.003, Fig. 2A) corresponding to down 
regulation of DIO2 expression (p=0.004, Fig. 
2B). Having observed the association 
between DIO2 expression and OA associated 
methylation at CpG -2031, we applied a 
multivariate model to asses the individual 
effects of CpG -2031 methylation, joint site, 
sex, BMI, age and rs225014 alleles on DIO2 
expression in articular cartilage (Table S3). 
We could hereby ratify the association 
between increased CpG -2031 methylation 
and DIO2 expression (Beta: 4.008, p=0.019). 
The most notable observation, however, was 
the significant independent association of 
rs225014 genotype on DIO2 expression 
(Beta: 0.557; p=0.0003), indicating additive 
effects of both genotype and DNA 
methylation differences on DIO2 expression. 
This effect appeared to be mainly driven by 
the risk allele. Upon stratification by the 
rs225014 alleles, no significant differences 
were observed between preserved and OA 
affected cartilage among homozygous 
carriers of the rs225014 wildtype allele T in 
methylation (Beta: 0.018, p=0.112, Fig. 1E) 
or expression (Beta: -0.017, p=0.929, Fig. 
1F). In carriers of the risk allele, however, an 
increase was observed in OA cartilage as 
compared to the preserved tissue, both in the 
difference of CpG -2031 methylation (Beta: 
0.034, p=0.00002, Fig. 1H) and in expression 
(Beta: 0.35, p=0.012, Fig. 1I), conconmittant 
with an increased association between 
methylation and expression (Beta: 6.816, 
p=0.00001, Fig. 1J). As expected, this 
association between expression and 
methylation was much smaller among 
homozygous wildtype allele carriers (Beta:  
3.863, p=0.050, Fig. 1G). 
 
DIO2 effects on in vitro chondrogenesis; 
DIO2 overexpression. To assess the direct 
effect of DIO2 upregulation upon cartilage 
matrix homeostasis, we examined in vitro 
chondrogenesis of human bone marrow 
derived stem cells (hBMSCs) in a pellet 
culture for 5 consecutive weeks and 
generated lentiviral-mediated overexpression 
of DIO2 (Fig. 3A and Fig. S3). As a result, we 
observed a greatly reduced expression of 
genes encoding the main proteins of articular 
cartilage ECM, COL2A1, ACAN and 
COL10A1, by reverse transcriptase qPCR 
(p<0.0001; Fig. 3A). In parallel, we observed 
profound and significant upregulated gene 
expression of the OA markers of 
hypertrophy and ECM breakdown 
ADAMTS5, MMP13, RUNX2 and EPAS1 
(encoding HIF-2α) from 3 weeks onwards 
(p<0.05, Fig. 3A). Histology confirmed a 
reduced deposition of glycosaminoglycans 
(GAGs; Fig. 3B, 3C). Although we did not 
have data to apply proper statistics to 
produce a significant number, pixel intensity 
measurements of the pictures reproduced as 
in Figure 3 (B-C) showed us a 35% 
difference after 35 days between control and 
DIO2 over-expressing pellets, concurrent 
with visual lower collagen type-II (COL2) 
and collagen type-X (COL10) protein 
expression by immunohistochemical staining 
at consecutive weeks as compared to controls 
(Fig. 3D-G). 
 
DIO2 effects on in vitro chondrogenesis; 
thyroid hormone signaling. To explore 
whether the effects of DIO2 overexpression 
is due to enhanced thyroid signaling, we 
examined in vitro chondrogenesis of hBMSCs 




cultures for 7 consecutive weeks (Fig. S4) 
while adding active T3 to the chondrogenic 
medium from 2 weeks onwards (Fig. 4A-F). 
Excess T3 resulted in a significant, 
progressive reduction in pellet sizes as 
compared to controls, at consecutive weeks 
of culturing (P<0.05, Fig. 4G). Respective 
expression analyses showed a reduced 
expression of the ECM genes ACAN and 
COL2A1 (Fig. 4J), albeit that the 
downregulation of COL2A1 appeared not 
statistically significant. Assesing the 
chondrogenic potential by measuring the 
ratio between COL2A1 and COL1A1 
expression showed a dramatic effect on the 
chondrogenic effect of the cell system upon 
addition of T3 (Fig. 4I). Moreover, the OA 
markers of hypertrophy and ECM 
breakdown genes ADAMTS5, RUNX2 and 
EPAS1 were consistently up-regulated from 
3 weeks of treatment onwards across the 
donor cultures (P<0.05 Fig. 4J). The 
differences in mean expression of MMP13 
between controls and T3 treated cells across 
the donors at consecutive timepoints was not 
significant. Immunohistochemical studies 
contributed to the confirmation that excess 
T3 resulted in a reduced expression of 
COL2(Fig. 4C-D) and COL10 (Fig. 4E-F) 
and a pronounced reduction of GAGs (Fig. 
4A-B) as reflected by the reduced Alcian blue 
staining at consecutive time points with an 
 
 
Figure 3. Overexpressing DIO2 has a detrimental effect on cartilage extracellular matrix 
homeostasis. A) RT-qPCR analysis of DIO2, COL2A1, ACAN, COL10A1, RUNX2, EPAS1, 
MMP13, ADAMTS5 and ALPL at 21 and 35 days of treatment in the chondrogenic hBMSC 
transduced with respectively control vector (eGFP) and DIO2 (DIO2_eGFP; Fig. S3). (B-G) 
Sections comparing control (top) and DIO2 overexpressing (bottom) chondrogenic hBMSC pellets 
at 21 and 35 days of treatment. (B-C) Alcian Blue staining. (D-E) Immunohistochemical staining of 
collagen type II. (F-G) Immunohistochemical staining of collagen type X. (B, D and F) Scale bar, 
400 μm. (C, E and G) Scale bar, 100 μm. The expression levels were arbitrarily defined as ‘1’ in the 
pellets grown under control conditions (white), and data from the pellets over-expressing DIO2 
(black) are given as the means ± s.e.m. Legend: *p <0.05, **p <0.01, ***p <0.001. S.e.m. <0.05 are 
not distinguishable in the figure. 
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overal mean decrease of 35% (p=0.0002) as 
measured by the quantitative pixel-intensities 
(Fig. 4H).  
 
Pharmacological inhibition of D2. To 
investigate whether thyroid signalling 
blockade attenuates the detrimental effect on 
cartilage matrix homeostasis, pellet cultures 
were treated with the pharmacological 
deodinase inhibitor iopanoic acid (IOP) 
during in vitro chondrogenesis of hBMSCs of 
the 5 donors. Quantification of surface areas 
indicated increasing sizes at consecutive time 
points in the IOP-treated pellets comparable 
to non-treated, control pellets (Fig. 5G). 
Respective expression analyses showed a 
significantly increased expression of the 
ECM genes ACAN, COL2A1 and 
COL10A1 after 3 weeks of treatment (p 
<0.01, Fig. 5J), whereas the OA markers of 
hypertrophy and ECM breakdown genes 
ADAMTS5, RUNX2 and EPAS1 were 
similar to control cultures (Fig. 5J). 
Furthermore, we found no significant 
difference in chondrogenic potential between 
control and IOP treated pellets, when 
assesing the ratio between COL2A1 and 
COL1A1 expression (Fig. 5I). Following 
these expression patterns, histological 
analysis of matrix components showed 
slightly higher levels of COL2 and COL10 
staining (Fig. 5C-F) and higher levels of 
GAGs as reflected by a significant 4% 
increase in Alcian blue staining at week 5 of 
treatment (p=0.018; Fig. 5A-B and Fig. 5H). 
Of note is the denser cartilage matrix 
structure with less cellular lacunae at week 5 
of treatment in cells treated with IOP as 
compared to controls (Fig. 5A). By 
discriminating “cartilage” form the “lacunae” 
using the ImageJ data, we could show that 
administration of IOP resulted to an 10.92% 






In the current study, we provided insights 
into how genetic variation at the DIO2 locus 
confers risk to OA. As a result of OA related 
changes in articular cartilage, loss of 
epigenetic silencing results in upregulation of 
DIO2 expression among DIO2 rs225014 risk-
allele carriers (Fig. 1, Fig. 2). By applying an 
in vitro chondrogenesis model with genetically 
modified hBMSC, it was subsequently shown 
that genetic upregulation of DIO2 expression 
resulted in a marked reduction of the capacity 
of chondrocytes to deposit ECM 
components, concurrent with induction of 
OA specific markers of cartilage matrix 
degeneration (ADAMTS5 and MMP13) and 
mineralization (ALPL) (Fig. 3). Given their 
concurrent upregulation, this process is likely 
mediated via HIF-2α/RUNX2 signalling, a 
hallmark of the OA disease process.[6, 24-26] 
Moreover, we show that the detrimental 
effects of DIO2 upregulation are a result of 
increased T3 synthesis as reflected by the 
identical results when adding T3 to the 
culture medium (Fig. 4). Given that the 
effects observed in both treatments are very 
similar and the fact that the specific 
downstream effect of D2 action is the 
conversion of inactive T4 to active T3, we 
are confident that the reported effects in 
both experiments are reflecting the same 
mechanism, albeit that we did not directly 
asses the levels of the trace-element T3 in our 
in vitro chondrogenesis model. Together, our 






Figure 4. Thyroid hormone is believed to be a key regulator in human cartilage 
development. (A-F) Sections of a representative donor (See Figure S4) comparing control 
(top) and T3 treated (bottom) chondrogenic hBMSC pellet at 7, 21 and 35 days of treatment. 
(A-B) Alcian Blue staining. (C-D) Immunohistochemical staining of Collagen type II. (E-F) 
Immunohistochemical staining of collagen type X. (A, C, and E) Scale bar, 400 μm. (B, D 
and F) Scale bar, 100 μm. (G) Mean surface area measurements at 7, 21 and 35 days of 
treatment with N = 3 donors in each group. (H) Mean quantitative pixel-intensity 
measurements (Fig. S1) at 7, 21 and 35 days of treatment with N = 5 donors in each group. 
(I) Log2 Ratio of COL2A1 and COL1A1 with N = 5 donors in each group. (J) Mean real 
time RT-qPCR analysis of COL2A1, ACAN, COL10A1, COL1A1, ALPL, ADAMTS5 
MMP13, RUNX2, and EPAS1 at 7, 21 and 35 days of treatment in chondrogenic hBMSCs 
of N = 5 donors in each group. The surface area measurement, pixel intensities and level of 
expression were arbitrarily defined as ‘1’ in the pellets grown under control conditions 
(white) and the data from the pellets grown in the addition of excess T3 (black) are given as 
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Figure 5. Counteracting thyroid signalling by inhibiting deiodinases in human 
cartilage development. (A-F) Sections of a representative donor (See Figure S4) comparing 
control (top) and IOP treated (bottom) chondrogenic hBMSC pellet at 7, 21 and 35 days of 
treatment. (A-B) Alcian Blue staining. (C-D) Immunohistochemical staining of Collagen 
type II. (E-F) Immunohistochemical staining of collagen type X. (A, C, and E) Scale bar, 
400 μm. (B, D and F) Scale bar, 100 μm. (G) Mean surface area measurements at 7, 21 and 
35 days of treatment with N = 3 donors in each group. (H) Mean quantitative pixel-intensity 
measurements (Fig. S1) at 7, 21 and 35 days of treatment with N = 5 donors in each group. 
(I) Log2 Ratio of COL2A1 and COL1A1 with N = 5 donors in each group. (J) Mean real 
time RT-qPCR analysis of COL2A1, ACAN, COL10A1, COL1A1, ALPL, ADAMTS5 
MMP13, RUNX2, and EPAS1 at 7, 21 and 35 days of treatment in chondrogenic hBMSCs 
of N = 5 donors in each group. The surface area measurement, pixel intensities and level of 
expression were arbitrarily defined as ‘1’ in the pellets grown under control conditions (white) 
and the data from the pellets grown in the addition of IOP (grey) are given as the mean ± 




observations that carriers of the DIO2 risk 
allele are prone to improper endochondral 
ossification and respective skeletal 
morphogenesis that could result in subtle 
malformations of joints or articular cartilage 
ECM composition.[27] 
In contrast, we showed that inhibiting 
deiodinases by addition of IOP, contributed 
to prolonged ‘healthy’ cartilage homeostasis 
by virtue of attenuated upregulation of matrix 
degrading enzymes, a constant 
COL2A1/COL1A1 ratio, denser cartilage 
matrix structure with significant less cellular 
lacunae which indicates a reduced propensity 
of chondrocytes to enter the terminal 
maturational process (Fig. 5). In view of 
these findings, we advocate that attenuation 
of thyroid signalling by for example 
inhibiting deiodinases, could contribute to 
novel therapeutic options of OA or could 
improve outcomes of cartilage tissue-
engineering approaches. Nevertheless, given 
that T3 has many and various biological 
functions, both in the circulation as well as in 
a tissue specific manner, local administration 
of an thyroid-blocking agent is likely 
necessary and a challenging aspect. 
Furthermore, the effect of, for example, IOP 
on other joint-tissues (e.g. ligament and 
synovium) requires investigation. It should be 
noted that IOP is a general inhibitor of 
deodinases and as such could have aslo 
inhibited D1 and D3 action. In this respect, 
expression of DIO1, being important mainly 
in the circulation, is likely absent in cartilage 
tissues. Furthermore, by inhibiting D3, we 
prevented the conversion of active T3 to 
inactive T4 thereby ruling out the effect of 
T3 depletion due to inactive D2. Despite the 
beneficial effects of IOP, we observed 
upregulation of COL10 similar to control 
cultures reflecting the normal initiation of 
chondrocyte hypertrophy (Fig. 5J). Vice 
versa, we showed that upon addition of T3, 
chondrocytes directly enter the terminal 
maturational process towards bone, as 
reflected by the up-regulation of enzymatic 
breakdown (ADAMTS5) and mineralization 
(ALPL, COL1A1), this without significant 
induction of COL10 deposition (Fig. 4E-F). 
Together, these data indicate that 
chondrocyte hypertrophy in our model was 
not neccesarily detrimental to cartilage 
homeostasis this in contrast to DIO2 
upregulation. Our data, therefore, indicates 
that upregulation of DIO2 does not affect the 
‘early’ hypertrophic expression of COL10A1 
but induces the later “progression stage”-
marker MMP13, and the “late stage”-markers 
ALPL and COL1A1.[28] In our model, we 
used the expression of EPAS1 and RUNX2 
to shown downstream effects of up-
regulation of DIO2 and observed a significant 
positive association between T3 and EPAS1. 
Although such an observation based on 
association does not imply a direct causal 
relationship, recent data of Chatonnet et al., 
(2013)[29] showed, in a ChIP-seq analysis in 
mouse C17.2 neural progenitor cells, that 
EPAS1, harbours specific thyroid hormone 
nuclear receptor (THR) binding sites and is 
directly reactive to thyroid hormone. In view 
of these data, we advocate that active thyroid 
hormone, likely by local DIO2 action, could 
have an important impact on EPAS1 up-
regulation during the pathophysiology of 
OA. Additional studies are, however, 
necessary to elucidate whether T3 is directly 
affecting expression of EPAS1, or RUNX2 
for that matter, by binding to a positional 
thyroid receptor in humans.  
Despite the fact that the direction of gene 
expression changes of COL2A1 and MMP13 
upon addition of T3 to the culture media 
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appeared consistent with our overall results 
(Fig. 4J), the mean differences in expression 
were not statistically significant across the 
donors. Most likey this was the result of the 
considerable heterogeneity in the differential 
gene expression patterns of these specific 
genes across donors, especially with respect 
to timing the respective down and up-
regulation at consecutive time-points (Fig. 
S4), a phenomenon generally recognized in 
the in vitro chondrogenesis models of primary 
hBMSCs[30].  
We detected several CpG dinucleotides 
across the DIO2 locus that were differentially 
methylated between preserved and OA 
affected cartilage. Although we have only 
verified their functionality with respect to 
DIO2 expression, we cannot exclude that 
methylation at these sites regulates 
expression of more distal genes. We found a 
consistent positive correlation between 
methylation at CpG -2031 and DIO2 
expression in articular cartilage among 
carriers of the rs225014 risk allele, which may 
not comply to the conventional inverse 
relation between CpG methylation and gene 
expression. However, in recent genome wide 
approaches, it has been recognized that this 
conventional relation primarily holds among 
CpG dinucleotides residing in CpG islands 
and proximal promotors, whereas gene body 
and distal enhancer methylation, as is the case 
for CpG -2031, has been shown to correlate 
in either direction with gene expression.[31-
33] 
With respect to our observations of DIO2 
expression in preserved and osteoarthritic 
cartilage, it should be noted that, in contrast 
to previously reported high upregulation of 
DIO2 expression in osteoarthritic when 
compared to healthy cartilage[5, 11] we 
showed a moderate upregulation in 
osteoarthritic when compared to preserved 
cartilage of the same joint only among 
carriers of the rs225014 risk allele (Fig. 1I). 
This difference suggests that upregulation of 
DIO2 expression may be an early event in 
OA pathophysiology and might be set to 
continue progressively among rs225014 risk 
allele carriers. 
We were unable to validate the 
functionality of a putative CTCF binding site 
directly at the rs225014 locus nor for that 
matter the causality of the previously assessed 
consistent allelic imbalance.[11] Possibly, the 
rs225014 SNP affects three dimensional 
chromatin conformations underlying the 
relation between the rs225014 tagged allelic 
imbalance and methylation dependent 
upregulation of DIO2 among rs225014 risk 
allele carriers. 
 
In conclusion, our data provides evidence in 
humans that genetic predisposition combined 
with early OA related changes results in loss 
of epigenetic silencing of DIO2, which likely 
induces EPAS1 and RUNX2 mediated up-
regulation of cartilage matrix degrading 
enzymes (ADAMTS5 and MMP13) and 
mineralization of matrix (ALPL and 
COL1A1), thereby driving the OA process 
most distinctly among DIO2 risk allele 
carriers. Furthermore, our data shows that 
counteracting the thyroid signalling by 
inhibiting deiodinases could contribute to 
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The ongoing RAAK study is approved by the ethical committee of the LUMC (P08.239) and is 
aimed at the bio-banking of joint materials (cartilage, bone and where available ligaments) and 
mesenchymal stem cells (hip joints only) and primary chondrocytes of patients and controls in 
the Leiden University Medical Center and collaborating outpatient clinics in the Leiden area. 
Informed consent was obtained from each patient. In the current study we used paired 
preserved and OA affected cartilage samples from 52 Caucasian end stage OA patients 
undergoing joint replacement surgery for primary OA (23 hips, 29 knees) in the Leiden 
University Medical Centre (Table S1). At the moment of collection (within 2 hours following 
surgery) tissue was washed extensively with phosphate buffered saline (PBS) to decrease the 
risk of contamination by blood, and cartilage was collected of the weight-baring area of the 
joint. Initial classification of cartilage was performed macroscopically and collected separately 
as OA affected or preserved regions. Classification was done according to predefined features 
for OA related damage based on color/whiteness of the cartilage, based on surface integrity as 
determined by visible fibrillation/crack formation, and based on depth and hardness of the 
cartilage upon sampling with a scalpel. During collection with a scalpel, care was taken to avoid 
contamination with bone or synovium. Collected cartilage was snap frozen in liquid nitrogen 
and stored at -80°C prior to RNA extraction. We histologically assessed cartilage samples with 
the modified Mankin scoring system. 
 
Nucleic acid isolation and genotyping 
Snap frozen cartilage was powderized using a Retsch Mixer Mill 200 with continuous liquid 
nitrogen cooling. DNA was isolated using the Promega Wizard Genomic DNA Purification kit 
according to the manufacturer’s protocol. RNA was isolated using the Qiagen RNAeasy Mini 
kits, followed by cDNA synthesis using 1 μg of RNA and random hexamer primers (First 
Strand cDNA Synthesis Kit, Thermo Scientific). Samples were genotyped for rs225014 using 
restriction fragment length polymorphism analysis with RsaI (Forward primer (F): 5’-
AGTGGCAATGTGTTTAATGTGA-3’, Reverse primer (R): 5’-
CACACACGTTCAAAGGCTACC-3’).) DNA fragment length of wild type alleles were called 
after gel electrophoresis and were 121, 30 and 389 base pairs. The risk allele C affects the first 
cut site resulting in two fragments consisting of 151 and 389 base pairs. All primers were 
ordered at Invitrogen. 
 
Electrophoretic mobility shift assay 
For Electrophoretic Mobility Shift Assays (EMSAs) synthetic oligonucleotides containing the 
putative CTCF binding site were 5’-end labeled by γ-32P-ATP and subsequently purified by gel 
filtration on Sephadex G-25 Medium columns. The CTCF-11 zinc finger (11ZF) DNA binding 
domain, full-length CTCF using pIVEX1.4 WG CTCF-11ZF and CTCF-FL constructs were 
synthesized with the RTS 100 Wheat Germ CECF kit (5 PRIME). For binding reactions, we 
used buffer containing standard PBS with 5 mM MgCl2, 0.1 mM ZnSO4, 1 mM DTT, 0.05% 
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NP40, 50 ng/μl poly(dI-dC) and 10% glycerol. The reaction mixtures were incubated for 30 
min at RT and analyzed by 5% native PAGE in 0.5x Tris-borate-EDTA buffer. Table S5 
contains the sequences of the used probes. Expression of DIO2 was assessed using TaqMan 
probe Hs00988260_m1 (Applied Biosystems), normalized for GAPDH expression (real-time 
PCR, F: 5’-TGCCATGTAGACCCCTTGAAG-3’, R: 5’-ATGGTACATGACAAGGTGCG 
G-3’) and subsequently log transformed for downstream analysis. 
 
Quantification of methylation 
Using the ZymoResearch EZ DNA Methylation kit isolated genomic DNA was treated with 
sodium bisulphite (BS), thereby reducing unmethylated cytosine residues to uracil, while 
methylated cytosines remain unchanged. The methylated fraction of CpG dinucleotides was 
assessed with MALDI-TOF mass spectrometry (Epityper, Sequenom), a commonly applied to 
quantify CpG methylation. Samples were randomly distributed on PCR plates prior to BS 
treatment and PCR amplification. PCR amplification and MALDI-TOF measurements were 
performed in triplicate as technical replicates. Using MethPrimer 9 amplicons (Table S6) were 
designed upstream, downstream and intragenic of DIO2. Amplicons were designed to cover 
conserved transcription factor binding sites (TFBS) according to Human Genome Assembly, 
build 19. To avoid interference of SNPs in the MALDI-TOF measurements we avoided SNPs 
in the amplified regions using dbSNP137. Methylation of several CpG dinucleotides was 
measured redundantly by separate amplicons, measurements of CpG dinucleotides with the 
most successful observations per amplicon were used for downstream analyses. Finally, the 9 
amplicons constituted 4 independent regions covering 23 unique CpG dinucleotides. 
 
AZA treated cell cultures 
Primary articular chondrocytes were isolated from cartilage derived from three OA patients 
who underwent total joint arthroplasty of the hip (RAAK study). Cartilage tissue was incubated 
overnight in DMEM (high glucose; Gibco, Bleiswijk, The Netherlands) supplemented with 
10% fetal bovine serum (FBS; Gibco), antibiotics (100 U/ml penicillin, 100 μg/ml 
streptomycin; Gibco) and 2 mg/ml collagenase Type I at 37 ºC in a humidified 5% CO2 / 95% 
atmosphere. Subsequently, primary chondrocytes were resuspended and filtered through a 100 
μm mesh to remove undigested cartilage fragments and extracellular matrix debris. Cells were 
expanded at 37 °C in a humidified 5% CO2 / 95% atmosphere in DMEM supplemented with 
10% FBS, penicillin (100 units/mL), streptomycin (100 units/mL) and 0.5 ng/ml FGF-2 
(PeproTech, Heerhugowaard, The Netherlands) for 2 passages. 24 Hours into the second 
passage 1.5 μM of the demethylating agent 5-aza-2 –deoxycytidine (AZA) (Sigma Aldrich; 
Zwijndrecht, The Netherlands) was added. Cells were harvested for DNA and RNA isolations 
after being grown to confluence, obtained after three more days. 
 
Analysis of methylation data 
Methylation of CpG dinucleotides with fewer than two out of three triplicate measurements or 
with a SD > 0.1 were discarded prior to analysis. CpG site-containing fragments that had equal 
or overlapping mass, making them irresolvable by mass spectrometry, and CpG sites 
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containing fragments whose measurement was confounded by SNPs were removed prior to 
analysis[1]. Samples with bisulphite conversion rates < 98% were discarded.  
All statistical analyses were performed by fitting Generalized Linear Mixed Models 
(GLMMs). To account for inter-individual differences a random effect for sample donor was 
added to each model. Homozygous carriers (N = 3) of the rs225014 “C” risk allele were 
pooled with heterozygous carriers (N = 27). Analyses were carried out using the R 
programming language with the lme4 (GLMMs) package.[2] To assess the relation between the 
cartilage phenotype and methylation of separate features, we fitted the following model: 
Methylationi ~ (1|Donor) + Phenotype. To identify functional CpG dinucleotides, we fitted the 
following model: DIO2 Expression ~ (1|) Donor + Methylationi. Where, in both models, 
Methylationi represents the methylated fraction of the i-th CpG feature. To explore other 
possible significant covariates, we fitted the following model: DIO2 Expression ~ (1|Donor) + 
Joint site + rs225014 alleles + MethylationCpG-2031. Finally, p-values were adjusted for multiple 
testing using Bonferroni correction. Analyses of differences in methylation and expression in 
chondrocyte cultures after AZA treatment were done by paired-student T-tests. 
 
Cell culture and in vitro chondrogenic differentiation 
HEK 293T cells were grown in DMEM (Gibco; high glucose) supplemented with 10% fetal 
calf serum (FBS; Gibco, Bleiswijk, The Netherlands) and antibiotics (100 U/ml penicillin, 100 
μg/ml streptomycin; Gibco) at 37ºC in a humidified 5% CO2 / 95% atmosphere.  
Human bone marrow derived mesenchymal stem cells (hBMSCs) were isolated from hip 
joints of 5 OA patients who underwent total hip arthroplasty as result of end stage OA as part 
of the RAAK study at the Leiden University Medical Centre (LUMC). Cells were expanded at 
37ºC in a humidified 10% CO2 / 90% atmosphere in DMEM (high glucose) supplemented 
with 10% FBS, antibiotics, and 0.5 ng/ml FGF-2 (PeproTech, Heerhugowaard, The 
Netherlands) for 5 passages. Subsequently, 3D pellets were formed using centrifugal forces 
(1200 rpm; 5 min) on 2.5 x 105 cells in 15 ml polypropylene conical tubes. Chondrogenesis was 
initiated in 1 ml serum-free chondrogenic differentiation medium (DMEM, supplemented with 
Ascorbic acid (50 μg/ml; Sigma-Aldrich; Zwijndrecht, The Netherlands), L-Proline (40 μg/ml; 
Sigma-Aldrich), Sodium Puryvate (100 μg/ml; Sigma-Aldrich), Dexamethasone (0.1 μM; 
Sigma-Aldrich), ITS+, antibiotics, and TGF-β1 (10 ng/ml; PeproTech)). Medium was changed 
every 3-4 days. From day 14 onwards cell pellets were maintained either in the standard 
chondrogenic differentiation medium or in the presence of T3 (10 nM) or IOP (10 μM). Pellets 
were collected for immunohistochemistry and RNA isolation at the time points indicated for 
up to 49 days total. Literature search on the use of T3 in mammalian cell-models showed that 
in a wide variety of cell-lines and phenotypes, a wide range of concentrations is used (10 nM[3], 
100 nM[4] and 1uM[5]). To induce OA-symptoms in chondrogenesis models we tested two 
concentrations, namely 10 and 100 nM. Using 10 nM T3 was shown sufficient in our model 
system to induce an OA phenotype comparable to over expressing DIO2 (Data not shown). 
 
Lentiviral constructs and transduction 
C-terminal FLAG-tagged cys-D2 (kindly provided by Prof. Dr. Bianco) was digested with 
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EcoR1 followed by Klenow-treatment and digestion with Xba1. Inserts were inserted into the 
EcoRV-XbaI sites of the pLV-CMV-IRES-eGFP Lentiviral backbone (kindly provided by Prof. 
Dr. R. Hoeben; Dept of Molecular Cell Biology; LUMC). Lentiviral production was performed 
in HEK 293T cells as described previously.[6] In short, for lentiviral transduction, hBMSCs (6 
x 105 cells) were seeded onto 20 cm plates. After one day in culture (approximately 80% 
confluence), cells were incubated for 16 hr with the corresponding Lentiviruses at a multiplicity 
of infection (MOI) of 1 in the presence of 15 μg/ml Polybrene (Sigma-Aldrich) before the 
medium was replaced to regular growth medium. 
 
Histochemistry and immunohistochemistry 
hBMSC pellets were fixed in 4% formaldehyde upon harvesting and embedded in paraffin. 
Sections were stained for GAGs with Alcian blue and counterstained with nuclear fast red 
(Sigma-Aldrich). 
For immunohistochemistry, paraffin sections were deparaffinized and rehydrated. 
Endogenous peroxidase was blocked with MeOH / 0.3% H2O2, and antigen retrieval was 
performed by incubation with proteinase K (5μl/ml; Sigma-Aldrich) for 10 minutes at 37ºC 
and subsequently with Hyaluronidase (5mg/ml; Sigma-Aldrich) for 30 minutes at 37ºC. 
Sections were blocked for 30 minutes at room temperature in TBST (2.5mM Tris-HCl pH 7.6, 
7.5mM NaCl, 0.1% Tween-20) with 5% normal goat serum (R&D Systems, Abingdon, Great 
Britain). Incubation with the primary antibodies was performed overnight at 4°C with 
commercially available antibodies for collagen type 2 (COL2; MAB1330 Millipore; Amsterdam, 
The Netherlands; 1:100 in TBST / 10% NGS) and collagen type 10 (COL10; Clone X53, 
Quartett; Berlin, Germany; 1:100 in TBST/10% NGS). The next day, Powervision 
(Immunologic; Duiven, The Netherlands) was applied and visualization was carried out in a 3-
diaminobenzidine (DAB)-solution (Sigma-Aldrich) for 1 and 10 minutes for COL2 and 
COL10 respectively. The sections were then counterstained with haematoxylin. 
 
Relative pixel intensity 
The relative pixel intensity was computed by loading the photos into ImageJ (v.1.47).[7],[8] 
Automated thresholding (IsoData) was used to separate the glycosaminoglycans staining and 
the background (vacuoles and surroundings), after using the concept of rolling ball algorithm 
to correct for uneven illumination (Fig. S5, panel A-C). The regions depicted as 
glycosaminoglycans by the automated thresholding were semi-automatically filled by using the 
4-connected background elements (Fig. S5, panel D). The glycosaminoglycans-staining was 
separated from the background (Fig. S5, panel E) by splitting the image into separate channels 
and only using the red channel. Every pixel of the image was then weighed for color intensity 
(0 – 255) and the sum of al intensity was averaged by the number of pixels, giving the average 
pixel intensity per condition. 
 
Surface area meusurements 
Surface area measurements were performed using the standard CellSens (Build 9164; 
version1.5) software from Olympus. Within this microscope software, we used the option to 
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manually draw a border and let the software calculate the surface area within this border. 
Measurements are derived from 3 individual pellets per condition, per time point, per donor. 
 
RNA isolation 
RNA isolation from the pellets was performed by pooling two pellets for every given 
condition. The isolation of RNA was performed as described previously.[9] RNA quantity was 
assessed using a nanodrop spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, 
USA). 
 
Real time quantitative reverse transcription PCR 
RNA was processed with the First Strand cDNA Synthesis Kit according to the 
manufacturer’s protocol (Roche Applied Science, Almere, The Netherlands). cDNA pre-
amplification was performed with a DNA Engine Tetrad® 2 Peltier Thermal Cycler (Bio-Rad) 
for 5 cycles under standard PCR conditions and using the multiplexed primers (Table S8). 
Primer efficiencies were verified in advance, by performing a concentration curve experiment. 
Only primers showing a perfect correlation between Ct-value and concentration and with a 
single peak in the melting-curve calculation (Lightcycler480 SW 1.5 software) were used. The 
housekeeping gene GAPDH was used as a single reference gene for qPCR.[10, 11] A custom 
sample-mix was made using the EvaGreen® dye (Biotium, Amsterdam, The Netherlands), 
ROX reference dye (Life technologies), and FastStart Taq polymerase (Roche Applied 
Science). Subsequently, qPCR was performed using the custom-designed primers (Table S8) in 
triplicate with the using BiomarkTM 96.96 Dynamic Arrays (Fluidigm). Additional RT-qPCR 
measurements were performed on the Roche Lightcycler 480 II, using FastStart SYBR Green 
Master reaction mix according to the manufacturer’s protocol (Roche Applied Science). 
 
Gene expression and pixel intensity analyses 
Relative gene expressions were corrected for GAPDH by using the 2-ΔΔCt method, in which Ct 
indicates cycle threshold, the fractional cycle number where the fluorescent signal reaches 
detection threshold. All values were calculated relative to the first timepoint measured in the 
assay. For the hBMSC pellet-model, time point t = 7 days of treatment of the control was 
taken as reference point for expression analysis. 
The paired-student T-test was used to calculate the significance of changes in expression. 
The same method was used to calculate significance of the changes in size of the pellets over 
time. To calculate the significance of differences in pixel intensities relative to the control 
conditions, the Wilcoxon–Mann–Whitney test was performed. All nominal P-values < 0.05 
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Table S1. Characteristics of samples used in methylation and expression assessment. (a) 
Genotype for the rs225014 SNP 
 
Donor Gender Age Joint rs225014a 
1 Female 78 Hip TC 
2 Female 79 Hip TT 
3 Male 67 Hip TT 
4 Male 69 Knee TC 
5 Female 77 Hip TC 
6 Female 74 Hip TT 
7 Male 72 Hip TC 
8 Female 75 Hip TT 
9 Male 54 Knee TT 
10 Male 64 Knee TC 
11 Female 65 Knee TT 
12 Female 68 Hip TT 
13 Male 61 Hip TC 
14 Female 75 Hip TT 
15 Male 61 Knee TT 
16 Female 80 Hip TT 
17 Female 78 Knee TT 
18 Male 44 Hip TC 
19 Female 79 Hip TC 
20 NA NA Knee CC 
21 NA NA Hip TC 
22 NA NA Hip TC 
23 Male 63 Hip TC 
24 Female 69 Hip TC 
25 Female 46 Knee TT 
26 Female 68 Knee TT 
 
 
    
 
 
27 NA 69 Knee TT 
28 Male 64 Hip TC 
29 Female 58 Knee TC 
30 Female 57 Knee TC 
31 Female 62 Hip TC 
32 Female 67 Knee TC 
33 Male 68 Hip TC 
34 Male 67 Hip TC 
35 Female 53 Hip TT 
36 Male 82 Knee TT 
37 Female 70 Knee TC 
38 NA NA Knee TT 
39 Female 60 Knee TT 
40 NA NA Knee TC 
41 Male 69 Knee TT 
42 Male 77 Hip TC 
43 Female 66 Knee TT 
44 NA NA Knee TC 
45 Female 80 Knee CC 
46 Female 80 Knee TT 
47 NA NA Knee CC 
48 NA NA Knee TC 
49 Male 69 Knee TT 
50 Male NA Knee TC 
51 Female 62 Knee TC 
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Table S2. Overview of quantified CpG dinucleotides across the DIO2 locus, as 
depicted in Figure 2. (a) Location of the respective CpG dinucleotides in relation to the 
DIO2 TSS. (b) Difference in methylation between preserved and matched OA affected 
samples. (c) Crude P-value of differential methylation. (d) Bonferroni adjusted P-value of 
differential methylation. (e) Number of samples used in the analyses for quantification of 
methylation (f) β-estimate of the methylation variable in the regression analysis with DIO2 
expression as outcome. (g) Crude P-value of the methylation variable in the regression 
analysis. (h) Bonferroni adjusted P-value of the methylation variable in the regression analysis. 
(i) Number of samples used in the regression analysis. P: preserved 
 
    
Differential methylation 
P vs OA cartilage 
 
Correlation DIO2 
methylation & express 
Locationa Mean P 
Mean 
OA 
 Betab pc padjd Ne  Betaf pg padjh Ni 
CpG +15180 0.377 0.391  0.015 0.12293 1 102  -0.581 0.57794 1 85 
CpG +15148 0.897 0.902  0.005 0.42454 1 103  -1.960 0.23275 1 86 
CpG +15015 0.846 0.842  -0.004 0.39223 1 103  -3.284 0.10764 1 86 
CpG +8802 0.678 0.681  0.001 0.92605 1 76  -2.745 0.04668 1 64 
CpG +8771 0.852 0.846  -0.007 0.03448 0.793 98  -0.303 0.90671 1 82 
CpG +8758 0.906 0.903  -0.003 0.36266 1 101  -1.245 0.69968 1 84 
CpG +8742 0.944 0.942  -0.002 0.42346 1 99  -0.126 0.97346 1 82 
CpG +8731 0.972 0.974  0.001 0.58860 1 103  -8.680 0.12942 1 86 
CpG +8635 0.716 0.724  0.009 0.12923 1 102  0.422 0.80058 1 85 
CpG +8547 0.872 0.866  -0.005 0.13632 1 97  2.832 0.35395 1 80 
CpG +8527 0.758 0.779  0.017 0.01689 0.389 100  -0.904 0.49324 1 83 
CpG +8481 0.167 0.182  0.015 0.00913 0.210 103  -0.201 0.91184 1 86 
CpG -219 0.011 0.012  0.000 0.92106 1 94  7.420 0.19666 1 79 
CpG -322 0.024 0.026  0.002 0.60637 1 98  -2.373 0.59233 1 83 
CpG -473 0.015 0.016  0.001 0.15828 1 102  -7.684 0.64305 1 85 
CpG -571 0.031 0.032  0.002 0.28463 1 97  2.355 0.77655 1 80 
CpG -642 0.013 0.015  0.003 0.08636 1 98  5.473 0.41953 1 81 
CpG -1754 0.874 0.908  0.032 0.00449 0.103 63  1.089 0.42829 1 54 
CpG -1761 0.947 0.935  -0.012 0.00011 0.002 ** 98  -2.094 0.48780 1 82 
CpG -1838 0.763 0.732  -0.031 0.00129 0.030 * 102  -2.468 0.01598 0.368 86 
CpG -1942 0.940 0.934  -0.006 0.02555 0.588 103  -1.530 0.67832 1 86 
CpG -2009 0.950 0.942  -0.008 0.01004 0.231 103  -2.142 0.54294 1 86 
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Table S3 Multivariate analysis the individual effects. Effects of CpG -2031 methylation, 
joint site (hip or knee) and rs225014 alleles on DIO2 expression in articular cartilage 
 
 Beta Standard Error Statistic p 
Intercept -0.905 0.808 -1.120 0.262 
CpG -2031 4.008 1.708 2.347 0.019 
Joint -0.247 0.168 -1.471 0.141 
rs225014 0.557 0.154 3.629 0.0003 
Gender 0.202 0.146 1.385 0.166 
BMI -0.017 0.013 -1.260 0.208 






























Donor Sex Age rs225014a 
53 female 66 TC 
54 female 72 TT 
55 female 81 CC 
56 female 59 TC 
57 male 80 TC 
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Figure S1. TF binding evidence at the rs225014 locus. UCSC browser hg19 screenshot. 
Darker bars indicate stronger evidence for binding. CTCF shows a black bar, while the other 
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Figure S2. The rs225014 risk allele does not influence local CTCF binding. 
Electromobility shift assays (EMSAs) using full-length CTCF (CTCF-FL) and a truncated 
protein, containing just the 11 Zinc Finger binding domain (CTCF-11ZF). We have used three 
different probes containing the rs225014 common allele (T, Fig. 1, lane 1-2), the minor allele 
(C, Fig. 1, lane 3-4) and a non-existent allele (G, Fig. 1, lane 5-6). The latter is in highest 
agreement with the consensus CTCF-binding sequence. As a positive control, a known CTCF 
site 90 base pairs upstream of rs225014 was used (ENCODE project[1]) (DIO2-CTCF2; Fig. 
1, lane 7-8). Lanes 1, 3, 5 and 7 depict the truncated CTCF protein, containing just the CTCF 
DNA binding domain whereas lanes 2, 4, 6 and 8 depict the full length CTCF protein. For lane 
1 to 6 no band shifts were observed, indicating that CTCF does not bind the putative CTCF 
binding site located at the rs225014 SNP. However, we were able to confirm the putative 
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Figure S3. DIO2 overexpression in hBMSCs, proven by 
co-transduced eGFP expression. A) GFP expression seen 
in cells cultured on culture dishes B) Normal light 
microscopy picture of a hBMSC pellet after 3 weeks of 
culturing. C) Fluorescence picture of a non-transduced 
hBMSC pellet after 3 weeks of culturing. D) Fluorescence 
picture of an hBMSC pellet transduced with the control 
vector containing only the sequence for eGFP after 3 weeks 
of culturing. E) Fluorescence picture of a hBMSC pellet 
transduced with the DIO2 overexpressing vector containing 
both the sequence for eGFP and DIO2. (B, C, D,and E) 





Figure S5. Calculating the relative pixel intensity; an automated histology 
quantification method. A) Original image algorithm. B) IsoData thresholding without rolling 
ball algorithm. C) IsoData thresholding after roling ball algorithm. D) masking-area after 








Figure S4 (next page). The effect of excess T3 and IOP in a human BMSC in vitro 
chondrogenesis model. (A-G) Alcian Blue staining of sections comparing control (top), 
thyroid treated (middle) and IOP treated (bottem) chondrogenic hBMSC pellets of (A-B) 
donor 54, (C-D) donor 55, (E-F) donor 56, and (G-H) donor 57. (A, C, E, and G) Scale bar, 
400 μm. (B, D, F, and H) Scale bar, 100 μm. 
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Osteoarthritis (OA) is a complex heterogeneous disease with a considerable heritable 
component. While the incidence of the disease is steadily increasing, up until now no treatment 
options are available that could cure or stop disease progression. Main impediments in OA 
management are the lack of biomarkers that detect OA at an early stage when damage is still 
reversible, or that allow stratification of subsets of OA patients with different disease modes. 
This considerably hampers development of effective therapies and requires insight into the 
heterogeneous etiology of OA. 
The aim of this thesis was threefold. Firstly, to address OA biomarker impediments by 
exploring gene expression profiles as biomarkers in osteoarthritic cartilage and blood (chapter 
2 and 3), and by investigating whether we could identify genetic factors that influence levels of 
promising OA biomarkers such as serum COMP and urinary CTX-II in the common 
population independent of OA status (chapter 4). We hypothesized that sensitivity of such 
biomarkers could be improved by taking into account these genetic factors. Secondly, to 
explore the possibility to identify OA susceptibility genes by either applying a GWA study with 
sibling pairs (familial OA cases) towards the severe end of common/late onset OA phenotype 
(symptomatic OA at multiple joint sites) of the GARP study (chapter 5) or by applying whole 
exome sequencing of family members with early-onset symptomatic OA at multiple joint sites 
(chapter 6). Thirdly, to initiate the necessary shift from genetic towards functional genomic 
studies in OA research for the deiodinase iodothyronine type-2 (DIO2) gene using in vitro 
chondrogenesis models (chapter 7). Together, results will contribute to the selection of 
druggable targets and the badly needed development of new treatments as well as the 






At present, timely diagnosis of OA before 
joint damage becomes irreversible is still 
lacking. This is one of the impediments in 
OA treatment and thus, biomarkers that can 
ascertain OA at an early stage are urgently 
needed. In addition, clinical biochemical 
markers to classify patients with different OA 
subtypes and to sensitively monitor OA 
disease activity in an individual over time or 
to assess quantitative joint tissue remodeling 
are required. In 2006, Bauer and colleagues 
proposed the BIPED biomarker 
classification to be applied in development 
and analysis of OA biomarkers.[1] BIPED 
stands for ‘Burden of Disease, Investigative, 
Prognostic, Efficacy of Intervention and 
Diagnostic’ and serves to facilitate research 
(both independent and collaborative) and to 
reduce redundancy while specifying and 
accelerating the validation of potential 
biomarkers. 
Studies thus far have suggested that 
serum cartilage oligomeric protein (sCOMP) 
and urinary C-telopeptide of type II collagen 
(uCTX-II) are promising candidates hence 
they were listed among a number of 
biomarkers recommended to focus on in 
biomarker research.[2] However, due to the 




relatively large inter-individual variation also 
among healthy subjects, the use of 
biomarkers is complicated. In chapter 4, we 
have investigated whether we could identify 
genetic variants affecting innate levels of 
sCOMP and uCTX-II that could possibly 
explain the variance and improve the use of 
respective biomarkers in the clinic. We found 
specific loci in association with biomarker 
levels. Among others, we found a single 
nucleotide polymorphism (SNP) in close 
vicinity to the Mannose receptor C type 1 
(MRC1) gene in association with levels of 
sCOMP with genome wide significance 
which was not in association with hip or knee 
OA. MRC1 is a membrane receptor highly 
expressed by macrophages and it has been 
shown that MRC1 mediates specific 
recognition of sugar residues to allow 
endocytosis of glycoproteins.[3] Since MRC1 
is only lowly expressed in articular cartilage 
and carriers of the risk allele have decreased 
levels of sCOMP, we hypothesize that 
carriers of the risk allele may have enhanced 
phagocytosis of serum glycoproteins such as 
sCOMP which could negatively affect the 
sensitivity of sCOMP as biomarker of OA in 
a clinical setting. Our findings are 
encouraging and incite additional studies to 
identify genetic loci associated with other 
biomarkers. However, most important now is 
to investigate whether taking the genetic 
variation into account will improve the use of 
these biomarkers and may allow for the 
distinction of OA subtypes. 
Unconventional biomarkers. Traditionally, 
biomarkers are thought of as biochemical 
substances and studies for development of 
biomarkers are still mainly focused on 
biochemical components in body fluids that 
mark either cartilage, bone, or synovial 
metabolism, or a combination of these.[4] In 
addition to these more traditional 
biomarkers, imaging methods such as 
quantitative magnetic resonance imaging 
(MRI) to assess cartilage volume and 
thickness or shape by statistical shape 
modeling have shown to be suitable as 
biomarkers for OA.[5-7] Disadvantage of 
these methods is, however, their relatively 
high costs. Currently, molecular profiles of 
genome wide gene expression or epigenetic 
variation are increasingly considered as 
optional targets in biomarker development. 
The fact that organ-specific pathologies can 
be detected from easily accessible tissues 
such as blood which was recently confirmed 
by integration of multiple studies,[8] 
encourages research for the identification of 
novel molecular markers. Differentiation of 
patients based on gene expression profiles in 
blood has been successfully performed for 
example for coronary artery disease,[9, 10] 
and several types of cancer.[11-13] Also for 
knee OA patients, gene expression profiles in 
blood were generated successfully and 
resulted in the identification of different 
subsets of patients.[14] In this thesis we have 
used gene expression profiles in blood to 
identify diagnostic biomarkers that could 
distinguish patients from the GARP study 
from healthy controls. Inclusion of the 
potential molecular biomarkers in the 
estimated cross-validated algorithm in 
receiver operating curve (ROC) analysis 
yielded a 20% increase of the area under the 
curve (AUC) to 91-95% (chapter 3). This 
clinically relevant AUC obtained in our 
analysis is expected to be accomplished by 
virtue of the combination of body mass 
index (BMI), also augmenting the AUC with 
20% to approximately 72%, with the 




confirmed in an independent selection of the 
GARP study, however, controls were 
overlapping and results await replication with 
population-based controls. Moreover, 
because our study has a cross-sectional 
design, further investigation in a longitudinal 
study is necessary to assess predictive value 
and putative benefit for early diagnosis as 
well as disease progression in a population-
based setting. 
Gene expression profiles in blood may 
either be more systemic and thus 
independent of OA pathophysiological 
processes in the joint or reflect ongoing OA 
processes. Therefore we explored the overlap 
between expression profiles in blood and in 
cartilage and found that around 25% of the 
genes with fold-changes of ≥1.5 coincided. 
For example, a gene overlapping between our 
blood and cartilage expression profiles was 
Serine/Arginine-Rich Splicing Factor 5 
(SFRS5), highly expressed in cartilage, and in 
blood contributing most to our prediction 
model of OA patients. SFRS5 encodes one 
of the members of the SR family of proteins 
that binds to exonic splicing enhancer cis-
sequences and it was shown to be involved in 
alternative splicing of the fibronectin gene 
specifically in chondrocytes.[15] Another 
gene overlapping between blood and cartilage 
profiles was H3F3B, encoding the H3 
histone family 3B. While in cartilage H3F3B 
was only 1.2-fold decreased, in blood the 
reduction was more than 2-fold making it 
particularly attractive to further study its 
putative application as a biomarker. A recent 
study showed association of a specific 
mutation in H3F3B with chondroblastoma, 
while mutations in H3F3A, a homolog of 
H3F3B, were exclusively found in association 
with giant cell tumors of the bone.[16] 
Interestingly, in H3F3B knockout mice 
reduced H3K4me3 (a marker for active gene 
transcription) was observed preferentially 
near genes related to extracellular matrix.[17] 
Together, this could suggests an essential role 
for H3F3B in chondrocyte proliferation and 
cartilage homeostasis, and maybe in 
susceptibility to OA development. However, 
this needs further investigation. 
Remarkably, of the genes overlapping 
between blood and cartilage expression 
profiles only half appeared to have the same 
direction of effects. Possibly, this stems from 
the differences in the study set-up: while the 
cartilage expression profiles were generated 
from joints of patients with end-stage OA, 
patients from the GARP study have 
symptomatic OA at multiple joints and blood 
profiles were compared with those of healthy 
subjects. Expression differences may 
therefore relate to the differences in timing 
and mechanism of development of OA. 
Alternatively, since expression of genes in 
blood may rather reflect a systemic profile, 
this can be different from the more direct 
pathophysiological processes taking place in 
the joint tissues. For example, a gene that is 
increased in blood of OA patients but 
decreased in OA cartilage is TGFBR3 
(transforming growth factor beta receptor 
III). As known, involvement of members of 
the TGF-β superfamily in cell proliferation, 
differentiation, morphogenesis, tissue 
homeostasis and regeneration is highly cell- 
and context-dependent.[18, 19] Therefore, it 
could very well be that OA patients have 
increased levels of TGFBR3 in blood cells 
while the processes taking place during OA 
development in articular cartilage result in a 
decreased expression of the gene. For future 
studies, combining joint tissue databases with 
blood expression profiles as well as the 




from healthy individuals may be of help for 
the selection of biomarkers that are able to 
sensitively monitor disease activity. 
A field in development in biomarker 
research is the use of non-coding RNAs as 
biomarkers. Several types of non-coding 
RNAs can be distinguished that are generally 
classified as small RNAs such as miRNA, 
piRNAs, and long non-coding RNAs or 
lncRNAs.[20] Micro RNAs can be detected 
in circulating body fluids such as plasma and 
serum where they are relatively stable because 
they are protected from RNAse activity by 
virtue of their association with secreted 
membrane vesicles or RNA-binding 
proteins,[21] and multiple studies now 
suggest that specific circulating miRNAs 
sensitively reflect ongoing pathophysiological 
processes[22] thereby qualifying their use as 
potential biomarkers, also for OA. Studies 
investigating expression of OA-specific 
miRNAs however, are still limited. To our 
knowledge, the largest study thus far was 
performed by Beyer et al including 816 
individuals of the Bruneck cohort.[23] In this 
longitudinal study, miRNA-let-7e was 
identified as a negative, dose-dependent 
predictor for severe knee or hip 
osteoarthritis. Further research is needed 
with replication and validation in other 
cohorts, to obtain data on specificity and 
sensitivity of miRNAs to monitor dynamic 
changes in the OA pathophysiological 
processes over time. In addition, it could be 
investigated whether miRNAs serve to 
identify patients prone to fast progression. 
This would allow for more adequate OA 
disease management and more efficient 
design of clinical trials. 
IDENTIFYING OA 
SUSCEPTIBILITY GENES 
One of the drawbacks scientists encounter in 
their research to discover genetic variants 
causing susceptibility to OA is the so-called 
‘missing heritability’.[24] In part, the problem 
might be caused by an overestimation of 
heritability in the general population based 
on results of twin and family studies. 
Alternatively, this may be due to the fact that 
population-based or case-control studies with 
GWAS are designed specifically to detect 
common variants which usually have small 
effect sizes.[25] As a result, variants with 
larger effect sizes and/or that associate 
specifically with more rare and severe OA 
phenotypes, such as the variants identified 
for DIO2 and FRZB, are not detected at the 
genome wide significance level in GWA 
studies.[26-28] Nevertheless, given the 
functional impact, these variants are likely 
contributing significantly to the percentage of 
heritability. To illustrate, the DIO2 
susceptibility SNP rs225014 was shown to 
have an odds ratio of OR = 1.79 
consequently involving a heritability of 5.3 
which is in sharp contrast to the average 
heritability of established loci as identified by 
GWAS (H2average = 0.8). In general, family-
based studies are prone to detect variants 
with moderate to large effect sizes. We 
investigated whether selection based on cases 
with familial and relatively severe phenotypes 
could contribute to the identification of 
variants with larger effects in GWAS (chapter 
5) and in whole exome sequencing (chapter
6). Although identified variants will be rare 
and frequently private to the respective 
family their value lies in the expectation that 
more common variants in the same gene or 




present in a larger population.[29] In these 
studies, the availability of a gene expression 
dataset of (OA affected and unaffected) 
articular cartilage (the RAAK study) allowed 
efficient selection of putative candidates and 
generalizability of the results. 
 
Whole exome sequencing. In chapter 6 we 
applied whole exome sequencing to 2 distant 
members of a family suffering from early-onset 
OA. A suitable prioritization scheme and 
analysis of gene expression levels in articular 
cartilage indicated a mutation in the tumor 
necrosis factor receptor superfamily member 
11B (TNFRSF11B) gene encoding 
osteoprotegerin (OPG) to be likely causal to the 
phenotype in our family. This was in line with 
the genome wide significant linkage analysis at 
this locus (LOD-score of 3.48) and complete 
segregation of the mutation with early-onset 
OA in the family. 
The decoy receptor OPG antagonizes 
receptor activator of NF-κB (RANK) in the 
process of osteoclastogenesis. Functional in vitro 
analysis now showed that the mutation in 
TNFRSF11B results in enhanced OPG-
mediated RANK antagonism and the 
significant upregulation of TNFRSF11B in 
articular cartilage suggests that this is a 
phenomenon in general OA pathology. Our 
results that the mutation in OPG is causal to 
the FOA phenotype in our family are highly 
convincing, nevertheless, further research is 
required. The phenotype of the family has to be 
studied in more detail and final proof for the 
causal role of OPG in OA should be provided 
by the performance of in vivo experiments in 
transgenic mice bearing the identified mutation 
to confirm the role of the identified mutation in 
development of OA. OPG transgenic and 
knockout mice have been generated previously 
and are viable,[30, 31] nonetheless, they were 
never challenged with OA-inducing trials such 
as mechanical loading through forced running. 
Interestingly, OPG transgenic mice are 
osteopetrotic which is caused by the impaired 
bone remodeling due to failure of the 
osteoclasts to resorb bone, but their phenotype 
is different from other mouse strains with 
osteopetrosis. The phenotype, also 
characteristic for RANKL knockout mice,[32] 
is impaired tooth eruption and shortened, ‘club-
shaped’ long bones due to complete lack of 
mature osteoclasts. It was suggested that, 
depending on the differences in bone surfaces 
(e.g. endosteal and periosteal surfaces), the 
capacity of systemic OPG to inhibit RANKL 
varies. These circumstances make the 
application of experimentally induced OA in 
OPG transgenic mice even more interesting 
since results are likely to lead to deeper insight 
into the role of the bone-cartilage interaction in 
OA. Further in vitro analyses which can be 
performed among others by comparing 
chondrogenic and osteogenic potential of iPS 
cells derived from affected and unaffected 
family members can give more insight into the 
underlying mechanisms of the mutated OPG in 
OA.  
Increased RANK antagonism leads to 
decreased osteoclastogenesis and it may thus 
result in concurrent increased bone mineral 
density (BMD). The variation in BMD towards 
higher levels would be in line with standing 
epidemiological studies showing increased 
BMD as a potential risk factor for OA.[33-37] 
On the other hand, 2 clinical studies,[38, 39] 
although subject of debate,[40-42] suggested 
that OA patients benefit from treatment with 
strontium renalate, an anti-osteoporotic drug 
that increases bone formation while decreasing 
bone resorption. Also in vitro[43] and in vivo[44-
46] experiments indicated putative beneficial 




should be noted that the methods applied in the 
in vivo studies are broadly used in animal studies, 
nevertheless, it has been questioned whether 
these methods are the best to investigate 
pathophysiological processes of primary OA as 
it occurs in humans (see ‘In vivo animal models in 
OA’). Possibly, subtypes of OA exist that will 
benefit from bone forming therapies while 
others will not. For example, among patients 
suffering from hip OA those with atrophic OA 
had systemically lower BMD as compared to 
those with normotrophic OA and as compared 
to the controls, while those with hypertrophic 
(osteophytic) OA had higher BMD.[47] Given 
that gene expression profiles of human 
osteoarthritic cartilage indicated enhanced 
OPG-mediated RANK antagonism as a more 
general phenomenon in the OA 
pathophysiological process (chapter 2 of this 
thesis), we advocate that careful investigation of 
the long term effects of these bone forming 
therapies in osteoarthritis are required and that, 
in contrast to the use of bone-forming therapies 
such as strontium renalate, (at least for some 
patients) agents counteracting OPG function 
could contribute to the development of new 
disease modifying treatments in osteoarthritis.  
GWAS using familial phenotype towards 
the severe end of the OA spectrum. By 
performing a genome wide association study 
in a very specific cohort consisting of familial 
cases with severe symptomatic and 
radiographic OA (KL>2) in at least two 
joints (the GARP study) we aimed at the 
identification of loci that may be less 
common but with larger effect sizes.[25] 
Several loci annotated to interesting genes 
(e.g. the calcium sensing receptor or CASR) 
were identified with larger effect sizes (mean 
odds ratio 1.8 with range: 1.5-2.1). However, 
none of these loci were genome wide 
significant (smallest p-value: 1.2 x 10-7) which 
may indicate a lack of power despite the 
predictions of power calculation programs. 
Besides lack of power, a problem when 
performing GWAS with a specific phenotype 
is subsequent replication of the results 
obtained in the discovery stage. The more 
specific a cohort is, the smaller the chance to 
find another study with the same phenotype. 
We have not been able to find other cohorts 
with genotype data of cases with familial 
generalized OA comparable with the GARP 
study. Furthermore, effect sizes of a study 
with more severe phenotype (deCODE), 
albeit not selected for familial affiliations, 
were again much smaller indicating either 
heterogeneity in the phenotype or false 
positive findings in the discovery cohort. 
Since GWAS platforms are generally based 
on common variants the causal (less 
common) SNP may not be included or 
removed by selection for allele frequencies of 
at least 5%. Replication in cohorts with more 
common phenotypes did not result in robust 
associations. This was also demonstrated by a 
GWA study from Evans et al for hip OA.[48] 
For the discovery analysis with genome wide 
significant results, cases were carefully 
examined and strictly selected to acquire a 
more homogeneous cohort. However, results 
of the combined analyses of discovery and 
replication were not genome wide significant 
(p=1×10−6). In conclusion, genome wide 
significant results in GWAS derive from a 
trade-off between large sample sizes and 
homogeneous cohorts. Confirmation of our 
results in a cohort similar to the GARP study 
could ascertain whether selection of samples 
towards the severe end of the spectrum of 
OA and with a familial phenotype may 
indeed be a promising approach to find loci 




Table 1 Top 25 of gene-based association 
analysis. Analysis was performed by joining all 
SNPs within known druggable genes (N= 4,290) 
and subsequently testing each of the genes for 
association with OA. 
 
Gene Symbol # SNPs p FDR 
SLCO2B1 12 7.17E-05 2.79E-01 
CXCL11 3 1.62E-04 3.15E-01 
KCNQ4 14 2.72E-04 3.53E-01 
ABCB11 26 5.82E-04 5.66E-01 
SLC12A6 22 6.45E-04 5.02E-01 
SELP 24 7.07E-04 4.59E-01 
FTL 3 7.44E-04 4.14E-01 
SLCO5A1 49 8.46E-04 4.12E-01 
KITLG 12 1.02E-03 4.43E-01 
STRADA 1 1.36E-03 5.30E-01 
DPYD 117 1.50E-03 5.30E-01 
RHBDL1 6 1.53E-03 4.96E-01 
NCOA3 20 1.86E-03 5.58E-01 
BAI3 148 2.08E-03 5.79E-01 
GRIN2B 154 2.12E-03 5.50E-01 
ADAMTS12 108 2.14E-03 5.20E-01 
RPP25 1 2.29E-03 5.25E-01 
ASPRV1 1 3.08E-03 6.66E-01 
KCNK4 1 3.24E-03 6.64E-01 
BNIP3 1 3.33E-03 6.47E-01 
CD44 47 3.34E-03 6.20E-01 
CTRB2 7 3.45E-03 6.10E-01 
IGFBP3 7 3.59E-03 6.07E-01 
CRABP2 9 3.92E-03 6.36E-01 
PCDHB9 3 4.02E-03 6.26E-01 
 
established OA susceptibility loci detected in 
large meta-analyses with genome wide 
significance is 1.2 with range 1.1-2.0 
compared to 1.8 in our study). 
In the genomic region around rs347842, 
locus with strongest evidence for association 
with OA, another strong signal was identified 
which may be independent but which may 
also be (partially) shared: rs17236749, located 
close to C15orf29. Therefore, we reasoned 
that analysis for burden of association per 
gene could possibly increase the power to 
identify genetic regions or genes involved in 
development of OA. Results of our GWAS 
were used to perform gene-based association 
analysis by joining all SNPs within known 
druggable genes (N= 4,290). Subsequently, 
each of these genes was tested for association 
with OA. Table 1 shows the 25 most 
significant genes [YFMR & S Tsonaka, 
unpublished results]. Unfortunately, none 
was significant after correction for multiple 
testing. However, besides SLC12A6 several 
other genes previously identified in 
association with OA were present such as 
NCOA3[28] and IGFBP3.[48] This 
observation may add to the credibility of our 
GWAS results and validate selection of loci 
close to druggable targets for further analyses 
despite the absence of genome wide 
significant loci. 
 
Identifying strong candidate genes. 
United efforts of large consortia have 
ensured the discovery of loci within or close 
to compelling OA candidate genes by 
applying GWAS (see Table 1 of the 
Introduction). However, different from 
whole exome sequencing where high impact 
mutations are identified that are damaging 
for protein function, OA susceptibility loci 
identified by GWAS generally represent 
intergenic loci, in regions with multiple genes 
that have not yet been implicated in OA 
etiology, or within gene deserts and 
establishment of the causal gene has been 
proven difficult. Even when a SNP is 
localized within a plausible gene, such as the 
SNP identified within the CASR gene that 




(chapter 5), after confirmatory genetic 
replication consecutive verification at 
multiple levels (molecular, cellular, whole 
organism) is required before definitive 
conclusions can be drawn. This was 
emphasized by the study of Smemo et al[49] 
for a locus associated with obesity in a very 
large GWAS and localized within the FTO 
(fat mass and obesity associated) gene that 
recently appeared to mainly target the IRX3 
gene, localized mega bases further away from 
the SNP. The finding stresses the 
observation of Freedman and colleagues[50] 
that ‘even if a transcript is associated with a 
risk allele, it does not necessarily mean that 
the annotated gene is definitively involved in 
the trait of interest and that functional 
follow-up with assays relevant to the trait are 
needed to actually show that a gene is directly 
involved with disease development’.  
Risk alleles likely act by affecting joint 
tissue specific gene expression.[51, 52] 
Therefore, a starting point to come to the 
gene affected by the genetic variant is analysis 
of expressed quantitative trait loci (eQTL) 
which should be performed on a more 
regular base in GWAS.[53] Challenge for 
studying eQTLs is the availability and 
selection of disease relevant tissues beyond 
the collection of blood. Although online 
databases exist (http://biogps.org) cartilage is 
not a tissue commonly included and in this 
respect comprehensive biobanking in OA 
research is of enormous importance. In 
chapter 2, we have shown how comparison 
of a relatively large number of samples from 
diseased and unaffected areas of cartilage 
from the same joint hint at generic 
pathological processes causing OA. Genome 
wide eQTL analysis was not performed 
within the RAAK study, but the generated 
dataset has been extensively used to prioritize 
genes in subsequent studies within the scope 
of this thesis (chapter 3-6) and follow-up 
research.[28, 54] A typical example for 
prioritization in regions with multiple genes 
could be the SNP identified within the 
ASTN2 gene, rs4836732, associated with hip 
OA with genome wide significance in 
females and thus put forward as novel likely 
OA susceptibility gene.[27] Although we do 
not exclude the possibility that ASTN2 
affects OA susceptibility, the gene was not 
detected well in our microarray expression 
analysis. Having said this, we advocate that 
PAPPA, a protease for IGF binding proteins 
localized 100 kb upstream of ASTN2 which 
increases osteoblast proliferation[55] and is 
2-fold up-regulated in OA affected cartilage, 
should be considered as the OA susceptibility 
gene. 
Taken together, when the correct datasets are 
available these can be used to identify, in 
high throughput manner, strong positional 
candidates that subsequently can be 
employed to cell models to address the 
specific effects of the genetic variation. 
MOLECULAR PROCESSES 
IN OA 
During OA, several processes take place in 
the joint such as cartilage degradation, bone 
remodeling, and inflammation. At the 
molecular level, each of these processes is 
reflected by specific gene expression 
networks, however, these networks are 
strongly intertwined among each other. 
Figure 1 shows a schematic representation of 
the different processes and some of the genes 
involved. 










the chondrocytes have lost their specific 
maturational arrested phenotype and are 
characterized by hypertrophy. This results in 
various degrees from detrimental genetic 
variation, cellular responses required for 
matrix-repair processes in damaged cartilage, 
and deregulated gene expression following 
loss of epigenetic control due to 
pathophysiological processes and/or aging. 
Chondrocyte hypertrophy results in 
mineralization of the cartilage due to 
increased expression of RUNX2 and 
concurrent increase of COL10 making the 
cartilage more prone to damage following 
mechanical stresses. In addition, hypertrophic 
chondrocytes express higher levels of 
secretion factors such as cytokines (IL1B, 
TNF-α), catabolic enzymes (MMPs, 
ADAMTSs) and members of the 
transforming growth factor-beta superfamily 
(reviewed in [56] and [57]). These are 
responsible for the inflammatory aspects of 
the arthritic joint. 
One of the genetic loci underlying 
susceptibility to OA is annotated to the DIO2 
gene, and our studies showed that indeed 
impaired thyroid signaling predisposes 
articular chondrocytes towards hypertrophy 
with concurrent increased expression of 
COL10, and catabolic genes such as MMP13, 
resulting in mineralization of the articular 
cartilage (chapter 7). Possibly, aberrant 
thyroid signaling involves one of the first 
episodes on the way to OA. It has been 
shown that the EPAS1 promoter encoding 
Hypoxia-inducible factor-2α (HIF-2α) 
contains a thyroid binding element both in 
mice[58] and man.[59] While HIF-1α 
contributes to cartilage extracellular matrix 
preservation via induction of SOX9, 
COL2A1, and AGC,[60] expression of HIF-
2α results in cartilage hypertrophy due to up-
regulation of RUNX2 and catabolic factors 
(ADAMTS5, MMP13, etc.).[61, 62] 
During ongoing OA, expression of 
TNFRSF11B is increased in cartilage (chapter 
2) which may contribute to the mineralized
phenotype of arthritic cartilage. This 
increased expression during OA 
pathophysiology is in line with the 
identification of a gain of function mutation 
as probably causal in a family with early onset 
OA. It has been shown that the promoter of 
TNFRSF11B contains a thyroid binding 
element.[59] This could be underlying the 
increased expression of TNFRSF11B in 
arthritic cartilage since also DIO2 expression 
is increased and thus the thyroid signaling. In 
addition, it could be speculated that 
augmented thyroid signaling not only 
predisposes to OA via mechanisms that are 
detrimental to the cartilage, but also via 
increased bone remodeling. In fact, arthritic 
bone was also found to express increased 
levels of TNFRSF11B.[63] 
The increased bone remodeling in OA 
triggers formation of channels which extend 
from the subchondral bone into the articular 
cartilage thereby breaching the tidemark. 
These channels allow for increased 
vascularization which is frequently 
accompanied by innervation, both of 
sympathetic and of sensory nerves.[64] 
Among others, this results in increased nerve 
growth factor expression within vascular 
channels and may explain that, besides genes 
involved in bone development, GWAS and 
gene expression analyses also have identified 
multiple genes involved in neurogenesis. 
Alternatively, it could link to aberrant 
neurogenesis during development with a 
concurrent irregular locomotor system. This 
would predispose to OA during aging as a 




In line with this, in mice targeted deletion of 
SLC12A6, identified in our GWAS as a 
putative OA susceptibility gene (chapter 5), 
leads to a locomotor and a sensorimotor 
gating deficit, suggesting a critical role for 
SLC12A6 in development of the nervous 
system.[65, 66] 
Blood expression profiles of OA patients 
from the GARP study were found to be 
enriched for genes involved in apoptosis 
(chapter 3). This is striking given previous 
observations of increased apoptosis in OA 
cartilage at early as well as at late stages[67] 
despite the fact that OA cartilage expression 
profiles were not enriched for apoptosis-
related genes (chapter 2). However, it should 
be noted that the study had a cross sectional 
design. Consequently, gene expression 
differences between cases and controls can 
be both, the result of OA pathophysiological 
processes or innate processes. Until further 
studies have been performed the blood 
expression profiles should only be used for 
diagnosis but not for prediction or prognosis. 
In addition, it is known that multiple 
interactions exist between apoptotic genes 
and cytokines (e.g. IL1B and IL8, also 
present in the blood expression profiles). 
Therefore, it is also possible that the 
apoptotic genes rather reflect an 
inflammatory state which is also recognized 
in OA patients.[14] 
 
 
COMING FROM, GOING TO: 
FUNCTIONAL GENOMICS 
 
Although the number of published genetic 
studies that lack experimental data showing 
the biological relevance of identified genetic 
variation is still large, in the field of OA the 
step from genetics to biological function, also 
named ‘functional genomics’, has currently 
started to be implemented.[48, 54, 68, 69] To 
proceed and improve the approaches taken 
we propose a combination of those 
suggested by Freedman et al[50] and by 
Sunyaev[70] (Figure 2), which are similar to 
those applied in this thesis for OA. 
Knowledge of the direction of effects of 
the susceptibility locus and understanding the 
functional consequences of the genetic 
variation of candidate genes is required 
before translation to the clinic can be 
considered. Alterations in gene expression 
most likely originate from changes in 
epigenetic control mechanisms[51, 71] or 
from changes in transcription factor binding 
sites[72] as generally acknowledged and 
outlined previously.[50, 73] Therefore, a first 
approach especially interesting for intronic or 
intergenic SNPs is to investigate whether 
genetic variation at the identified locus results 
in differential allelic expression (DAE) of the 
susceptibility gene as was done for example 
for GDF5,[74] ALDH1A2,[54] and DIO2 by 
our own group.[52] Alternatively, for high 
impact protein variants, the effect of the 
variant needs to be established starting from 
in silico analysis of the predicted impact of the 
variant (more specifically for protein 
mutations), to proceed via in vitro cell models 
to the in vivo effects. 
 
In vitro cell models in OA. In vitro cell 
models can be broadly applied and are 
especially suitable to investigate 
transcriptional regulation of a gene of interest 
and the consequences of genetic variation[69, 
71, 72] which eventually may serve to 
interfere with its regulation in a clinical 
setting. Cell models can also be used to 
determine the gene targeted by the 




Table 2 Comparison of different cell models 
cell lines primary cells iPS cells 
lifespan Unlimited Limited Unlimited 
transformation Yes No No 
donor variation No Yes No 
phenotypic stable Yes No Yes 
3D pellet model doable No Yes Yes 
experiment duration 3 weeks 3 months 3 months 
mation Capture (3C), Circularized 
Chromosome Conformation Capture (4C), 
or Carbon-Copy Chromosome 
Conformation Capture (5C) can be applied to 
explore chromosome folding and regions of 
the genome interacting with the site of 
interest. In fact, the use of 4C sequencing has 
been of valuable help in the identification of 
IRX3 as the gene genetically targeted by the 
obesity associated locus within the FTO 
gene.[49] 
Besides the study of gene and protein 
perturbations to obtain mechanistic insight of 
OA risk genes, cell models can be used to 
select drugs or biologicals that in vitro 
counteract the detrimental effect of the 
mutations and may therefore also be selected 
for in vivo studies. In chapter 7 this was done 
to investigate the effects of counteracting the 
thyroid hormone pathway on deposition of 
cartilage extracellular matrix. Iopanoic acid 
(IOP), a pharmacological inhibitor of 
deiodinases, was added to our 3-dimensional 
(3D) pellet cultures and was found to be 
beneficial: upregulation of catabolic enzymes 
was attenuated, while the COL2A1/COL1A1 
ratio was more stable and cartilage matrix 
structure denser leading to prolonged 
‘healthy’ cartilage homeostasis. Although 
encouraging, results await confirmation of 
the effects of IOP on articular cartilage in 
vivo. IOP belongs to the so-called ‘oral 
cholecystographic agents’, originally used as 
alternative contrast agent to identify 
gallbladder pathology.[75] The drug is 
primarily a potent inhibitor of the conversion 
of peripheral serum inactive thyroid (T4) to 
active thyroid (T3) making it an effective 
medication for the control of 
hyperthyroidism and thyrotoxicosis. IOP 
appears to have few side effects within the 
window of its application, however, long-
term effects and consequences for joint 
health following oral use remain to be 
established. This should first be tested in 
mice and can be combined with methods 
used to induce OA to investigate whether 
intake of IOP reduces development of the 
disease. In addition, for the long-term use it 
could be an advantage to screen for small 
molecules that act more specifically to inhibit 
DIO2 but not the other deiodeninases. 
Different cell models can also be employed 
to investigate the effect of strong OA 
candidates. In these studies, the most 
important choice is which cells to use. The 
easy way out is to use established cell lines 
such as the mouse ATDC5 (chondrogenic) 
or MC3T3 (osteogenic) cells which, typically, 
are easy to obtain and maintain promoting 
that studies can be performed within a 
relatively short period of time (around 3 
weeks). However, within the scope of this 
thesis, we have used primary human cells 
since established cell lines are usually 




modified during the transformation process. 
Furthermore, in cell lines the association 
between growth and differentiation may be 
altered and they have frequently accumulated 
mutations in the course of the extended 
proliferation thereby changing the responses 
such that they do not necessarily reflect the 
effect of gene variations in vivo in humans. 
Challenges of primary cells such as their 
phenotypic instability and limited lifespan 
thereby restricting study possibilities can be 
circumvented by using induced pluripotent 
stem cells (iPS) that provides a stable source 
of cells and which can also be differentiated 
towards multiple lineages including 
chondrogenesis and osteogenesis,[76] 
reflecting more likely the effects of genetic 
variants in men. Table 2 summarizes 
properties if the different types of cells. 
For models of chondrogenesis it was 
shown previously that monolayer 
chondrocyte cultures mainly result in a 
hypertrophic phenotype,[77] thereby 
hampering the investigation of the effects of 
variable expression of the gene of interest. 
We observed the same for the ATDC5 cells, 
and attempts to form 3D pellets with 
ATDC5 cells similar to those formed with 
human bone marrow derived mesenchymal 
stem cells (hBMSCs) failed (data not shown). 
Therefore, we think that to study 
chondrogenesis the best option is to perform 
3D pellet cultures with hBMSCs (chapter 7) 
or with primary human chondrocytes. To 
study the effect of the OPG mutation 
(chapter 6) we also used primary human cells 
for the generation of mature osteoclasts: 
commercially available pre-osteoclasts. An 
alternative for the use of the commercial pre-
osteoclasts could be blood mononuclear cells 
that also can be differentiated towards 
osteoclasts, but in these cells we observed 
enormous donor variation and therefore this 
option was discarded [YFMR & AE 
Oostlander, unpublished data].  
Cell lines are less well fitted to learn 
about the organic consequences on the joint 
as a whole since the different tissues actively 
interact with each other during development 
and disease. Therefore, likely more suitable 
although not applied in this thesis is the 
performance of cocultures. Indirect 
cocultures can be applied by exchange of 
conditioned medium as well as by culturing 
cells in transwell chambers that allow the 
diffusion of secreted factors to investigate 
effects on cell function, extracellular matrix 
deposition, and survival. Direct cocultures 
can be performed by using different 
combinations of mesenchymal stem cells, 
chondrocytes, osteoblasts, explants or 
synoviocytes. Frequently applied in studies 
for development of tissue regeneration and 
replacements suitable for implantation is the 
combination of mesenchymal stem cells and 
chondrocytes.[78-81] Of note are some 
studies in which even multiple-lineage 
coculture models were employed. Recently, 
in the lab of R. Tuan a 3-dimensional 
‘microtissue’ was developed suitable to study 
OA pathogenesis.[82] The model system can 
also be used to evaluate the effects of 
different reagents and compounds on 
osteochondral health.[83] He et al[84] 
established cultures of osteoblasts, 
mesenchymal stem cells, and fibroblasts on a 
hybrid silk scaffold to investigate whether 
BMSCs cocultured in the presence of 
ligament and bone cells would differentiate 
into fibrocartilage, and Leyh et al[85] showed 
that mechanical and biochemical properties 
of extracellular matrix deposited by 
mesenchymal stem cells and chondrocytes is 




explants due to altered fibrillar network. To 
study the interaction between cartilage and 
bone, chondrocytes-osteoblasts-osteoclasts, 
isolation of explants from patients 
undergoing joint replacement surgery may 
also be a good alternative.[86] These multi-
lineage 3D in vitro models are the ‘last best’ 
option before getting to animal models.[87] 
In vivo animal models in OA. As stated by 
Sunyaev et al[70] genetic manipulation of 
organisms (mouse, rat, rabbit, horse, 
zebrafish) provide a possibility to test the 
phenotypic rather than molecular 
consequences of human allelic variants, 
which is by some considered the ultimate 
proof for the causal effect of a susceptibility 
locus. Animal models can also be used to 
investigate new treatment options and to test 




compounds selected because of their positive 
effect in in vitro assays as discussed before for 
IOP. Use of drugs with encouraging 
outcome, i.e. inhibited or reversed disease 
severity, can subsequently be put forward in 
clinical trials. 
Of the different types of laboratory 
animals, mice are used more frequently 
because they are fairly cheap, and relatively 
easy to handle and to breed. Although 
multiple different mouse strains have been 
generated for candidate genes, known to be 
involved in chondrogenesis or endochondral 
ossification, this has hardly been done for 
discovered OA susceptibility genes. An 
exception has been the generation of FRZB 
knockout mice of which its characteristics 
were studied using established OA 
models.[88, 89] GDF5 knockout mice were 
generated long before the identification of 
the GDF5 susceptibility locus and were post-
hoc used to study development of OA 
following different established methods 
(reviewed by Cornelis et al, 2011[90]). Also 
DIO2 knockout mice were generated before 
discovery of the association with OA to 
investigate the intracellular effect of thyroid 
hormone bio-availability with respect to brain 
function.[91] So far, no studies applying OA 
models on mice have been published but 
transgenic rats overexpressing DIO2 in 
articular cartilage were shown to be more 
prone to cartilage damage,[92] thereby 
confirming that the detected overexpression 
of DIO2 in OA cartilage[52] is most likely 
not only the result of OA pathophysiology 
but may underlie disease development. 
Results presented in chapter 7 suggest that 
inhibition of the deiodinases is protective in 
cartilage, however, this awaits confirmation 
in in vivo studies to determine whether 
counteracting the thyroid signaling pathway 
may be a novel therapeutic approach. 
Although not identified as an OA 
susceptibility gene, in 2005, a study was 
published reporting for the first time on a 
single gene deletion, ADAMTS5, that 
resulted in the abrogation of cartilage 
degeneration in an animal model of 
osteoarthritis.[93] Many other mouse models 
for OA have followed since, such as for HIF-
2α,[61, 62] and for TGF-β,[94] and most of 
the recently developed mouse models are 
inducible and chondrocyte-specific such as 
the transgenic BMP2 mice[95] or the mTOR 
knockout mice.[96] This allows controlled 
expression of the gene of interest: during 
embryogenesis or post-natal, prior to injury 
or after the induction of OA. Most 
transgenic or knockout mice do not 
spontaneously develop OA but its 
development is provoked by means of 
surgery (destabilization of the medial 
meniscus or DMM; cruciate ligament 
transection), with enzymes or chemical 
substances (intra-articular collagenase 
injections), or by mechanical loading (Figure 
2). An exception are STR/Ort mice that 
upon aging spontaneously develop OA with 
unknown cause,[97] and the recently 
generated cartilage-specific double knockout 
mice Nfatc1/Nfatc2-/- which exhibit early-
onset, aggressive OA affecting multiple 
joints.[98] According to the authors this is 
highly favorable in OA research since it 
reduces the time-cost ratio of the model and 
does not require further surgical or chemical 
intervention. However, the fact that these 
mice are extremely prone to develop OA 
shortly after birth points out that it is a very 
specific model system, more resembling cases 
of early-onset OA during development than 




OA at older age. We should be more aware 
of the susceptibility loci that are identified in 
genetic studies and generate mice with these 
variants to functionally characterize the 
effects of this ‘natural’ variation as it occurs 
in humans. 
It is of note that, although destabilization 
of the medial meniscus was called ‘minimally 
traumatic’[99] and here development of OA 
is less ‘aggressive’ than when using enzymes, 
it is yet more similar to the type of 
osteoarthritis developing in humans after an 
injurious event better known as secondary or 
post-traumatic OA.[100, 101] In addition, as 
reviewed by Aigner et al,[102] the 
pathophysiology and severity of the different 
methods used to induce OA are diverse and 
thus far no paradigm has been formulated 
that encompasses all of its aspects in 
particular its relation to aging which is an 
important risk factor in OA. This is not 
surprising since we know that OA itself is a 
heterogeneous disease. We should therefore 
take advantage of the differences between the 
different methods and, in case economic 
possibilities permit, try to include aging in the 
mouse models. Personally, I think mechanical 
loading (running) is the most appropriate 
stimulus since it provides a subtle way to 
induce OA and in particular when performed 
at different ages (young versus old mice) it 
may largely resemble the human situation. 
FINAL REMARKS AND 
SUGGESTIONS FOR FUTURE 
STUDIES 
 
To improve the clinical application of 
biochemical markers in OA, the genetic 
factors identified for sCOMP and for uCTX-
II should be taken into account. In addition, 
it should be considered to perform further 
meta-analyses of GWAS for other promising 
biomarkers such as serum hyaluronan and 
serum Procollagen type II N-terminal 
propeptide (sPIIANP). Additionally, these 
efforts could identify genetic loci that 




influence the OA biomarker levels as well as 
OA (endo)phenotypes thereby actually 
reflecting OA status as we have found for the 
COMP gene and sCOMP levels (chapter 4). 
The use of gene expression profiles which in 
our hands seemed very promising to 
distinguish patients from controls could be 
further analyzed. These profiles should be 
examined in prospective studies to establish 
whether the biomarkers are predictive for 
OA. Alternatively, in case the expression 
profiles in blood correlate to expression of 
respective genes in cartilage its change over 
time could be investigated which would learn 
whether the profiles are useful as markers to 
monitor the ongoing disease process. 
With respect to genetic studies, given the 
fact that scientists have been able to collect 
large numbers of samples by collaborations 
towards large consortia, we have been able to 
discover several compelling OA susceptibility 
loci. To come to clinical applications and 
druggable targets, the next step in these 
analyses should be taken. The most recent 
large-scale analyses were done upon 
stratification for joint resulting in additional, 
joint-specific, OA susceptibility loci.[26, 28] 
We could move forward by performing 
rigorous phenotyping to identify more 
homogeneous subtypes for selection of 
samples as suggested previously by Kerkhof 
and colleagues.[103] It would be very 
interesting to investigate whether performing 
GWAS for the different OA phenotypes as 
distinguished by Castaño-Betancourt et al 
(atrophic, normotrophic, and hypertrophic[47]) 
would point towards variation in different 
genetic loci. Nevertheless, it is likely that the 
problem will be to replicate the findings since 
few groups have collected or characterized 
such particular phenotypes. Depending on 
the effect sizes of such less heterogenic 
groups, this may result in lack of power and 
thus genome wide significant loci may not be 
found. In fact, this occurred with the GWAS 
analysis performed within the GARP study 
(chapter 5). It could be questioned how many 
of the suggestive loci contain genes relevant 
for the trait. And instead of only focusing on 
p-values for ‘genome wide significance’ we 
may as well investigate potential susceptibility 
loci in the neighborhood of compelling genes 
at multiple biological levels before 
considering these loci false positives. This 
approach could very well open doors to 
interesting new targets in drug research. 
Functional studies are highly time 
consuming, however, hence applying 
balanced selection criteria based on both 
statistical and biological evidence may be 
more optimal. 
In the course of the studies described in 
this thesis we have tried to make a step 
forward in functional genomics. In particular, 
this was performed by setting up in vitro 
model systems to functionally characterize 
identified mutations in the TNFRSF11B 
(chapter 6) and the DIO2 gene (chapter 7), 
and these can be used in future studies to 
characterize other genes and variants such as 
NCOA3[28] and ALDH1A2.[54] Besides the 
models used in the course of this thesis, for 
further investigations I suggest investment in 
the development of co-culture models in 
which the interaction between different cell 
lineages can be studied in more detail since 
the interactions between the different joint 
tissues have a high impact on development of 
OA. This may also be very helpful in drug 
discovery research, since it can be 
investigated whether particular drugs have 
opposite direction of effects on different 
types of cells which is very important before 




In conclusion, the doors are open towards improvement of genetic studies and their 
interpretation and towards development of new strategies for the application of functional 
genomics in OA. 
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Osteoarthritis, also referred to in short as OA, is a disorder of the joints characterized by pain, 
crepitus, and stiffness resulting in decreased mobility. Cause is degeneration of the cartilage 
and/or the development of protrusions of the bone in medical terms named osteophytes. 
Ongoing disease can also be accompanied by inflammation. Prevalence of OA rapidly 
increases with increasing age. Due to a growing elderly population currently OA is ranking 11th 
of 291 diseases causing lack of mobility among elderly. 
OA can occur in any joint, however, it is most common in hands, hips, and knees. 
Development can be triggered by several factors such as joint injury, suboptimal metabolism 
(e.g. obesity or a particular dietary pattern), and sex. Also genetic predisposition plays an 
important role in development of OA. It can determine which joint becomes affected, what are 
the roots for its development (defective cartilage or bone), and how is the shape of the joint. 
At present, treatment options for OA are still limited. Reason is the relatively limited 
knowledge of its etiology and that it is not diagnosed until at late stages, in addition to the high 
heterogeneity among OA patients. Medication is mainly directed at pain relief until joint 
arthroplasty at end stage is required. 
 
Most important questions of this thesis 
In the course of this PhD we aimed to improve research related to OA at 3 points. Firstly, with 
respect to the application of biomarkers. To gain insight into OA pathophysiological 
processes, markers in cartilage and blood were studied. Also, it was investigated whether 
genetic variants exist that influence levels of known biochemical markers possibly resulting in 
the perturbation of their application in the clinic. Secondly, it was investigated which variants 
in the human genome are associated with susceptibility to OA. Therefore, a genome wide 
association study was performed with a group of patients suffering from familiar and severe 
OA at multiple joint sides and the genetic make-up (exome sequencing) of 2 distant family 
members with severe, early-onset, OA was determined. Thirdly, by combining genetic and 
functional studies we tried to come to deeper insight into mechanisms underlying susceptibility 
to OA. Filling this gap will, in due time, facilitate translation of scientific studies to the 
application in the clinic. 
In order to perform their research, scientists depend on patients that want to participate in 
a study. Research described in this thesis was mainly based on 2 groups of patients. In 
collaboration with the Department of Rheumatology we previously included patients for the 
‘Genetics osteoARthritis and Progression’ or GARP study. This group exists in 191 sib pairs 
suffering from symptomatic and radiographic OA in 2 or more joints. The other group is the 
ongoing RAAK study (Research Artrose en Articulair Kraakbeen’) consisting in patients that 
underwent joint arthroplasty. Within the RAAK study a wealth of cells and tissues, such as 
cartilage, bone, and blood, have been collected. Besides the GARP and the RAAK study, 




TREAT~OA and arcOGEN, that have the availability of information on thousands of OA 
patients which can be analyzed together. Such collaborations are required for epidemiological 
research. 
Biomarkers in OA 
Biomarkers are biological variables which can be quantified and used to indicate existing 
biological circumstances or to predict occurrence of pathological conditions. Good biomarkers 
have to be sensitive as well as specific for a certain disorder. With respect to OA biomarkers 
are required for early diagnosis, ideally even before damage becomes visible with x-ray, to 
monitor disease progression, and for prognosis. Available are traditional biochemical markers 
that reflect joint damage. For example, cartilage matrix molecules and fragments thereof 
released and measurable in blood serum (e.g. serum COMP or sCOMP) or urine (e.g. uCTX2). 
Unfortunately, sensitivity and specificity of these markers are relatively low hampering their 
application in the clinic. This urges further research. Recently it has been studied whether joint 
shape can serve as a marker to predict development of OA. In addition, currently molecular 
biomarkers such as DNA and RNA in tissues and body fluids received a lot of attention. 
By comparing gene expression in OA affected cartilage with that in macroscopically 
‘normal’ cartilage of the same joint in the RAAK study, it was investigated in chapter 2 which 
genes are changed during ongoing OA. Although these changes can be cause as well as 
consequence of the arthritic processes, it gives insight into the different pathways taking place 
in chondrocytes during development of OA. Results showed that especially genes involved in 
skeletal development were changed. This suggests that processes normally taking place during 
growth to become inactive in adulthood, become activate again in OA. In addition, also several 
genes involved in neurogenesis were identified. Thus, creating a potential link to nociception. 
Development of treatment options incurring at these mechanisms could result in more 
efficient therapy of OA. 
In chapter 3 a gene expression profile was generated in blood of OA patients of the 
GARP study. It was found that in particular genes involved in cell death (apoptosis) were 
different in blood of patients when compared to healthy controls. A link between OA and 
apoptosis has been described before in chondrocytes, however, this finding in blood is 
remarkable. Besides the specific arthritic profile it was also found that, based on expression of 
not more than 4 genes, OA patients could be distinguished very well from healthy subjects 
(~90% certainty). It is important now to investigate whether the genes identified here can also 
be applied to other groups of OA patients, and whether the genes differ already at an early 
stage and may thus contribute to early diagnosis. 
Besides interest in the (relatively new) molecular markers such as gene expression that was 
studied in chapter 2 and 3, there is still interest in the more traditional biochemical markers. 
Perturbation of their application in the clinic could be the existence of particular genetic 
factors that, independent of OA, affect innate levels. This was investigated in chapter 4 for 
sCOMP and uCTX2. Meta-analysis of many patients of the TREAT~OA consortium 
identified genetic variants influencing variation of sCOMP and uCTX2 in serum and urine, 




biochemical markers in OA. However, is cannot be excluded that also other factors interfere, 
such as differential clearance of degradation products of cartilage and bone in kidney. 
 
Genetic variation underlying OA 
It has been known for many years now that OA has a considerable genetic component. Based 
on family and twin studies, heritability was estimated between 40 and 60 percent. Genetic 
studies identified a number of the susceptibility genes such as DIO2, GDF5, and NCOA3, 
however, these seem to contribute very little to the total percentage of heritability. In part, this 
could be caused by overestimation in the family studies. Also, heterogeneity among OA 
patients may hamper the identification of genes underlying susceptibility to OA and result in 
discovery of variants with small effect sizes. To find genes with moderate effects, a genome 
wide association study was performed with the GARP study. Unfortunately, the study 
appeared too small to come to genome wide significant signals, and too specific to replicate 
findings in other cohorts. However, the analysis provided with several interesting variants. For 
example, CDKAL1 was identified, previously found in association with diabetes (a risk factor 
for progression of OA), and expression of CDKAL1 is different in blood of OA patients when 
compared to healthy controls. 
Another way to determine which genetic factors contribute to development of OA is by 
applying exome sequencing to highly affected family members. This is described in chapter 6. 
Although the variant that is detected will most likely be particular to the family involved, it is 
established that results point towards common genetic pathways underlying OA in the general 
population. Our analysis resulted in the identification of a specific genetic variant highly likely 
to be causal in the family. It was also observed that expression of the gene, TNFRSF11B, was 
highly abundant in OA affected cartilage of the RAAK study. The fact that the identified 
variant of TNFRSF11B results in increased bone formation is very important with respect to 
the current discussion whether OA patients may benefit from strontium ranelate, a medicine 
that enhances bone formation. Our study suggests that for certain patients this treatment could 
be highly disadvantageous, and that before establishing treatment options it is very important 
to classify the patient (occurrence of increased bone formation or not). 
 
A bridge from laboratory to clinic 
In the course of the studies described here we have tried to go beyond the results of molecular 
epidemiological studies to increase insights into underlying mechanisms. This will facilitate 
translation of knowledge of genetic variants to the needs of OA patients and thus to 
application in the clinic. Therefore, in chapter 6 and particularly in chapter 7, model systems 
were developed to investigate the effect of genetic aberrations on extracellular matrix 
deposition of cartilage or bone. Results of the studies performed here underline the causal role 
of the genetic variants in OA and show the importance of combining genetic and functional 
studies. Such an approach can result in better selection of medical treatments of OA: following 
the identification of the DIO2 gene as a risk factor for OA, the effect on cartilage formation 
was investigated. It appeared that DIO2 negatively affects genes involved in cartilage matrix 




DIO2 is an enzyme that converts inactive thyroid hormone to active thyroid hormone. 
Inhibition of this conversion by addition of the drug iopanoic acid or IOP to our model 
system showed a structural improvement of the cartilage matrix. 
Conclusion and recommendation 
Studies described in this thesis suggest that the application of known biochemical markers in 
OA may possibly improve by taking genetic variation of the patients into account. Moreover, 
additional research for the application of molecular markers to diagnose, monitor, and possibly 
also for the prognosis of OA seem worthwhile. For the first time, it was shown that, using an 
easily accessible tissue such as blood, it is possible to distinguish OA patients from healthy 
controls. This is encouraging and stimulates subsequent research for the application of 
molecular markers for diagnosis, monitoring, and prognosis of OA. 
Our studies show the importance of patient classification before starting a specific 
treatment. Wrong combinations of respectively the needs of the patient and the underlying 
mechanism may result in acceleration of the pathophysiological process leading to more total 
joint replacement surgeries. 
Studies described in this thesis show how functional genomics can be achieved by 
combining genomic and functional studies. Model systems were developed for the 
investigation of the mechanisms underlying susceptibility to OA via genetic variants. In 
addition, systems serve to determine which drugs potentially inhibit these mechanisms. Taking 
into account that OA is a disease of the whole joint, I suggest to invest in development of 
complex, multi-lineage, co-culture systems that can also address the interaction between the 
different tissues in a joint. In addition, this could also be of importance to determine putative 
controversial effects of drugs on different types of tissues. A 
207 
Appendix II 




Osteoartrose, kortweg ook wel artrose genoemd, is een aandoening van de gewrichten die 
gekenmerkt wordt door pijn, kraken van het aangedane gewricht (crepitus), en stijfheid, met als 
gevolg verminderde mobiliteit. Oorzaak is de afbraak van kraakbeen en/of het ontstaan van 
botuitstulpingen bij de gewrichten aangeduid met de medische term ‘osteofieten’. Bovendien 
gaat het ziekteverloop gepaard met ontstekingsverschijnselen. De kans op artrose neemt snel 
toe bij het ouder worden. Door de toenemende vergrijzing staat artrose nu al op de 11de plaats 
van 291 aandoeningen die onderzocht zijn als oorzaak voor immobiliteit bij ouderen. 
Artrose kan zich voordoen in vrijwel elk gewricht, maar komt voornamelijk voor in hand-, 
knie- en heupgewrichten. Hiervoor zijn verschillende oorzaken te benoemen zoals 
(sport)blessures, een suboptimale stofwisseling (bijvoorbeeld door obesitas of een bepaald 
voedingspatroon) en geslacht. Ook erfelijke aanleg beïnvloedt het risico op de ontwikkeling 
van artrose. Deze kan beïnvloeden welke gewrichten gevoeliger zijn, waar de basis ligt voor het 
ontstaan (zwakker kraakbeen of juist zwakker bot), en welke vorm het gewricht heeft. 
Tot op heden zijn de behandelmogelijkheden voor artrose zeer beperkt. Dit komt doordat 
er nog relatief weinig bekend is over de oorzaken, diagnose pas in een gevorderd stadium 
gesteld wordt, en er onder patiënten grote verscheidenheid voorkomt in het ziektebeeld. 
Medicatie is voornamelijk gericht op pijnvermindering tot tenslotte een gewrichtsvervangende 
operatie moet plaatsvinden. 
 
Belangrijkste vragen die in dit proefschrift gesteld zijn 
In het kader van dit promotieonderzoek is getracht het onderzoek naar artrose op drie punten 
vooruit te brengen. Ten eerste betreft dit de toepassing van biologische markers (biomarkers) 
voor artrose. Er is gezocht naar bepaalde markers in kraakbeen en bloed om een beter inzicht 
te krijgen in het ziekteproces en naar mogelijke genetische factoren die de toepassing van 
bekende biomarkers negatief beïnvloeden. Ten tweede is onderzocht welke variatie in het 
menselijke genoom, al het DNA in een cel, de kans op artrose verhoogt. Hiertoe is een 
genoomwijde associatieanalyse gedaan bij een groep van patiënten met familiaire en 
symptomatische artrose in meerdere gewrichten. Daarnaast is de erfelijke code bepaald van 
twee verre familieleden met ernstige artrose beginnend op jonge leeftijd door middel van de 
zogeheten exome sequencing techniek. Ten derde is er gewerkt aan het slaan van een brug 
tussen genetische en functionele studies om te komen tot kennis van de mechanismen die ten 
grondslag liggen aan het ontstaan van artrose. Dit vergemakkelijkt de translatie van 
bevindingen in het laboratorium naar toepassingen in de kliniek. 
Voor onderzoek naar ziekten zijn wetenschappers altijd afhankelijk van patiënten die bereid 
zijn deel te nemen aan hun studies. Onderzoeken, beschreven in dit proefschrift, zijn 
gebaseerd op twee groepen patiënten die hieraan hun deelneming verleenden. Gegevens van de 
‘Genetics osteoARthritis and Progression’ of GARP studie waren voorheen bijeengebracht op 
onze afdeling in samenwerking met de afdeling Reumatologie van het Leids Universitair 
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Medisch Centrum. Deze groep bestaat uit 191 broer-zus (zus-zus) paren die lijden aan relatief 
ernstige symptomatische en radiologische artrose in meerdere gewrichten. De andere groep is 
de lopende RAAK studie (‘Research Artrose en Articulair Kraakbeen’) welke bestaat uit 
patiënten die een gewrichtsvervangende operatie hebben ondergaan. In het kader van deze 
studie is een grote verscheidenheid aan cellen en weefsels verzameld, zoals kraakbeen, bot, en 
bloed. Behalve de GARP en de RAAK studies wordt voor het genetische onderzoek naar 
artrose binnen Europa, maar ook daarbuiten, samengewerkt in grote verbanden zoals de 
TREAT~OA en arcOGEN consortia, waarbij gegevens van duizenden patiënten beschikbaar 
zijn en gezamenlijk worden geanalyseerd. Voor epidemiologisch onderzoek zijn zulke 
samenwerkingen een noodzaak. 
 
Biomarkers in artrose 
Biomarkers zijn meetbare biologische variabelen die gebruikt kunnen worden als indicator van 
een bepaalde bestaande biologische situatie of die het optreden van een aandoening kunnen 
voorspellen. Een goede biomarker moet zowel gevoelig als specifiek zijn voor een bepaalde 
aandoening. Met betrekking tot artrose zijn biomarkers nodig voor het stellen van een 
vroegtijdige diagnose, idealiter nog voordat de schade zichtbaar wordt op een röntgenfoto, 
voor het monitoren van het ziekteproces, en voor prognose. Beschikbaar zijn de meer 
traditionele biochemische markers die gewrichtsschade reflecteren. Voorbeelden zijn 
restproducten van afgebroken kraakbeen welke in bloedserum (bv. serum COMP of sCOMP) 
of in urine (bv. uCTX2) gemeten kunnen worden. Helaas zijn de sensitiviteit en de specificiteit 
hiervan relatief laag wat de klinische toepassing ervan belemmert en uitnodigt tot het 
verrichten van verder onderzoek. Zo is recentelijk bijvoorbeeld bekeken in hoeverre informatie 
over de vorm van een gewricht kan dienen als biomarker om te voorspellen of iemand binnen 
bepaalde termijn artrose zal ontwikkelen. Daarnaast is er op dit moment veel belangstelling 
voor nieuwe moleculaire biomarkers, zoals DNA en RNA in weefsels en lichaamsvloeistoffen. 
Door de expressie van genen in artrotisch kraakbeen te vergelijken met die in 
macroscopisch ‘normaal’ kraakbeen van hetzelfde gewricht in de RAAK studie is in hoofdstuk 
2 onderzocht welke veranderingen plaatsvinden gedurende het artroseproces. Hoewel deze 
veranderingen zowel oorzaak als gevolg kunnen zijn, geeft het inzicht in de verschillende 
wegen die een kraakbeencel doorloopt tijdens het ziekteproces. De resultaten lieten zien dat 
met name genen die betrokken zijn bij skeletontwikkeling veranderd zijn. Dit suggereert dat 
processen die normaal gesproken alleen plaatsvinden tijdens de vroege ontwikkeling om daarna 
tot stilstand te komen, bij artrose weer actief zijn. Tevens vonden we een aantal genen die 
betrokken zijn bij neurogenese en dus mogelijk bij pijnperceptie. Het ontwikkelen van 
behandelingen die op deze mechanismen aangrijpen zouden een nieuw aanknopingspunt 
kunnen zijn om te komen tot een efficiëntere behandeling van artrose. 
In hoofdstuk 3 is een profiel gemaakt van genexpressie in bloed van artrosepatiënten van 
de GARP studie. Uit onze studie bleek dat met name genen die betrokken zijn bij celdood 
(apoptose), verschilden in bloed van patiënten en gezonde mensen. De link tussen artrose en 
apoptose was al eerder gevonden in kraakbeencellen, maar het is opmerkelijk dat dit ook in 
bloed van patiënten naar voren is gekomen. Naast het specifieke artroseprofiel werd ontdekt 




van gezonde mensen konden worden onderscheiden (met ~90% zekerheid). Het is nu zeer 
belangrijk te onderzoeken of deze bevindingen ook in andere groepen artrosepatiënten 
bevestigd kunnen worden om te zien of het genexpressie profiel met vergelijkbare efficiëntie 
deze patiënten van gezonde personen kan onderscheiden. Vervolgens moet onderzocht 
worden of deze genen al in een vroeg stadium anders zijn en dus zouden kunnen bijdragen aan 
een vroegtijdige diagnose van de ziekte. 
Naast interesse in (relatief nieuwe) moleculaire markers zoals genexpressie welke in 
hoofdstuk 2 en 3 werden onderzocht, is er nog steeds belangstelling voor de meer traditionele 
biochemische markers. Een mogelijke beperking bij de klinische toepassing hiervan is het feit 
dat erfelijke, aangeboren verschillen tussen mensen de meetwaardes beïnvloeden, onafhankelijk 
van artrose. Deze optie is onderzocht in hoofdstuk 4 voor sCOMP en uCTX2. De 
gezamenlijke analyse van een groot aantal mensen van TREAT~OA heeft aangetoond dat 
bepaalde genetische factoren invloed hebben op de variatie van sCOMP en uCTX2 in 
respectievelijk serum en urine. Hoewel de effecten van erfelijkheid op de meetwaardes klein 
lijken te zijn zou het benutten van deze wetenschap toepassing van genoemde biomarkers in de 
kliniek mogelijk kunnen verbeteren. Het mag echter niet uitgesloten worden dat ook andere 
factoren van invloed kunnen zijn zoals bijvoorbeeld de snelheid waarmee in de nieren 
afbraakproducten van kraakbeen en bot uit het bloed worden gefilterd. 
 
Erfelijke factoren betrokken bij artrose 
Reeds vele jaren geleden is er op basis van tweeling- en familiestudies vastgesteld dat 40-60 
procent van het risico om artrose te ontwikkelen door erfelijkheid wordt bepaald. Genetische 
studies hebben al een aantal van de risicogenen geïdentificeerd zoals DIO2, GDF5, en 
NCOA3, maar deze lijken slechts in geringe mate bij te dragen aan het totale 
erfelijkheidspercentage. Voor een deel zou er sprake kunnen zijn van een overschatting in de 
eerdere studies, en voor een ander deel wordt het veroorzaakt door heterogeniteit onder de 
patiënten. Dit laatste bemoeilijkt namelijk de identificatie van risicogenen en resulteert vooral 
in factoren die een klein effect hebben in de populatie. Om genen te vinden die in een wat 
grotere mate bijdragen aan artrose is in hoofdstuk 5 een genoomwijde associatiestudie 
uitgevoerd met de GARP studie. De studie is echter te klein gebleken om te komen tot 
genoomwijd significante resultaten en te specifiek om de resultaten in andere studies te kunnen 
repliceren. Het heeft daarentegen wel een aantal mogelijke risicogenen aangeduid zoals 
bijvoorbeeld het CDKAL1 gen welke eerder ontdekt was in associatie met diabetes (een 
risicofactor voor progressie van artrose) en waarvan de expressie in bloed van artrosepatiënten 
anders blijkt te zijn dan in bloed van gezonde mensen. 
Een andere manier om genetische factoren te vinden die betrokken zijn bij de aanleg tot 
het ontwikkelen van artrose is met behulp van exome sequencing van familieleden met zeer 
ernstige artrose. Dit is beschreven in hoofdstuk 6. Hoewel het waarschijnlijk is dat op deze 
wijze afwijkingen worden gevonden die specifiek zijn voor de betrokken familie wees eerder 
gedaan onderzoek erop dat het wel bepaalde routes kan aanduiden die ook in de doorsnee-
populatie tot artrose leiden. De analyse heeft geresulteerd in de identificatie van een specifieke 
afwijking in het erfelijke materiaal van de familie, die met grote waarschijnlijkheid de 
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familieleden gevoelig maakt voor artrose. Het betrokken gen, TNFRSF11B, bleek ook een 
sterk verhoogde expressie te hebben in artrotisch kraakbeen in de RAAK studie. Het feit dat 
het betreffende gen een rol speelt in de botbalans en de afwijking resulteert in verhoogde 
botaanmaak is zeer belangrijk voor de huidige discussie betreffende behandeling van 
artrosepatiënten met medicijnen die de botaanmaak nog meer zouden stimuleren. Ons 
onderzoek laat zien dat zulk een behandeling nadelig kan zijn voor bepaalde patiënten en dat 
het vaststellen van het type artrose (al dan niet met verhoogde botaanmaak) vóór het bepalen 
van de behandelwijze erg belangrijk is. 
Een brug van laboratorium naar kliniek 
In de loop van het beschreven onderzoek is geprobeerd niet te blijven staan bij de moleculaire 
epidemiologie maar om te komen tot meer inzicht in onderliggende mechanismen. Dit 
vergemakkelijkt de ‘vertaling’ van kennis van een erfelijke variant naar de behoefte van de 
artrosepatiënt en dus naar het vinden van praktische toepassingen en behandelingen in de 
kliniek. In hoofdstuk 6 en met name in hoofdstuk 7 zijn hiertoe modelsystemen opgezet om 
de effecten van bepaalde genetische afwijkingen op kraakbeen- en botvorming te onderzoeken. 
Resultaten van deze studies onderstrepen dat gevonden genvarianten betrokken zijn bij de 
ontwikkeling van artrose en laten het belang zien van de combinatie van genetische en 
functionele studies. Een dergelijke benadering kan selectie van geschikte medicijnen voor de 
behandeling van artrose verbeteren: nadat een erfelijke variatie in het gen DIO2 gevonden was 
als risicofactor voor het ontwikkelen van artrose, is bestudeerd wat het effect hiervan was op 
de vorming van kraakbeen. De capaciteit om matrix te maken bleek verlaagd, terwijl stoffen die 
het kraakbeen afbreken juist verhoogd waren. DIO2 is een enzym dat schildklierhormoon 
activeert. Remming van deze activatie door het toevoegen van de drug IOP (iopanoic acid) in 
het modelsysteem lijkt de structuur van het kraakbeen dat is geproduceerd te verbeteren. 
Conclusie en aanbeveling 
De toepassing van bekende biochemische markers in artrose kan mogelijk verbeterd worden 
door rekening te houden met bepaalde genetische variatie in patiënten. Verder zijn de 
resultaten met moleculaire markers zeer veelbelovend. Voor het eerst is hiermee aangetoond 
dat een makkelijk af te nemen weefsel zoals bloed gebruikt kan worden om artrosepatiënten te 
onderscheiden van gezonde personen. Dit stimuleert tot verder onderzoek naar het gebruik 
van moleculaire markers voor diagnose, en mogelijk ook voor het volgen van pathologische 
processen in de tijd en prognose van artrose. 
Onze studies tonen aan dat het van groot belang is om patiënten beter te karakteriseren 
vóórdat de behandeling wordt vastgesteld. Verkeerde combinatie van respectievelijk de 
medische behoefte van de patiënt en werkingsmechanisme van de medicatie kan leiden tot een 
versneld ziekteproces met als gevolg méér gewrichtsvervangende operaties. 
Studies beschreven in dit proefschrift laten zien hoe geprobeerd is te komen tot ‘functional 
genomics’: de combinatie van genomische en functionele studies. Er zijn modelsystemen 
opgezet om te onderzoeken wat de onderliggende mechanismen zijn waarop erfelijke varianten 
resulteren in aanleg voor artrose en welke medicijnen dit eventueel zouden kunnen remmen. 




epidemiologische studies te verifiëren. Wetende dat artrose een ziekte is van het hele gewricht, 
is het sterk aanbevelenswaardig om, ter verbetering van de modelsystemen, complexe, 
meercellige systemen te ontwikkelen, die de interactie tussen de verschillende weefsels van het 
gewricht in het onderzoek kunnen betrekken. Dit is ook voor het selecteren van medicatie van 
belang, ter voorkoming van tegengestelde effecten die deze kan hebben op verschillende 
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Aan het einde gekomen van deze 2de promotie was het een aangename verrassing dat, in 
tegenstelling tot zo’n 10 jaar geleden, volgens het huidige promotiereglement iedereen die op 
de één of andere wijze betrokken is geweest bij de totstandkoming van dit boekje officieel 
bedankt mag worden! Je zult begrijpen, zo’n boekje komt er niet vanzelf. Zeker niet door het 
werk van één persoon alléén, hoe hard deze ook kan werken. Dus, het is erg fijn dat ik nu mijn 
waardering kan uitspreken. Daar komt’ie: 
Geachte Professor Slagboom, beste Eline, bedankt voor je inzet. Hoewel je uurtjes voor 
mij geteld waren, ze waren altijd vruchtbaar en leerzaam. Nooit ben ik zonder nieuwe moed en 
ideeën je kamer weer uitgelopen. Verder waardeer ik erg dat je als zeer actieve hoogleraar naast 
de wetenschap ook belangstelling hebt voor allerlei andere zaken waaronder muziek. Geachte 
dr. Meulenbelt, beste Ingrid, ontzettend bedankt voor je goede begeleiding, je hulp, en je 
interesse. Heel fijn dat je, intussen alweer 6 jaar geleden, met mij in zee wilde gaan. Zelf was ik 
na ons eerste gesprek erg enthousiast over je onderzoek en de moleculaire epidemiologie waar 
ik me eerder nooit in had verdiept. Gelukkig was het enthousiasme wederzijds. Ik heb in alle 
opzichten heel veel van je mogen leren de afgelopen jaren, en bewonder je gedrevenheid. Hoe 
druk je het ook hebt, je maakt altijd tijd voor overleg tot in de kleine uurtjes. Fantastisch! En 
fijn dat we de komende tijd nog samen verder kunnen werken. 
Geachte leden van mijn promotiecommissie: Professor Bovée, Professor Karperien, en dr. 
Van Meurs. Hartelijk dank dat jullie gelegenheid hebben gevonden het manuscript te lezen. Ik 
waardeer de suggesties die ieder van jullie heeft gedaan ter verbetering van dit proefschrift. 
Beste Judith, tijdens het scoren van de verschillende gewrichten heb ik veel van je mogen leren, 
en ik ben erg dankbaar dat je altijd bereid bent een professionele blik te werpen op de 
verschillende coupes waar ik telkens mee aankom. 
Rotsen in de branding: goede collega’s met wie je alles van werk samen kunt doen. Nils: 
bedankt voor de fijne samenwerking en dat je m’n paranimf wilde zijn, Wouter: wat had ik 
zondeR gedaan?, Evelyn: bedankt voor je enthousiasme en inzet. Dennis, die ons intussen 
alweer een tijd geleden heeft verlaten maar wiens bijdrage aan mijn eerste Sequenome ik niet 
ben vergeten, Eka, Nico: heel fijn zoals we de microarrays samen hebben gedaan, Ruud, 
Wesley. 
Speciale dank ook aan mijn kamergenootjes. De eerste 4 jaren Anika: ik vond het erg leuk 
dat ik je paranimf mocht zijn; Bianca met wie ik niet alleen over wetenschap maar regelmatig 
ook over de ‘Grote Vragen des Levens’ kan praten; Erik die net zelf deze mijlpaal achter de rug 
heeft en weet wat de steun van anderen hiervoor kan betekenen, Joris die altijd zo goed is mijn 
vragen over GWAS te beantwoorden of mee te kijken; last but not least: Matthijs, ‘chef-kabels-
en-méér’! Hartelijk dank dat je altijd bereid bent even mee te kijken, een sequentie uit de 
database te trekken, en heel veel méér. 
Natuurlijk wil ik ook alle andere (ex) Malle Eppies bedanken: Bas, Caroline, Elmar, Eric-
Wubbo, Jennifer, Jenny, Joyce, Kai, Koen, Leen, Maarten, Marian, Mark, Niels, René, Rita, 




werkbesprekingen, jullie suggesties, het meedenken, etc. Dan, zeker niet op de laatste plaats: 
Inge, waar zouden we zijn zonder jou? Ik wil je bedanken voor alles wat je altijd voor ons doet. 
Maar vooral wil ik je bedanken voor je voorbeeld: dat je altijd zo opgewekt voor iedereen 
klaarstaat, ook als je zelf heel druk met van alles bezig bent! 
Verder zo velen van andere afdelingen die op de één of andere manier hebben bij 
gedragen door onze samenwerkingen: Professor Jeanine Houwing-Duistermaat, Quinta, 
Ramin, Roula, Stefan; Inge Briaire; Professor Margreet Kloppenburg, Andreea; Professor Rob 
Nelissen, Angela, Karien, Kim, Monique, Nienke, Paul; Daan, Karoly; Henk, Yavuz; Professor 
Christine Mummery, Christian, en Valeria; Professor Peter ten Dijke, Amaya, Luuk; en Ietje, 
Kit, Shosh en Twan die ons op weg hebben geholpen in de wondere wereld van de stamcel. 
Ook wil ik mijn oud collega’s hier bedanken met wie ik zo’n goede tijd heb gehad en bij 
wie ik nog altijd terecht kan. Met name AG, Alfred, Alt, Amina, Hans, Kirsten, Mariam, Matty, 
Suzanne; Anabel, Hester, Leatitia. En ik wil niet nalaten Peter-Bram hier te noemen: 
uiteindelijk heeft onze samenwerking een paar jaar geleden er toe geleid dat ik deze kant van de 
wetenschap op ben gegaan. En natuurlijk alle mensen buiten het LUMC waar we zo fijn mee 
samenwerken; dank ook aan iedereen die ik niet persoonlijk hier heb genoemd of die ik 
onbedoeld vergeten ben! 
Ten slotte, na deze bijna oneindige lijst van genoemde en niet-genoemde collega’s die ik heel 
dankbaar ben en van wie ik veel heb geleerd, wil ik ook zeker niet vergeten alle artrose 
patiënten te bedanken die hun medewerking verlenen aan ons onderzoek, en natuurlijk ook 
mijn familie en vrienden. Marjolijn, samen uit, samen thuis: je was erbij toen ik begon, super 
dat je er bij kunt zijn nu ik afrond: bedankt dat je mijn paranimf wil zijn. 
Lieve (oud)huisgenootjes en familie die de ‘onderzoeks-perikelen’ van dag tot dag mee 
hebben moeten beleven: het wel en het wee van een onderzoeker. Bedankt, Bernadet, Elisa, 
Inma, Loles, Maaike, Marinke, Pascale, Tiny, Yvonne; Helena, Bregje, Miriam, Marta, Nelly, 
Bego, en Paula. Jullie zijn de èchte Toppers! Bedankt, lieve papa&mama, lieve 
Marjolein&Johan, Bart&Suzan, Eddy&Sharon, lieve familie, ik weet: met of zonder tijd, we 
zullen er altijd voor elkaar zijn! Van jullie heb ik het belangrijkste geleerd, dat wat we door ons 
werk soms een beetje vergeten: jullie leren me te Leven! En ook al zien jullie me vaak op het 
nippertje nog binnen rennen bij een verjaardag of ander feest, en veel te vroeg weer opstappen, 
op weg naar de volgende afspraak of activiteit, bij jullie kan ik altijd terecht. Voor veel plezier, 
maar ook voor de nodige steun, goede raad, of gewoon een luisterend oor. 
Voor allen: mijn dank is heel groot! 
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